wlm ɕʝջսɖɟ˛ԌϯȑϏϭϻȀȑʠιφϙϸǮωɮʝːˉċ̪̇ȑlαӀwϙϸÛï¾­µÌaсƐʧŸξʌŸɷjq¡ΫǸ¿Ìî¿¸ÒäʁЄbl˂ʫu¢w_șˡ̃ԧɕʝջսɖkջցɖɟ 5 ɖԧ^}ԧƱɖɟ 4,000 õťϙϸӐlԏɭu¢¡Ċȗy_Ŵɖɟϙϸҫōw^̷üĞǩ 5;72ճ.0/ õťմ^³ó®ð¿ҙҊŘՙɺԡճ(*()&, õťմ^«åó¾©Îë«¼ó#/-0&+ õť$ ӖŜlҸ¢w_" u̇Ûï¾­µÌ¥˅Ӹy¡Šήϙϸˡҫw^̽ȑԌ̇բ - ԷaсƐŸɷϙϸÁðÅóbl˞ҫкu¢w_șեȜЯՆϵ 0, ɕ˟åóÌí^sˡҫˣҫкͶaŗϽϯȑϙϸÁðÅób
ճ),. ɕ˟åóÌíմԺ˄wѨΰҏm̍y¡slm¡h˕Ǉwgy_ÁðÅóԣw˦Ʉͨճ˕ˀմ^ÁðÅóʢȻϘďŋǻճƉ˕մlģǀu¢^ÁðÅóӼǕfgy_ԏɭu¢ĊІ^̇Ûï¾­µÌϙϸ¥ҏḣȑʢȻ (+ Ƶϙϸуԏűwϙϸ¥˅Ӹwgy_" ̇þԧǰƼ˼Ûï¾­µÌż̃jq¡ϙϸʝ̓¥^sʝ̓÷^ɳ̃ƷqϙϸȺԦǮωwgтigy_sþԧǰƼ˼lŤǾϙϸуԧӶˋ¥Ͱ^˞ȑҐēͤŠƴϙϸ̵ħ¢ɗgy_ " ˽ɳ̇Ûï¾­µÌ¥ɑːˉwՊgg¡ϫȿȑǣίþŋ҆Ϊċԣ^ϫȿ̽ϯȀȑƑ̋ʛưȑԣxǿo˟`ʔӃwy_̇ϙϸĤδfŗϽϯȑϙϸÁðÅóԣf¡ԨƫϓȂ˕ˀjüҳ­µÌƢƈуw
f

Ƶ¥Ӷ

gg

^̇ȑ

w_Ԩƫ˕ˀÛï¾gyl^
aŗϽϯȑϙϸÁðÅóbșƌly̇ϙϸkϙϸӐԏű{zːˉgg

gy_"

"
  ɕʝ 26 ɖւ˾ĞҔу ˦Ʉ ͨ1ɕ ʝջսɖɟԃȗaϭϻȀȑʠιφϙϸǮωɮʝːˉċ̪b"ϙϸӸʾΠ͙ǰƼ˼""ȑ̚͝ĖƵ     ϫȿȑǣ         ȀȑƵ   ϫȿ̽ϯȀȑ   ""ϙϸРиƵ           сƐŸɷϙϸÁðÅó            ""Ûï¾­µÌʢǥǦ       ϫȿɍ˦Ѱƒί̋ջXպվXպ         ""ϙϸÛï¾­µÌƵ сƐʧŸξʌŸɷjq¡ΫǸ¿Ìî¿¸ÒäʁЄ   ""ϙϸңΏ   ϙϸʲΏ¥ɮʝy¡ϙϸ ""ϙϸĞҔу"
ϙϸĞҔуƵ"ʢȻԌȸƵ"чƵ"   ˦Ʉ ͨ"    ̽ȑԌ"     ˕ˀ""Ûï¾­µÌƢƈϙϸу˙  պւ Ƶ""ҴɭȨ̗ƒű    Ϊɇòʏǰ     άΝòƓ̽     Ė˛òϥħ ""ϙϸÛï¾­µÌƢƈy¡āϙϸу""ϙϸуƵ""  >ȑ" Ť?"ʢȻòчƵ"

Ûï¾­µÌϙϸҾՖ" Ûï¾­µÌɱƃ"

"

"

"

֍֌ֆԑƐсƐсƐʧŸ̵̭ҥ˩ ˦Ʉ  ͨ άƐȑò˕ˀ Ԩƫ ϓȂ ŗϽϯȑϙϸ֦֚֙֒ò˕ˀ ԑМ¿Ìî¿̜ԑԑƐ¸ÒäȓȗʇсƐŸɷ ˤը ϐЙ űȍ̵ёŸɷȑò˕ˀτl¦¥ʧŸy¡©áÌó½¿̵̭Оѐ̿ОѐсƐŸɷ Ӈƫ ԉĂ οʖ̭ӵȑò˕ˀl¦Оѐǹ͂ʧŸƫњl¦ӡϰʧŸ ̤͢ ̟ȍ άƐȑò˕ˀ ͐Ԇ ǈԊ ƫњǾϯȑò˕ˀԑМ¿Ìî¿¡¸ÒäŦбБѢòχѡсƐΎπ¿Ìî¿сƐӽϱjq¡¸ÒäŦб¸ÒäԑƐсƐʧŸ į҇ ƚł ǃƲńɸȑò˕ˀ՗զсƐ¹ëó¸ðсƐņıɋå±ÏÀäҥ˩ ȿԌ ɗư ОѐάΪȑò˕ˀզĞӃλɑ½¶ÎíĨӿզĞӃʇξʌοʖάΪ ͕  Ϫɯ ̵ё̭ӵȑò˕ˀќρӡϰŤχОѐʁЄξʌȩy¡άı¸ÒäʁЄ Ȁ˫ ƚ˩ Ťϯȑò˕ˀїҎЇԹȞŚνòԑМ¿Ìî¿їҎЇԹȞοʖсƐ Ʉԕ ɢô ϑϯȑò˕ˀϑΎπʇξʌοʖҥ̑ŚνλɑʧŸ2 ǧ÷ ϼӒ ƫњ͗ςȑò˕ˀƫњ÷χОѐűƐ¸Òä®Ø¾­ÑÊªÈµǽƐ¸ÒäȓȗʇсƐŸɷ ɣ҇ ƗԻ ЯƲ̽ϯȑò˕ˀÛïÔ«°Êªµ¿ƫњξʌըհуƫњξʌŸɷ Ѝί Լҗ ЯƲ̽ϯȑò˕ˀƈհĩhƫњΫǸǽƐсƐjq¡άıԫɷճŠƴϙϸ̵
ԨЂմ







?B133;>:3

֑֢֖֜֒֒ɅϻȀȑճ֤֓֠֔մò˕ˀ

ͣʇԑМ¡։֌ֆԹȞԫɷτl¦ʧŸ̵̭

&=03?A%%
B16@

֥֟֙֒֡Ȁȑճ֣֦֝֘մ
ò˕ˀ ։֌ֆˊŏҸӄůΪ̵̭҄ žɕ

ƑĔƓԯճþǢմò˕ˀͣʇԑМ¡сƐ}ʧ
ŸсƐʧŸ̵̭

'/;B3:+7:@=<֌֋֊ճ֤֓֠֔մòԌԣ

# ֤֣֧֞֨֠֒֙λɑǽλΫǸǽλƟсƐ

??=:
?73203?5֛֕֗֘Ȁȑ֤֓֠֔ò˕ˀńɸ̶ˊԄĨοҥ˩

# ńɸτl¦òсƐʧŸ։֌ֆˊŏτl¦""ϙϸÛï¾­µÌϊφòʒоƣҨδ̬Ҝ"" ƈհĩgτπy¡l¦ξʌƟǝԄĨȍǽλτΨλɑlэ˳f
ƈi

^}¢

άͣпʗŚνƆĮø¡ї̥Ǵզʪ^ʔ̕l}¢¥ʎƐu{¡_̇ϙϸϊφ¸Òä¥ȓȗЩʶy¡űȍ̵̭¥˩ky¡sсƐĩhτl¦ʧŸʤlk¥ɶ¡ԄĨȍτΨ¥̺Ϟșҏy¡űȍ̵̭¥˩kw^сƐʧŸʤlk¥ɶhy¡f¡_uξʌʎʇƐ^ƞl¦ӡϰї̥ǴԔЋƐ^զϛǺʇξʌ¥ʎƐu{¡å±ÏÀä¥˩ky¡s^s¢ξοa͸οƐb˟Ѕ¥Ҟgw^ϕφшıφŋɡըհу¥ǹyǮω¥o¡s¥ϊφy¡_ aсƐbùƭԅf¡w^}űȍ̵̭¥˩kw^сƐ¥Ÿɷy¡sƭётi¢¡_сƐå±ÏÀäg̮`ĠҼlˆǌu¢}þԑƐ¿Ìî¿Ҽ}¢ĠҼ¥Əʴy¡wɚoҸ¢g¡l^g¡_̺ɑĞӃͣƋάıŤάx¡ͣʇԑМ̮`άıըűȍ¥ԑƐy¡_}þсƐl¦τάό˄ԨӶy¡тi¢g¡̜ԑԑƐ͟ϊw^ԑƐ¿Ìî¿øԄĨʏǰЩʶ}ԄĨȍτΨ̺Ϟu¥ŁҰy¡ěРŝӋ¥˩ky¡_ al¦bĺΓwˤ̇Ė̿đΦ˽÷ĭ¥ƛ^}ř̀ҧhoԔҜҾՖf¡_ƈհlτl¦ǝȍպf¡Ԯ^ըհуτl¦Φ÷˨ùƭԅf¡{^өӴ̺Ϟү˝^jӡϰԬ̹ξοŸɷ÷ùƭ̶fµÌôнϙϸуǮϢѧɛӶˋs¢ƨ aї̥Ǵbaզʪbըհуjg3^̇Ûï¾­

Р¦g¡_

ԔҜҾՖf¡_ї̥Ǵτάόɳw

k¡m͗ςlu¢¢ȀɒπΠӢ͸u¢¡u¢¡l^˰ԧφŸИlȀmoΨșǏՖw

Հwg_wkwlτάɳf¡ϱɟ˰ԧlСӽw

πΠ¥Ӣ͸Ű̍¡ʤ͝lϞϻm¢ȀmӸ̼¡_̇Ûï¾­µÌї̥ǴʎƐå±ÏÀä¥˩kw^}¢¥Ӣ͸y¡͗ς͝Ϟϻ¥ϊʷwg¡_ըհуjq¡զʪĊɳʌу QOL ͑ȗφɰՉ¥ʶ^զϛǺþɾφɱƃ¥̓yϛզОѐ«°ðӧӮ^զƹƧ^Ϙ΍Ɛűȍå±ÏÀä¥˩kw^űȍ̰φ¡͗ς͝Ϟϻ¥ϊʷwg¡_ ÷Ҫϊφΐ^Ɠϯ̽ϯЯƲοԯ¥Ķҫw^kűȍάǀϯȑkǮϢ̽ϯòƓȑ^ѧɛ̽ϯòƓȑϙϸɵċy¡̇ȑǣЯƎ 14 Ƶϙϸу¥ТԽwaűȍbkaÝÈÍ»«Íbȭϱ¥ʶϙϸÛï¾­µÌ¥˅Ӹy¡_}¢ƈi^ͪǾsűԕjq¡ÌÈÛµë¿ϙϸу^ЍǢòNY ɅϻȀ B. Demple ˕ˀ^Ùëð¿òâíÁ«éȀ R. Fuchs ˕ˀ^þǢòƑĔƓԯ҄˕ˀ^ЍǢ NIH  S. Wilson Ԍԣ^ЍǢòÊ³»¿Ȁ E. Friedberg ˕ˀƢƈ̇Ûï¾­µÌ¥Ӹ¡_s¢ͪǾϙϸуs¢ƢƈåðÔólŠƴϙϸ¥ҏg¡_shϙϸ̇ȑȀȑԯάlƈ¤¡sѷʤыʝȀmƊ̓l̃ɲŰ̍¡_shwͣƋ¥̇ȑŗϽφϙϸʲΏ¥ɮʝŰ̍¡тi

g¡_

ϙϸРи"
 Ûï¾­µÌ¥ӿʝy¡ΐ̇ȑ (+ ƵϙϸуlÇóä¥Р¦Ҩδφϙϸ¥Ӹg¡_}¢~¢ϙϸуȬ˒űԕч^ϙϸҾՖżՋϣyj̇ϙϸȀmoջǏՖƷk

ϙϸ¥Ӹ

f¡_"

g¡_"

   ճֆմτl¦сƐʧŸ̵̭ҥ˩   ճևմξοŸɷ"ճֆմϙϸǮϢάǀϯȑjǮϢ̽ϯòƓȑϙϸуl^ճևմϙϸѧɛ̽ϯòƓȑϙϸɵċy¡ϙϸуlΡѨȬԤʇ¥άkwl^ɿҜʁxŁϙϸͣƋ¥ӸϙϸуwвkӶˋ¥g¡_ ƱϙϸʯɭуȀȑԯά¥ƸǿoϙϸуlŠƴƢƈw^sÛï¾­µÌ¥ːiϙϸ¥ӸȺu{g¡_}¢ϣyτҔӁ˛ǿoȀȑԯάlÙ¨ó¿Ì°ó»ówƵż¥Ӷ }Ĝ^sÛï¾­µÌ}¢~¢űԕjgŗȱφϙϸ¥ӸÙëð¿^þǢϙϸуӶˋwŠƴϙϸ¥Ӹg¡skŵ¡_g¡ЍǢ^g¡_}ʝ̓ˣӁ˛ɮ˩Ҫy¡^½ðá¾¬ä K:JDA@HDIB"=HFBGG"@EA"1CDECLşԦu¢_" ̇ϙϸĞҔуf¡˦ɄͨėǜȀȑŤ˞ҫкu¢сƐŸɷϙϸÁðÅóÁðÅóԣwӼǕɭ^åðÔój}ŠƴϙϸуlѨΰķήm¡h^}ЇΪòg ¡ _ Á ð Å ó ā Ŏ  ½ ð á ¾ ¬ ä ճ Ѐ ô ǜ с Ɛ Ÿ ɷ ½ ð á ¾ ¬ ä

K:JDA@HDIB" =HFBGG" @EA" 1CDECL)'(* ɖ 0 ˾ 0 ˤմ^ջǜϙϸτҔħճ)'(* ɖ - ˾ )- ˤ^4)'(+ ɖ . ˾ *' ˤմ¥āŎw_s¢½ðá¾¬äjgǢòþǢksűԕŗϽφϙϸ¥Ӹ^ȑŤǾzЍg¡ϙϸу¥ʱm^ǢԸφʏǰēˇǱ

w_}Ĝs¢^ЍǢĖպƵ¥Ƹ 0 Ėϙϸу¥ʱm^˽˞ϙϸʝ̓g ƲҨտǜϙϸÁãÎó¥āŎwʏǰēˇ¥js_""ϙϸˡҫòҫōЂ" ̇Ûï¾­µÌ¥˅Ӹy¡Šήϙϸˡҫw^̽ȑԌ̇բ - ԷaсƐŸɷϙϸÁðÅóbl˞ҫкu¢_șեȜЯՆϵ 0, ɕ˟åóÌíŝıʳ˖ԫ̹ȫxӨîÝí ;) f¡_sˡҫˣҫкͶaŗϽϯȑϙϸÁðÅóճ),. ɕ˟åóÌíմ
bԺ˄wѨΰҏm̍y¡slŰ̍¡hg¡_}ˣŗϽϯȑϙϸÁðÅóҫкͶˡҫճОѐǭաȜ^ĮͺșեȜ^¬«í¿șեȜմҖкճÅðÕµӕГҙű̑Җк^391 ҥ̑½¿Êä^Әԁɾ̵^;) îÝíȓŝ³ç×
ÑÈÌ^2:) «ð³èÝóÅó^ŠΒΏîó¼ó¿³çðՙɺԡ^ì©íÅ«ä ;2<^Ùïó»«ÌåÌìó½¿ÊäЂմύčѨΰķήm¡ıŸg¡_̇ϙϸӐ˞ҫкwҖк̷üĞǩ 5;72ճ.0/ õťմ^³ó®ð¿ҙҊŘՙɺԡճ(*()&, õťմ^«åó¾©Îë«¼ó#/-0&+ õť$ ^ƊΦoŖșu{¡slŰ̍_s¢̵ǗՓжŷήu¢^Ξ«åó¾©Îë«¼ó³ó®ð¿ҙҊŘՙɺԡ
͆ˤķήu¢g¡_5ϙϸτҔħa сƐʧŸξʌŸɷjq¡ΫǸ¿Ìî¿¸ÒäʁЄbˤ˰փɕʝ 26 ɖ 7 ˾ 30 ˤճ͋մ9 ˰ 30 űe17 ˰ 30 ű
Ǳʢփϫȿ̽ϯȀȑ̇բ 5 Է 504 ˕Ȝȑԣʻʵ                          

ÁÈ½êð I (9:30~12:00)  ưħփԨƫ ϓȂ ԑƐRNAˁ԰̵̭ ԑƐÐµî°ÇÍԄĨʏǰτΨλɑƑ̋ ʛư     ˦Ʉ  ͨďƫ ŞԊ aըհуƫњБѢОѐűȍάΝȑφǮωgϙϸ eԑƐ¿Ìî¿¡ ·ëÇÒ»«ÌОѐсƐτl¦Ԩľe b       ͐Ԇ ǈԊ

 µïâÇðìæËìð¶ǝȍ Rdh54 ¡̕ѱıȓȗƐ̵̭ eÁðÌïå©ΞλφÖ¿Ìð Cse4 ¥Ęw˞ҟĴήge     ̤͢ ̟ȍ τl¦¥ʧŸy¡©áÌó½¿̵̭             ˤթ ϐЙĦʚÁÈ½êð II (13:00~15:00)

ưħփ˦Ʉ  ͨ

 (&% űȍ¡ϝРиϘ΍Ɛξʌτπ̵̭ҥ˩   ȿԌ ɗư ̽ƽοƟѻΰ̍ (!& ì²ðÍ¡Дȷοʇљπτπ   ͕  Ϫɯ '%& «°ð΀ŰͭlƫњΫǸjyɰՉ         ЍίԼҗ șեφѨɌŚνʇhѢΎjq¡ !   !  ɱƃ   Ʉԕ ɢôĦʚ
ÁÈ½êð III (15:10 ~17:10)

ưħփˤթ ϐЙ ÛïÔ«°Êªµ¿ƫњξʌ           ɣ҇ ƗԻ ОѐǭաʦҐ¥ήg̽̽ƽРиŦάԨy¡ϙϸ   ǧ÷ ϼӒ ՗զ¹ëó¸ðΞλʇԨy¡ϙϸ   į҇ ƚł їҎЇԹȞŚνòԑƐ¿Ìî¿



6



  Ȁ˫ ƚ˩ ϙϸτҔħҜ˥ҾՖƵ   ƚ°  FÿƣĝěϙϸĞҔу ˦Ʉ ͨʢȻ    ̵ёάΝƐȑӂɠòάƐȑűԕτҔҜ˥s¢ϙϸԑƐ RNA ΞλφТƲy¡ÅðÕµӕ^Auf1/HNRNPD ¥ƴȗwl^ėǜ}άƐȑφʇӕgğøs¥˩kw_ճպմƐȑƲʝu¢ԑƐǩ¶©Ïð(8oxoG)¥Ƹìàǩ°ìºâó¥©²ïó¿×óÀŠ˿ТƲu{˞ҟÛïóÚ¥Ԧτw_ճջմ÷ҪÛïóÚ¥ήg^ОѐʮŰͭþ Auf1/HNRNPD ÅðÕµӕ 8oxoG ¥ΞλφҸӄw^ТƲy¡s¥˩kw_ճռմГҙu¢Рˇi Auf1/HNRNPD ÅðÕµӕ}¢ƙΡԑƐ RNA ¥Ξλφ
Ҹӄwgl^Auf1 ÒÈµ©¬ÌОѐОѐʮŰͭГҙРˇiÅðÕµӕ¥Ͳǂy¡ԑƐ RNA ΞλφТƲёlǜɸy¡_ğ÷sk^Auf1/HNRNPD ÅðÕµӕĜÅðÕµӕҚƲıЂ¥ɮʝw^8oxoG¥ƸԑƐ RNA ΞλφТƲy¡sԑƐˊŏ RNA ¥ӡŨòрҭЖkˁ԰w¡тi^sĠҼΨǥϙϸ¥Ӹ

g

g¡_


ҾՖƵ   ƚ°t`]lqBƔöÉńĴĽàϙϸĞҔу ďƫ ŞԊʢȻ    ŗϽϯȑϙϸÁðÅóȚǇ˕ˀτҔҜ˥Ȁѝѻ mutT ԄĨȍ̶ˊ̛ԑƐÐµî°ÇÍ 8-°³Ã¶©Ïð (8-oxoG)  a©ðÔóϹΓǽλҽӽtwblӗs¡slϕ¢g¡_sΨӉ in vivo

 8-oxoG ԄĨʏǰτΨλɑghҠΏk͟ϊu¢¡_̇ϙϸ^8-oxoG ӗǝy¡©ðÔóϹΓǽλҽӽtwlըՓɟӗs¡ȀѝѻãèóÅðÌ¥ǿ˙űԿwҥ̑w_}Т̓^űԿwãèóÅðÌ^Ðµî°ÇÍάƲʝľ¤¡ԄĨȍ^RNA  DNA áìåëóÂԄĨȍ^ѢÅðÕµӕԄĨȍ^ÅðÕµӕάƲʝőoҥԿǝȍԄĨȍãèóÅðÌf¡sl¤k_s¢ԄĨȍ^ĸi
8-oxoG ¥ƨӨgh^f¡gĴήwghőg}hwŸɷ¥ҬȠy¡hf¡˅ͻw
ÅðÌ¥ҥ̑y¡sky¡Ҳg^ԑМ¿Ìî¿ȩʩw

ǰƼy¡_
7

g¡l^ãèóÅðÌg¡_ЫлφôӶãèóőoԄĨȍτΨҿЈ̵̭¥˩ҾՖƵ  - ƯưŬ·ŰŝŲFŤŭ©ÏķıÑŅÈŇE?0@Fōŕ       /ƚ°hphEOQblveXpFŤŭŪ°Bń5TBFƟ¡/ .
ϙϸĞҔу ͐Ԇ ǈԊʢȻ    ƫњǾϯȑűԕ τҔҜ˥̺ɑОѐ &$' ȩy¡̮`ԫɷƦʁ¥˿y¡_}ԫɷƦʁպlОѐсƐf¡тi¢¡_ОѐсƐ˽ԔҜΞɼùƭӰφОѐƽ̃Ŋ̹f¡_̺ɑОѐОѐсƐy¡sl¦Ɛ¥ԫgg¡ҧi¡_}s^̺ɑ·ëÇÒ»«Ìƫњʣɕ÷χσОѐ¥ǭաw^&$'ճӽԑƐ͋МմůΪw
͇ӣw_}Т̓^̺ɑ·ëÇÒ»«Ì &$' ^ОѐсƐ̵̭Ԁg¥ОѐсƐâó±óf¡ % # /τΨlĒӸwl^ƫњʣɕ÷χσОѐ % # / ǽƐlk_% # / τΨ¥ҿЈy¡®Ø¾­ÑÊªÈµΠʖ¥ҿ¡^̺ɑ·ëÇÒ»«Ì &$' % # / ÛïæóÅóՎǬåÇíƐîÝílĮøw

g_åÇíƐʧŸ% # / τΨlǹƈy¡slтi¢_̺ɑ·ëÇÒ»«Ìƫњʣɕ÷χσОѐԀg % # / τΨf¡slϣǊu¢_l¦ОѐОѐсƐ¥ǜԅw

g¡f£

h_

ҾՖƵ  `loaÄÏ   EOQĖŶÒÓ°ĝě /ipVĲĽŅyhp $ S9=ĉƂĹE?0@/ϙϸĞҔу ̤͢ ̟ȍʢȻ ̵ёάΝƐȑӂɠòάƐȑűԕò˕ˀτҔҜ˥Ԑͅ Sacchaomyces cerevisiae ^Swi2/Snf2 »ÚÙ¨ãìóȻy¡ύƴʇըgµïâÇðìæËìð¶ǝȍ Rdh54  Rad54 lȎǥw^ŠύƴРˇi̵ёwg¡_ʞ`ԐͅČŇıОѐ¥ήg¸Òäȓȗʇҥ̑k^rdh54 ̶ˊ̛jg^Рˇiǝȍ Rad52 ̶ˊĺȎwÁðÌïå©ԏųĺȎw̕ѱıǓȄl÷˨y¡s¥ҞŰw_us̛^Ûë¿ãÍǓȄl÷˨w^Rdh54 ÁðÌïå©ՎǬ¥Ęw̕ѱıȓȗƐȢúy¡slϣǊu¢_ô˟^Rad54 Ö¿Ìð H3 ύčĴήy¡slϕ¢g¡sk^Rdh54 ÁðÌïå©ΞλφÖ¿Ìð H3 Ôì©ðÌf¡ Cse4 ύčĴήy¡ĠҼ¥ϻҰw_ҊŘÅðÕµӕҌƲu{^ОѐŤȸǥңȧŚν͒ԭ͝

ȸǥ¥ңȧy¡^Rdh54  Cse4 ÁðÌïå©

µë¿Åóтi¢¡ÍÈÌŠȸǥw_ȀѝѻτΨЖÞÛÇÍ¥ήgŚν͒ԭ̩ГҙwÅ¶ĝmáì

^Rdh54  Cse4 ό˄ύčĴήy¡slűk_

Rad54  Cse4 ύčĴήy¡l^Cse4 ¥˝ΚƐw8ҥ̑y¡ Rdh54 ΞλφТƲy¡ՎǬlɶ¢^˽Пφ Cse4 þȃԌИ 30 ©ãÒԑ́ǮΞȗu¢_©ãÒԑкˇ

^ТƲՎǬŤҚ˙ Lys ́Ǯ̺ѺՁlԨúwg¡slϣǊu¢_ô˟^Rdh54  Cse4 ТƲՎǬþȃԌИ 300 ©ãÒԑ́Ǯ^Ö¿Ìð

H3 ТƲՎǬλ¡slűk_ğ÷Т̓¥^ԐͅОѐŤ Rdh54
 Cse4 ԧύčĴή̕ѱıȓȗƐ̵̭Ԩ¤gҥ̑¥Ӹ¡Ċȗf¡_ҾՖƵ  ńń 5TSûª:QVpfhFĝěϙϸĞҔу ˤըϐЙʢȻОѐűȍάΝȑӂɠòűȍ̵ёŸɷȑűԕτҔҜ˥
# ÷άxńՠǵǮ $åÇí¶©Ïð # ҚҙӽϱǵǮһȩƲ¥ɮʝw^ϹΓǽλuτl¦¥mӗsyƟǝ¡_wkw^ըЂάΝsˊŏ¥ʶОѐ©áÌó½¿¥ҹȱwņıkˁ԰y¡sǽλОѐŰΨ¥ʧŸwg¡_ʞ`¾

óðÌëÈÛ͝¥ήg"%$  ;5^s©áÌó½¿ҹȱԨ¤¡˞ҟǝȍw¥ƴȗw_"%$ Оѐӕȸǥw^τl¦ʧŸǝȍôf¡ !#ОѐŤ®Ñí´óʔϕ³ÎóÂf¡ "% ύčĴήy¡_@7&#¥ήg ;>9Lf¡g :1< ԄĨȍÒÈµÆ¬ðОѐ^©í³íƐſůΪɳ»Ú  ОѐŰΨlՙҀʧŸu¢sk^"% !#  "%$ ƴ̮©áÌó½¿ҹȱ½¶ÎíĨӿСӜjg ɿҜf¡slϣu¢_}¢ȩwïµïâÇðƐ¥ĘwȍτΨʧŸОѐсƐjg^;5Оѐ̜ŤµïâÇðТƲw^ÜÊ̵ёy¡slǰƼu¢Оѐ̿ҹȱlՙҀʧŸu¢sk^;5g¡_;5ԄĨ̜Ťjg©áÌó½¿ҹȱŴ̃ӽϱ̵ёy¡slϣǊu¢_ҾՖƵ   ©ÏEOQŏťũŌĮ°BĿõńŁĝěFƃĎϙϸĞҔу ȿԌɗưʢȻОѐűȍάΝȑӂɠ ОѐάΪȑűԕτҔҜ˥̽÷χPԧѿЖύčĴή¢^0 ͬȄɳā $0 āӉΛѴОѐ$0®ÎåíѴОѐ0kɮʝuϘ΍ƐlЩʶҿЈu¢¡l^}¢~¢Ϙ΍Ɛӽϱ¥ʯhűȍƴȗϘ΍Ɛλɑ¥ϣyξʌԨľù˩f¡_ʞ`̽ΛϘ΍Ɛ¥ҿЈy¡˞ҟűȍw^άıþΞ $0  0 ̫ըτΨy¡ (&% űȍw

τҞw³ÎóÂͣʇ¥˿y¡éÏóµ / ӱӽǩԴ«°ðÇçÑíf¡ (&%" ͟ϊw^sűȍ¡ãÑëíӧӮ^ƣ^³ÎóÂͣʇs¢Шo̽Ϙ΍ƐҿЈ̵̭Ԩú9¥̩ҩw_â¬¿Риҥ̑ŝӟþ^(&%" ̽Λ $0  0 Ξɬoτ

Ψw^(&%" ³ÎóÂǽλâ¬¿ 3 ͒ϒ͸ȳ̽ΛϘ΍ƐԹȞlҸ¢_^$0  0Оѐ̛jg (&%" ɬgτΨŠ (&%" ̮Դ«°ðӧӮlŔĭϞҸu¢^(&%" ÒÈµÆ¬ðОѐǾǮӕϘ΍Ɛ¥ʧŸw_ğ÷^(&%" l̽ΛϘ΍ƐЩʶԔҜɱƃ¥̓yslϣǊu¢_ҾՖƵ  ğğ ¾ŀ´ŷĻĔ ^qEOQşÙŀóůŁFńŁϙϸĞҔу ͕ ϪɯʢȻάı̭ӵȑӂɠ τҔҜ˥ДȷοҎþҞ¢¡П̆ДƐέΝƙΩљРиОѐѨΓŚνƩȠı A=:::793
?313>A=?(!&τΨ¥ҹȱy¡_ėǜ^Дȷοâ¬¿љЕΩıjq¡ (!& τΨ (!&ì²ðÍ¡љπτπ¥̩ҩw_¿ÌîÛÌÄÌ½ðҹȱʇUǩДȷοâ¬¿jըђъ՟˜ҹȱʇVǩДȷοâ¬¿^     ΰ̍ !%' ʨúUǩДȷοâ¬¿¥ήg_Дȷοâ¬¿љЕΩıôѯРиҎЇλ(!& τΨlҞ¢_!%' ʨúДȷοâ¬¿ȩΕâ¬¿ŝ˙άȎ̃ԧŝ˙̿đw^}ȷÅðÕµòȷДըŉ^љЕΩı !(#L(Mjǩ¹ëó¸ðǹάlңȧu¢_ЕΩıП̆ДƐέΝ҂ϵ (!& τΨҹτ^Ҏþ !%'  (!& ¥Ęy¡ЕΩıŤχͣʇƐ^uå»ð´¬äŤχΰ̍»«Ì±«ð¡ͣʇƐlЕΩıϝƐ¥ĿӸu{¡тi¢_ҾՖƵ   X]Ĭ¨Ī5·ŰĶÊE3OK:ìƨϙϸĞҔу ЍίԼҗʢȻЯƲ̽ϯȑӂɠЯƲ̽ϯȑűԕτҔҜ˥εՆ̵ёʇ²ë¿ surface pre-reacted glass-ionomer (S-PRG) ÙÈМ^ß¬М^¿ÌïðÇ¬äЂ«°ð¥΀ŰwËðÅíÛëóµɬg̽ϯ̊˜w ͟ϊu¢ g¡_̇ϙϸ^S-PRG ΀ŰͭlƫњΫǸƣyɰՉg ̩ҩw_S-PRG ΀Űͭ

Porhyromonas. gingivalis ÛïÊ©óÂͣʇ^ÂëÇÎóÂͣʇ¥ʧŸw^P. gingivalis
 Fusobacterium nucleatum ŠŮԽʧŸw_¤¢¤¢ S-PRG ΀ŰͭlÔ«°ÙªíäjyɰՉg ̩ҩw_ S-PRG ΀Űͭ¶ëäԴʇѻjǍͭþОѻ¡Ô«°Ùªíäɮʝ¥ԬȞy¡sl˩k_u S-PRG ΀Űͭɮʝu¢Ô«°Ùªíä¥ϛǺy¡ёƆҸ¢_S-PRG ΀Űͭq
o S-PRG Ƹ˿̽ՆϙϠſƴ̮Ĵήlf¡sl¤k_10Ô ƭŅųÞ¤ľóIC1ŲįE37Q  B  Fí¬ҾՖƵ  ÔϙϸĞҔу ɄԕɢôʢȻЯƲƓȑòϑϯȑτҔҜ˥cϊφdSIL-27^IL-35IL-12ԨӶ»«Ì±«ð
ʇkϣu¢

f

^ŚνʧŸĴή¥ʶƭёg¡_șեφѨɌŚνʇhѢΎ(EAU)ΎπƱ̃®Ù­µÅóОѐȩy¡IL-27IL-35Ĵή¥˩ky¡s¥ϊφw_cȩӉ˟͝dSC57BL/6
â¬¿ЫѢʩƟ (IRBP)¥ήg

EAU¥ҹȱw_ 0, 7, 14, 21ˤϊʢȻìðÓЈjјѥ¥ˍŰwϟ͊Öó¿½¿Êä¥ήg§IRBP ź·øǭաw_ì¹ðÖÎðÌIL-27(rIL-27)IL-35(rIL-35)¥ͳƈw^

IFN-γ, IL-17έά¥3ˤɳELISAτΨ¥PCR

CD4 ԴʇTОѐ¥Гҙw^ʩCD3ʩıj

^7ˤɳFACS¥ήg̩ҩw_ӡŨǝȍ̩ҩw_cТ̓dSrIL-27d0, d7IFN γτΨ¥ǹƈu{^EAUƱ

̃IL-17έά¥ʧŸw_rIL-35IL-17έάɰՉ¥ƣukk^Ύπɳ̃
IFN-γτΨ¥ǹƈu{_EAUƱ̃jg

rIL-27Th1ΞλφӡŨǝȍ(T-bet) τΨ¥ǹƈu{^Th17ΞλφӡŨǝȍ(RORγt)τΨ¥ʧŸwk^rIL-35T-bet,
RORγt τΨɰՉ¥ƣuk_ScТӁdIL-27ΎπƱ̃Th17¥ό˄Ÿɷy¡ô˟^IL-35Ύπɳ̃CD4ԴʇTОѐkIFN-γ¥τΨu{^Th1¥Ęy¡ΎπʧŸ̵̭Ԩúy¡ƭёʇkϣǊu¢_ҾՖƵ  ~wX]nW`hB·ŰĿõϙϸĞҔу ɣ҇ƗԻʢȻ  ЯƲ̽ϯȑӂɠòЯƲ̽ϯȑűԕτҔҜ˥ćԑѻ^ŚνӔͣƐĴή^¹î¿ÊïóíĮ͸Ĵή^ʩѻĴή^άıԫɷ̵ё¥τˈy¡ѻ̛lǿo^ӫɖs¢¥ƫњŤΫǸŋŝƐŷήwhghƋmlŰ

g¡_¤¢¤¢ćԑѻ Lactobacillus salivarius WB21 (Ls WB21) ̛ϒϊw^̇ѻlƫњŤΫǸúi¡ɰՉg̩ҩw

m_̇ϙϸ Ls WB21 ԏƲÅÚîÈÌƫѩʧŸƊ̓¥˩ky¡^ƫѩʌу¥ȩӉČԔϋ̩ëðÆäƐµï¿°óÔóҲե¥șˡw^Ls WB21 ԏƲÅÚîÈÌƫѩ̽ƽРиˑǐƊ̓lf¡s¥˩kw_^ÅÚîÈÌһǙƝԳʇlf¡ԹȞуըհуʁή¥ʐȗw^Ls WB21 ԏƲ°«í¥Ԧτw^}Ɗ̓¥̽ƽοʌу¥ȩӉwÛëÁàȩΕČԔϋ̩͇ӣҲե̩ҩw_ćԑѻԑ¥έάw^hҋοɆϣǊu¢űԿu¢¡sk^hҋԨӶʇlg¡_}s 2 ϲ՚ćԑѻԏƲÅÚîÈÌˌƨόɳhҋì¿µǝȍǽƐ¥ҿ_ćԑѻg̮`ƫѩʧŸſg11^ƫѩƫњŤΫǸúi¡ɰՉ¥ҿ¡ɿҜlf¡_̇ϙϸ^ÖÒ³Ç°óíԏƲƫњ·©ή¾­í^ǵƐÁÇíØì
¾Ï¬äò¶ìÇíìÇðԑČ±ì¬äò³³ê¬®³¿ 3 ϲ˿Ɗʝű¥ԏƲwÌïóÇ^ĐԚ«°ð΀ͭg^ƫѩƫњŤΫǸ^ƫњŤОѻƪúi¡ɰՉ¥ҿ_ҾՖƵ   Ť ŭÇƬúżSĹ0=ğBğ¾ťũF§ķEƟ:Qōŕ ϙϸĞҔу ǧ÷ϼӒʢȻƫњ͗ςȑ ̽ƽοȑτҔҜ˥÷χԧѿӡˇ¥άx¡Оѐнw^τάӽϱjq¡ǾяѿkϧСǯ¥Сԧѿӡˇ^l¦Ɛӽϱjq¡÷χОѐ̅űƐОѐǽƐlʹr¢¡_w̺ɑΠʖʉɑφ÷χԧѿӡˇ¥ӗsyʝıОѐ¥ɶ¡slm¢^så±ÏÀäҥ˩ɱϻ^ŦάƓςjq¡ɘОѐОѐÃó¿w˿Ɗŷήm¡ƭёʇlf¡_ ¤¢¤¢^r̽՚Ų̽̽яôԌf¡»ó×±ííóÛОѐϒϊw^ƴԌΞλφɘОѐâó±óf¡ '=E ȩy¡Śν̕ѱ¥ҏ

ҥ̑¥w

m_

ӫɖs¢l^®Îåíӕz^®Îåíӕ˄y¡˄Ʋ÷χÁåðÌѴОѐűƐy¡gh®×Ëð¿l҂ϵwf¡_̇ϙϸ^sОѐ¥ŦάƓςОѐÃó¿ňҘw Ŧȗоw^}ƭёʇ¥  k¡s¥ϊφw

   ϙϸǿҤφϞ

g¡_ӲþСӽȮ̍Ⱥ̂¥τҔy¡_ҾՖƵ   ƫƮFdcFĲĽóEƟ:QōŕϙϸĞҔу į҇ ƚłʢȻƫњ͗ςȑ ũ̴о̽ȑτҔҜ˥ǁǚ̵ё¡Ξ˿ƆȑφΫǸf¡՗զյìæËìð¶¿ØóÍlӴgΞ˿ĞӃ¥Ǖ¦g¡շ}ĞӃ˽ПέΝf¡¹ëó¸ðզ̖Ӡʇ¥úiյ¹ëó¸ðрҭɳńՠf¡ì¾ð͋ԑƐϱɟզӕφʇΠ¥ɈƮy¡շÖÌΤıø՗զյ÷ћզjȀѠզ¹ëó¸ðԖճµg/mg ĈΙզմì¾ð͋ԑƐϱɟճ͋ԑƐì¾ðԖփmol/mol ¹ëó¸ðմ¥ȗԖű̑ws£յø՗զΞ˿¹ëó¸ðʇΠ¥˿y¡sl¤kշø՗զ¹ëó¸ðԖǿoյƦȩ͋ԑƐì¾ðԖȳkշ¹ëó¸ðԖ͋ԑƐì¾ðԖȀmņĖɋlflյø՗զ͋ԑƐ
ì¾ðԖņĖɋlȲukշ¹ëó¸ðԖǿgø՗զǁǚȩy¡̖Ӡʇ¥˿12wg¡ƭёʇlfյø՗զΞ˿ƆȑφΫǸlАՆȲѐıрҭɳńՠǝȍ¹ëó¸ð½çÞïðɰՉwյì¾ð͋ԑƐ¥Įøu{յ¹ëó¸ðаЩɮʝɰՉwg¡ƭёʇl˅ͻu¢¡շҾՖƵ   Ů ŻŚƤÕB¤ľƚ°hphϙϸĞҔу Ȁ˫ ƚ˩ʢȻЯƲƓȑӂɠ Ťϯȑűԕ τҔҜ˥їҎЇԹȞ^ʞlǢāҜ̿ǝf¡z^Ȧmǝf^Ǣ͉οwԔҜʇlǹw

̃φ͗ς͝̅Ԧτu¢ӿlɴ`˩kslϣǊu¢ҜĘӆ¡ЀպĭƟ

g¡_wkwl^}ɳԄπ¥Ӣ͸y¡δgg_ӫɖʆʇ̃ї̥Ǵjq¡űȍ̵̭ò½¶ÎíĨ^ї҈ҎτπɳїҎͤğǾǝȍlї̥Ǵ¥ʳȀòǹʎu{¡g¡l^ʞ`˽ӫ^ї̥Ǵǹʎӽϱjq¡«ðÅóï«³ð(IL)23-17 axis ԔҜʇ¥˩kw_̇ϙϸ^ԄĨȍˑǽƋΝЂ¥ήg^ї̥Ǵjq¡ŚνʁЄҎͭїԨԤϛЭЂΎπƦʁ̵̭¥ҥ˩w^˞ҟ͗ς͝̰φw
о¥˃ϸy¡s¥ϊφw

ʒ

g¡_

 ̇ϙϸ^ї҈Ҏ˦̃jq¡ѨΓŚν̵̭ҥ˩¥Ҳ^ˮɖ Toll ̮ƩȠı
TLR2  TLR4 j}øͤ½¶Îí MyD88 l IL23 έάȢúy¡s¥˩kw_^ŏȞїРиk˓Űu¢

(!&

u¢

^˞ҟ 2/;/53/@@=17/A32;=:31B:/?>/AA3?<@m >3?=E7?32=E7<4/;7:F f"%@w ¥ź·y¡Νӕl^ɵ̍ʩԑƐΝӕҸӄ^ї҈ҎɳΎπʑӗΝӕwőos¥˩kw_ėɖɟuї̥Ǵ 7<</A37;;B<7AF jq¡ãµï¶ì©òâµïÙ¨ó¾ɱƃj >3?71FA3
ҎͭїԨԤɱƃg̩ҩ¥ҏ_13 ÌƘƅ áø  âåćƘŒÑŉőŗÍÑùļŅōŕÈŇêøăāĚ-Ū°FûªBĿõFªïE37QĶÊhphBcvFòř.
«±  âƞFōŕĳģE×:QÌƘƅɕʝ 26 ɖ 7 ˾ 30 ˤ^ϫȿ̽ϯȀȑ 504 ƯȜjġϙϸϙϸτҔħlԦŎu¢^̷gğø̭ʝǇ¡þԧұĻԨ¤¡ǾԌұĻȊǇħlԦk¢_}ǰƼ¥ğøϣy_ұĻȊǇħ̭ʝճĎƔՈՌմЍǢ±ð¼¿ȀȑŬ˕ˀ ɀΖ˵Ի  (ќρȑ^άƐȑ)ęǢÎðÌȀȑƵҶ˕ˀ ը̴̺ҏ  (άΝΝΪȑ^űȍάΝȑ)ĄɅȀȑƵҶ˕ˀ    ̒ ŋʀճȊǇԣմ(¸Òäϯȑ^űȍάΝȑ)ҪϙϸτҔħjgƱϙϸҾՖʯɭуkӕμ¥ƸИ 30 űϙϸʝ̓ҵО¥цƨw

_τҔу}Ֆϊ̷ӳf¡_1. ˦Ʉ ͨԑƐ RNA ˁ԰̵̭

2. ďƫŞԊԑƐÐµî°ÇÍԄĨʏǰτΨλɑ

3. ͐ԇǈԊըհуƫњБѢОѐűȍάΝȑφǮωgϙϸQ ԑƐ¿Ìî¿¡·ëÇÒ»«ÌОѐсƐτl¦Ԩľ
4. ̤͢ĵȍ

µïâÇðìæËìð¶ǝȍ Rdh54 ¡̕ѱıȓȗƐ̵̭Q ÁðÌïå©ΞλφÖ¿Ìð Cse4 ¥Ęw˞ҟĴήg

5. ˤըϐЙτl¦¥ʧŸy¡©áÌó½¿̵̭

6. ȿԌɗư

TRP űȍ¡ϝРиϘ΍Ɛξʌτπ̵̭ҥ˩

7. ͕ Ϫɯ̽ƽοοƟѻΰ̍ TLR ì²ðÍ¡Дȷοʇљπτπ

8. ЍίԼҗS-PRG «°ð΀ŰͭlƫњΫǸƣyɰՉ

9. ɄԕɢôșեφѨɌŚνʇhѢΎjq¡ IL-27  IL-35 ɱƃ

10. ɣ҇ƗԻÛïÔ«°Êªµ¿ƫњξʌ

11. ǧ÷ϼӒОѐǭաʦҐ¥ήg̽̽ƽРиŦάԨy¡ϙϸ

12. į҇ƚł՗զ¹ëó¸ðΞλʇԨy¡ϙϸ

13. Ȁ˫ƚ˩їҎЇԹȞŚνòԑƐ¿Ìî¿

14τҔħŧՑ˦ɄͨϙϸĞҔk̇ċ̪Ӛ˥Ԩy¡Ҽ˩lf_}¢¡̇ċ̪˽ӫϥħφ}ԔҜʇl͟ϊu¢ʁ¥ϙϸȀǀՖwsɵg¡aсƐbԨy¡̵̭ҥ˩s¢ȩ^©µÊª×Êªըgϙϸуņ`ϙϸ¥ɬo»áóÌy¡^ɭҴˡҫƞϫȿ̽ϯȀȑɬǡϙϸǮω¥ɮʝy¡s¥ϊʷwg¡_÷ҪτҔҾՖk˩kh^̇ċ̪ʯgʤ^сƐĩhճʟ}Ɵǝ¡մԄĨʏǰĨӿ̵̭koĆԨy¡űȍάΝȑφϙϸ^ըհуΞǏՖ¡ƫњξʌǮϢƣѧɛϙϸ^uї̥Ǵjq¡ԹȞűȍοʖϙϸɚЉǟ¤¡ϙϸ¶íóÛͲʝԌԶf^ņ`Ѩΰɟըgϙϸ¥wτҔu¢ϙϸgz¢ըɟȬԤφϕӄʦҐ¥դķw̓}¢~¢űԕ˽ը͋Ϳf¡_}w
Ӂ˛w

τҔu¢

ҏ¤¢

j

g¡_
^s¢ʝ

}ʝ̓yôͤȑҐԾҷ˙ǿo

g¡_s¢̇ċ̪Ŗș¥Ȉșϣyf¡_ΞЁym^ƱϙϸҾՖ͇ӣφȳĖ˙ɭċуӹҏu¢z^üε˽ŗϽʦҐ¥ϵ̫φМ˦o˂ήw^Ѩwg¡Ԩ¤˿ʒоʝ̓¥ɶ¡_s¢ϙϸæÇÝó½êðըu^ņ`ϙϸуёƆըuӓΝfċ̪РиӼǕ̺wu¥Ұ˩wϙϸlτȺu¢g^̇g¡_̽ϯȀȑghΞɼlάku¢^̽ϯűԕg¡sըoұĻu¢¡_sċ̪ЀôǜϙϸτҔħճՅşԦմ͇

̞̓ϙϸlτȺwj^ǾԌϙϸу

ŠƴϙϸϒșŖșwf¡_ėɳċ̪ŤƱϙϸ¶íóÛԧ^ƣǢŤǾλűԕϙϸуēͤ˻¡ʳȀôȼϙϸτȺl̃ɲu¢¡_ͪǾϙϸСե¥ʶѷgϙϸу˂ήlu¢s^s¢k˻¡τȺlĊʐu¢¡_ǋôėɳˑǐymΏw^ǮϢϯȑуѧɛϙϸуēͤ̵ħ¥ǹƈy¡s^u¡ϙϸͣƋͣʇƐʝ̓l̃ɲm¡ʅ¤¢¡_sϙϸǰƼħ^ΪċԣƣȑԣƢƈlf^ȀʢըʢkԂŲƉҧЂ¥ɶ¡slmsk^ȀȑŝıϙϸƷ÷Ϊҥʒ͊Өlhkli_shwϙϸτȺl^˕ыƦˬu¢^˞wgϕӄɚgҠԕ¥ʶ̽ϯƓաʝlu¢¡sl̃ɲu¢¡_
ğ÷


15

  â4P  â«±LAFōŕøĕ
ńžƈć
1.

Yamada S, Tokumoto M, Tatsumoto N, Taniguchi M, Noguchi H, Nakano T, Masutani K,
Ooboshi H, Tsuruya K, Kitazono T. Phosphate overload directly induces systemic
inflammation and malnutrition as well as vascular calcification in uremia. Am J Physiol.
Renal. Physiol. ̗ҽ˿^306, F1418-1428 (2014)

2.

Wakisaka Y, Ago T, Kamouchi M, Kuroda J, Matsuo R, Hata J, Gotoh S, Isomura T, Awano
H, Suzuki K, Fukuda K, Okada Y, Kiyohara Y, Ooboshi H, Kitazono T; REBIOS
Investigators. Plasma S100A12 is associated with functional outcome after ischemic
stroke: Research for Biomarkers in Ischemic Stroke. J. Neurol. Sci. ̗ҽ˿^340, 75-79(2014)

3.

Kiyohara T, Kamouchi M, Kumai Y, Ninomiya T, Hata J, Yoshimura S, Ago T, Okada Y,
Kitazono T; Fukuoka Stroke Registry Investigators (Ooboshi H). ABCD3 and ABCD3-I
scores are superior to ABCD2 score in the prediction of short- and long-term risks of stroke
after transient ischemic attack. Stroke ̗ҽ˿^45, 418-425 (2014)

4.

Ishitsuka K, Kamouchi M, Hata J, Fukuda K, Matsuo R, Kuroda J, Ago T, Kuwashiro T,
Sugimori H, Nakane H, Kitazono T; FSR Investigators (Ooboshi H). High blood pressure
after acute ischemic stroke is associated with poor clinical outcomes: Fukuoka Stroke
Registry. Hypertension ̗ҽ˿^63, 54-60 (2014)

5.

Morotomi T, Kitamura C, Okinaga T, Nishihara T, Sakagami R, Anan H. Fever-Range
Heat Stress Induces Thermotolerance in Odontoblast-leneage cells, Archives of oral biology̗ҽ˿^59, 741-748 (2014)

6.

Nishida E, Miyaji H, Takita H, Kanayama I, Tsuji M, Akasaka T, Sugaya T, Sakagami R,
Kawanami M. Graphene oxide coating facilitates the bioactivity of scaffold material fortissue engineering, Jpn. J. Appl. Phys. ̗ҽ˿^53 06JD04 doi:10.7567/JJAP.53.06JD04,(2014)

7.

Matsuura T, Tokutomi K, Sasaki M, Katafuchi M, Mizumachi E, Sato H. Distinct
characteristics of mandibular bone collagen relative to long bone collagen: relevance toclinical dentistry. BioMed. Res. Int. ̗ҽ˿^DOI: 10.1155/2014/769414, (2014) (in press)8.

Matsuura T, Sasaki M, Katafuchi M, Tokutomi K, Mizumachi E, Makino M, Naito T, Sato
H. Characterization of the bone matrix and its contribution to tooth loss in humancadaveric mandibles. Acta Odontol. Scan. ̗ҽ˿^DOI: 10.3109/00016357.2014.903517,(2014) (in press)9.

Matsuura T., Mizumachi E, Katafuchi M, Tokutomi K, Kido H, Matsuura M, Sato H.
Sex-related differences in cortical and trabecular bone quantities at the mandibular molar.

16

J. Hard Tissue Biol. ̗ҽ˿^23, 267-274 (2014)
10. Suzuki N, Yoneda M, Tanabe K, Fujimoto A, Iha K, Seno K, Yamada K, Iwamoto T, Masuo
Y, Hirofuji T. Lactobacillus salivarius WB21-containing tablets for the treatment of oralmalodor: a double blind, randomized, placebo-controlled crossover trial. Oral Surg, OralMed. Oral Pathol. Oral Radiol. ̗ҽ˿^117, 462-469 doi;10.1016/j.oooo. 2013.12.400. (2014)
 Nakano Y, Takeshita T, Kamio N, Shiota S, Shibata Y, Suzuki N, Yoneda M, Hirofuji T,
Yamashita Y. Supervised machine learning-based prediction of oral malodor based on the
microbiota in saliva samples. Art. Int. Med. ̗ҽ˿^ 





12. ġқȕĘ^ԙ̄ȅȃ^ЍίԼҗ^ȽίΆô^ɣ҇ƗԻ^ƫѩ԰ơ¥Ɗёy¡ƫњǅǑ҅ÌïóÇſѧɛφұĻ^ˤ̽ŁȎҷ ̗ҽ˿^(2014) (in press)
13. Suzuki N, Yoneda M, Haruna K, Masuo Y, Nishihara T, Nakanishi K, Yamada K, Fujimoto
A, Hirofuji T. Effects of S-PRG eluate on oral biofilm and oral malodor. Archives of Oral
Biology ̗ҽ˿^59(4), 407-413 (2014).
14. Hanada H, Ohno J, Seno K, Ota N, Taniguchi K. Dynamic changes in cell-surface
expression of mannose in the oral epithelium during the development of graft-versus-hostdisease of the oral mucosa in rats. BMC Oral Health ̗ҽ˿^15, 5 (2014)
15. Ota N, Ohno J, Seno K, Taniguchi K, Ozeki S. In vitro and in vivo expression of aldehyde
dehydrogenase 1 in oral squamous cell carcinoma. Int. J. Oncol. ̗ҽ˿^44, 435-442 (2014)16. Sawa Y, Takata S, Hatakeyama Y, Ishikawa H, Tsuruga E. Expression of toll-like receptor
2 in glomerular endothelial cells and promotion of diabetic nephropathy by Porphyromonas
gingivalis lipopolysaccharide. PLoS One ̗ҽ˿^9, e97165 (2014)
17. Wu X, Fukushima H, North BJ, Nagaoka Y, Nagashima K, Deng F, Okabe K, Inuzuka H,
Wei W. SCFβ-TRCP regulates osteoclastogenesis via promoting CYLD ubiquitination.
Oncotarget. ̗ҽ˿^30, 4211-21 (2014)18. Sekigucgi T, Ito R, Hayakawa H, Sekiguchi M. Elimination and Utilization of Oxidized
Guanine Nucleotides in the Synthesis of RNA and its Precursors. J. Biol. Chem. ̗ҽ˿^288, 8128-35 (2013)
19. Nie B, Gan W, Shi F, Hu GX, Chen LG, Hayakawa H, Sekiguchi M., Cai JP. Age-dependentaccumulation of 8-oxoguanine in the DNA and RNA in various rat tissues. Oxidative
Medicine and Cellular Longevity ̗ҽ˿^ID 303181, http://dx.doi.org/10.1155/2013/303181(2013)
20. Inokuchi H, Ito R, Sekiguchi T, Sekiguchi M. Search for protein required for accurate gene
expression under oxidative stress: Roles of guanylate kinase and RNA polymerase. J. Biol.
Chem. ̗ҽ˿^288, No. 46, 32952-32962 (2013)
21. Ota N, Izumi K, Okamoto Y, Toshitani K, Nakayama K, Fukuzawa H, Ozeki S, Ikebe T.

17

Tapia’s syndrome following the orthoghathic surgery under general anaesthesia. Journalof Oral and Maxillofacial Surgery, Medicine, and Pathology ̗ҽ˿^25, 52-54, (2013)
22. Sano S, Sakagami R, Sekiguchi M, Hidaka M. Stabilization of MAPO1 by specific binding
with folliculin and AMP-activated protein kinase in O6-methylguanine-induced apoptosis.
Biochemical and Biophysical Research Communications ̗ҽ˿^430, 2, 810-815 (2013)
23. Iha K, Suzuki N, Yoneda M, Takeshita T, Hirofuji T. Effect of mouth cleaning withhinokitiol-containing gel on oral malodor: a randomized, open-label pilot study. Oral Surg,
Oral Med. Oral Pathol. Oral Radiol. ̗ҽ˿^ 116(4), 433-439. doi: 10.1016/j.oooo.
2013.05.021. (2013)24. Suzuki N, Yoneda M, Hirofuji T. Mixed red-complex bacterial infection in periodontitis. Int.
J. Dent. ̗ҽ˿^2013, Article ID 587279, 6 pages,
http://dx.doi.org/10.1155/2013/587279 (2013)
25. Murakami H, Okamura K, Aoki S, Sakagami R, Yamazaki J. Association of caspase-14 andfilaggrin expression with keratinization of the oral mucosa and reconstruction culture rat
models. Journal of Periodontal Research ̗ҽ˿^doi: 10.1111/jre.12152 (2013)
26. Mori N, Ohno J, Sakagami R, Hayakawa T, Fukushima T. Cell viabilities andbiodegradation rates of DNA/protamine complexes with two different molecular weights ofDNA. J. Biomed. Mater. Res. B Appl. Biomater. ̗ҽ˿^101, 743-751 (2013)
27. Ohgi K, Kajiya H, Okamoto F, Nagaoka Y, Onitsuka T, Nagai A, Sakagami R, Okabe K.

Anovel inhibitory mechanism of nitrogen-containing bisphosphonate on the activity of Clextrusion in osteoclasts. Naunyn Schmiedebergs Arch Pharmacol. ̗ҽ˿^386, 589-598(2013)
28. Namura S, Ooboshi H, Liu J, Yenari MA. Neuroprotection after cerebral ischemia. Ann. N.
Y. Acad. Sci. ̗ҽ˿^1278, 25-32 (2013)
29. Abe K, Uchiyama S, Matsubara E, Muramatsu S, Atsuta N, Kitagawa K, Iguchi Y, Ooboshi
H, Kaji R, Terao Y. IT network establishment for neuropatients. Rinsho Shinkeigak ̗ҽ˿^53, 1155-1158 (2013)
30. Seno K, Ohno J, Ota N, Horofuji T, Taniguchi K. Lupus-like oral mucosal lesions in
mercury-induced autoimmune response in Brown Norway rat. BMC Immunol. ̗ҽ˿^14,
47 (2013)
31. Nishimura S, Sawa Y. Risk factors to cause tooth formation anomalies in chemotherapy of
paediatric cancers. Eur. J. Cancer Care ̗ҽ˿^22, 353-360 (2013)
32. Takata S, Sawa Y, Expression of Toll-Like Receptor 4 in Glomerular Endothelial Cells
under Diabetic Conditions. Acta Histochem. Cytochem. ̗ҽ˿^46, 35-42 (2013)
33. Uchiyama , Sawa Y. Altered dynamics in the renal lymphatic circulation of type 1 and type18

2 diabetic mice. Acta Histochem. Cytochem. ̗ҽ˿^46, 97-104 (2013)
34. Tsutsumi T, Kajiya H, Fukawa T, Sasaki M, Nemoto T, Tsuzuki T, Takahashi Y, Fujii S,
Maeda H, Okabe K. The potential role of transient receptor potential type A1 as amechanoreceptor in human periodontal ligament cells. Eur J Oral Sci. ̗ҽ˿^121, 538-44(2013)
35. Tsutsumi T, Kajiya H, Goto KT, Takahashi Y, Okabe K. Hyperocclusion up-regulates
CCL3 expression in CCL2- and CCR2-deficient mice. J. Dent. Res. ̗ҽ˿^92, 65-70 (2013)
36. Shi F, Nie B, Gan W, Zhou XY, Takagi Y, Hayakawa H, Sekiguchi M, Cai JP. Oxidative
damage of DNA, RNA and their metabolites in leukocytes, plasma and urine of Macaca
mulatta: 8-oxoguanosine in urine is a useful marker for aging. Free Radic. Res. ̗ҽ˿^46,
1093-98 ճ2012մ
37. Shi F, Gan W, Nie B, Takagi Y, Hayakawa H, Sekiguchi M, Cai JP. Greater nucleic acids
oxidation in the temporal lobe than the frontal lobe in SAMP8. Neuroreport ̗ҽ˿^23,
508-512 (2012)
38. Gan W, Nie B, Shi F, Xu X, Jianchang Qian J, Takagi Y, Hayakawa H, Sekiguchi M, Cai
JP. Age-dependent increases in the oxidative damage of DNA, RNA and their metabolites
in normal and senescence-accelerated mice analyzed by LC-MS/MS: urinary
8-oxoguannosine as a novel biomarker of aging. Free Radical Biology & Medicine ̗ҽ˿^52, 1700-1707 (2012)
39. Zhang LQ, Dai DP, Gan W, Takagi Y, Hayakawa H, Sekiguchi M, Cai JP. Lowered Nudix
type 5 (NUDT5) expression leads to cell cycle retardation in HeLa cells. Mol. Cell. Biochem.
̗ҽ˿^363, 377-384 (2012)
40. Okamoto Y, Ohkubo T, Ikebe T, Yamazaki J. Blockade of TRPM8 activity reduces theinvasion potential of oral squamous carcinoma cell lines. Int. J. Oncol. ̗ҽ˿^40
1431-1440 (2012)
41. Ikebe T, Yamasaki K, Takamune Y, Nakayama H, Shinohara M. Reduced expression of
nuclear factor kB in oral mucosa undergoing preoperative chemoradiotherapy. Oral
Science Int. ̗ҽ˿^9, 33-37, (2012)
42. Fukawa T, Kajiya H, Ozeki S, Ikebe T, Okabe K. Reactive oxygen species stimulates
epithelial mesenchymal transition in normal human epithelial keratinocytes via TGF-betasecretion. Exp. Cell Res. ̗ҽ˿^318, 1926-1932 (2012)
43. Tanaka T, Nakayama H, Yoshitake Y, Irie A, Nagata M, Kawahara K, Takamune Y,
Yoshida R, Nakagawa Y, Ogi H, Shinriki S, Ota K, Hiraki A, Ikebe T, Nishimura Y,
Shinohara M. Selective inhibition of nuclear factor-kB by nuclear factor-kB essential
modulator-binding domain peptide suppresses the metastasis of highly metastatic oral

19

squamous cell carcinoma. Cancer Sci. ̗ҽ˿^103, 455-463, (2012)
44. Fujikane R, Sanada M, Sekiguchi M, Hidaka M. The identification of a novel gene, MAPO2,
that is involved in the induction of apoptosis triggered by O6-methylguanine.

PLoS ONE̗ҽ˿^7, 9, e44817 (2012)
45. Lim TH, Fujikane R, Sano S, Sakagami R, Nakatsu Y, Tsuzuki T, Sekiguchi M, Hidaka M.
Activation of AMP-activated protein kinase by MAPO1 and FLCN induces apoptosis
triggered by alkylated base mismatch in DNA. DNA Repair ̗ҽ˿^11, 259-266 (2012)
46. Masuo Y, Suzuki N, Yoneda M, Naito T, Hirofuji T. Salivary β-galactosidase activity affects
physiological malodour. Arch. Oral Biol. ̗ҽ˿^57(1), 87-93 (2012)
47. Takeshita T, Suzuki N, Nakano Y, Yasui M, Yoneda M, Shimazaki Y, Hirofuji T,
Yamashita Y. Discrimination of the oral microbiota associated with high hydrogen sulfide
and methyl mercaptan production. SCIENTIFIC REPORTS ̗ҽ˿^2, 215 DOI:
10.1038/srep00215 (2012)
48. Suzuki N, Tanabe K, Takeshita T, Yoneda M, Iwamoto T, Oshiro S, Yamashita Y, Hirofuji
T. Effects of oil drops containing Lactobacillus salivarius WB21 on periodontal health andoral microbiota producing volatile sulfur compounds. J. Breath Res. ̗ҽ˿^6, 017106(7pp) doi:10.1088/1752-7155/6/1/017106 (2012)
49. Yoneda M, Suzuki N, Masuo Y, Fujimoto A, Iha K, Yamada K, Iwamoto T, Hirofuji T.
Effect of S-PRG eluate on biofilm formation and enzyme activity of oral bacteria. Int. J.
Dent. ̗ҽ˿^2012, article ID 814913, 6pages, doi:10.1155/2012/814913. (2012)
50. Yoneda M, Suzuki N, Macedo SM, Fujimoto A, Iha K, Koga C, Matsuura M, Hirofuji T. The
variable etiology of oral pathologic halitosis: a case series. Smile Dental Journal ̗ҽ˿^
7 (3), 50-56 (2012)
51. Yoneda M, Kashio N, Uchida H, Suzuki N, Matsuura H, Naito T, Koga C, Yasukochi H,
Matsuura M, Hirofuji T. Awareness among dental hygienists with regard to treatment
options for halitosis. Int. J. Clin. Prev. Dent. ̗ҽ˿^8 (3), 173-179 (2012)52. ЍίԼҗ^ƬӑƕȰ^ԙ̄ȅȃ^ըƷǂț^Ť҇ɽ^ӈ̋ϙƺ^ԗŘѳԊ^ɣ҇ƗԻ^ƫѩʈʄГϧϯοԯŜԯƈς¥Ҝwπĸ^ˤ̇̽ϯɾӟƓȑħԾҷ ̗ҽ˿^27(1, 2),
31-36 (2012)53. ζԕŔȍ^ԙ̄ȅȃ^ЍίԼҗ^ɣ҇ƗԻ ćԑѻԏƲ̽Ϡſ©Ôð×óÀƫњґάˑǐƊ̓gѧɛϙϸ^ˤ̽ŁȎҷ ̗ҽ˿^55(3), 219-226 (2012).

54. Kuboki T, Ichikawa T, Baba K, Hideshima M, Sato Y, Wake H, Nagao K, Ueda Y, Ono Y,
Tamaki K, Tsuga K, Sakurai K, Sato H, Ishibashi K, Yatani H, Ohyama T, Akagawa Y,
Hirai T, Sasaki K, Koyano K. A multi-centered epidemiological study evaluating thereliability of the treatment difficulty indices developed by the Japan Prosthodontic Society.

20

J. Prosthodont. Res. ̗ҽ˿^56, 71-86 (2012)
55. Shichita T, Ago T, Kamouchi M, Kitazono T, Yoshimura A, Ooboshi H. Novel therapeuticstrategies targeting innate immune responses and early inflammation after stroke. J.
Neurochem. ̗ҽ˿^123S2, 29-38 (2012)
56. Shichita T, Hasegawa E, Kimura A, Morita R, Sakaguchi R, Takada I, Sekiya T, Ooboshi H,
Kitazono T, Yanagawa T, Ishii T, Takahashi H, Mori S, Nishibori M, Kuroda K, Akira S,
Miyake K, Yoshimura A. Peroxiredoxin family proteins are key initiators of post-ischemic
inflammation in the brain. Nat. Med. ̗ҽ˿^18, 911-917 (2012)
57. Arimura K, Ago T, Kamouchi M, Nakamura K, Ishitsuka K, Kuroda J, Sugimori H,
Ooboshi H, Sasaki T, Kitazono T. PDGF receptor ß signaling in pericytes following
ischemic brain injury. Curr. Neurovasc. Res. ̗ҽ˿^9, 1-9 (2012)
58. Kuwashiro T, Sugimori H, Ago T, Kamouchi M, Kitazono T; FSR Investigators (Ooboshi H).
Risk factors predisposing to stroke recurrence within one year of non-cardioembolic stroke
onset: the Fukuoka Stroke Registry. Cerebrovasc. Dis. ̗ҽ˿^33, 141-149 (2012)
59. Ozasa R, Ohno J, Iwahashi T, Taniguchi K. Tumor-induced lymphangiogenesis in cervicallymph nodes in oral melanoma-bearing mice. J. Exp. Clin. Cancer Res. ̗ҽ˿^31, 83(2012)
60. Kaji C, Kato Y, Sawa Y. The expression of podoplanin and classic cadherins in the mousebrain. J. Anat. ̗ҽ˿^220, 435-446 (2012)
61. Yamanouchi K, Tsuruga E, Oka K, Sawa Y. Fibrillin-1 and fibrillin-2 are essential for
Formation of thick oxytalan fibers in human nonpigmented ciliary epithelial cells in vitro.
Connect. Tissue Res. ̗ҽ˿^53, 14-20 (2012)
62. Nakatomi Y, Tsuruga E, Sawa Y, Intracellular interaction of EMILIN-1 with fibrillin-1 inhuman periodontal ligament cells. Orthodontic Waves ̗ҽ˿^71, 66-69 (2012)
63. Tsuruga E, Oka K, Hatakeyama Y, Sawa Y. Latent transforming growth factor-β binding
protein 2 negatively regulates coalescence of oxytalan fibers induced by stretching stress.
Connect Tiss. Res. ̗ҽ˿^53, 521-527 (2012)
64. Kaji C, Tsujimoto Y, Kaneko, MK, Kato Y and Sawa Y. Immunohistochemical examinationof novel rat monoclonal antibodies against mouse and human podoplanin. Acta Histochem.
Cytochem. ̗ҽ˿^45, 227-237 (2012)
65. Kaneko MK, Sawa Y, Kato Y. A chimeric anti-podoplanin antibody suppresses tumor
metastasis via neutralization and antibody-dependent cellular cytotoxicity. Cancer Sci. ̗ҽ˿^103, 1913-1919 (2012)21

66. Oka K, Tsuruga T, Hatakeyama Y, Sawa Y. Roles of collagen and periostin expression by
cranial neural crest cells during soft palate development. J. Histochem. Cytochem. ̗ҽ˿^60, 57-68 (2012)
67. Oka K, Sawa Y, Cellular turnover in epithelial rests of Malassez in the periodontal
ligament of the mouse molar. Eur. J. Oral Sci. ̗ҽ˿^120, 484-494 (2012)
68. Okabe K, Okamoto F, Kajiya H.Odontoclasts and calcitonin. Clin. Calcium. ̗ҽ˿^22,
19-26 (2012)
69. Masuyama R, Mizuno A, Komori H, Kajiya H, Uekawa A, Kitaura H, Okabe K, Ohyama K,
Komori T. Calcium/calmodulin-signaling supports TRPV4 activation in osteoclasts andregulates bone mass. J. Bone Miner. Res. ̗ҽ˿^27, 1708-21 (2012)Å Đ
1. Oral Health Care-Prosthodontics, Periodontology, Biology, Research and Systemic
Conditions (ISBN 978-953-51-0040-9) Chapter 9: Relationship between oral malodor andoral microbiota Authors: N. Suzuki, M. Yoneda and T. Hirofuji. Edt by Mandeep Singh
Virdi. In Tech (Croatia), pp 121-130, 2012

"
"
Ñńž
1.

į`̄öȅ^̧ЛôԊ^͌Ƀƍă^ίþ˛ʊ^ԣȿѰϤ^͌͘գи^ƍŃΰԓ^ȁίł˘^ɞɄ˱Ă^ŷӇɗ͗^̴̇ʛôԊ^͛ǒǂȍ^Ťίϼư^͐ԆǈԊ^ȀԨʋ  ̺ɑҤƐ÷χОѐ÷χԧѿϰҏjq¡ IKKalpha ½¶ÎíԨú_Ѐ  ǜˤ̇ƫњϯȑħȑҐԽħ^ɖ  ˾  ˤ ̎Ĕ2.

į`̄öȅ^͌͘գи^ϿȽՙȍ^ƍŃΰԓ^ȁίł˘^ɞɄ˱Ă^ȿ̇ʓɯ^̴̇ʛôԊ^͐ԆǈԊ^ȀԨʋ  ԑƐ¿Ìî¿ȩy¡l¦ʧŸԄĨȍ >  τΨҿЈ¥Ęy¡ОѐсƐҹȱĴή_Ѐ

ǜˤ̇ƫњќρȑħȑҐԽħ^ɖ˾  ˤ ̈ɓɍ3.

ɕɄ͔ɨգ^Ƴ̻̋^̻ίЋł^ȀɁҗư^Ʉԕɢô^Ϙ̴ӿ́  șեφѨɌŚνʇhѢΎjq¡ !  j !  ɱƃ_Ѐ  ǜˤ̇ϑϯȑħЯħ^ ɖ  ˾ ̎ĔԎ

4.

҇̇˶͏^Ӈƫȅȃ^ĥ͞ɗĴ^ЍίԼҗ^Ƚίǂɯ^Όԕʊғ^ɣ҇ƗԻ  ÖÒ³Ç°óí Porphyromonas gingivalis ȩy¡ʩѻĴήƫѩˑǐƊ̓gƓςЇΪȑħЯħòȑҐȀħ^5.

 ɖ  ˾ ˤ ̈ɓɍ

ġқȕĘ^ԙ̄ȅȃ^҇̇˶͏^ĥ͞ɗĴ^΋ďʙ^ϫǦͨ˛^ЍίԼҗ^ɣ҇ƗԻ  ƫѩ԰ơ¥Ɗёy¡ƫњǅǑ҅ѧɛφұĻ_Ѐ  ǜˤ̇ƫѩȑħ^6.

_Ѐ  ǜˤ̇̽ϯ ɖ  ˾ ̎ȀԪɍȽίΆô^ԙ̄ȅȃ^ġқȕĘ^ĥ͞ɗĴ^҇̇˶͏^΋ďʙ^ЍίԼҗ^Ƚίǂɯ^̢ȶԴ22Ę^ѽȶĵԈȍ^ɣ҇ƗԻ ϲ˿Ɗʝű¥ԏƲwƫњǅǑ҅ƫѩʧŸƊ̓_Ѐ ǜˤ̇̽ϯŁȎȑħ˭ȐȑҐȀħ^7.

 ɖ  ˾ ˤ Ȁ͢ɍ

қƟǈü^ԙ̄ȅȃ^҇̇˶͏^ЍίԼҗ^ίԇôʝ^Ƚίǂɯ^ɀŕϕă^ȓʂȀ^ĥ͞ɗĴ^Όԕʊғ^ɣ҇ƗԻ  ćԑѻԏƲÅÚîÈÌlhҋì¿µǝȍúi¡ɰՉѧɛφұĻ_Ѐ  ǜˤ̇̽ϯŁȎȑħ˭ȐȑҐȀħ^8.

 ɖ  ˾ ˤ Ȁ͢ɍ

Όԕʊғ^ȀԕЙ^Ƚίǂɯ^Ӈƫȅȃ^ɣ҇ƗԻ^ëÈÌ̽шΎæËíŚνʁЄP|ѧɛφʖɟԀglŰ¡kօ Ѐ  ǜˤ̇̽ϯŁȎȑħ˭ȐȑҐȀħ^ ɖ  ˾ ˤ Ȁ͢ɍ
9.

ԙ̄ȅȃ^ЍίԼҗ^ίԇôʝ^ɣ҇ƗԻ  ćԑ̣ѻ Lactobacillus salivarius ԏƲÅÚîÈÌlhҋì¿µǝȍúi¡ɰՉ_Ѐ  ǜˤ̇ƫњґάȑħЯħ^ ɖ  ˾ 

ˤ Ζ

̇ɍ
10. ÷̋ƶЦ^ЍίԼҗ^ѹǱҗм^ɀ̋җм^̉̇ΰЗȍ^Ȁȟϕȍ^ԙ̄ȅȃ^ɣ҇ƗԻ  ϫȿ̽ϯȀȑƫњƓςÁðÅóƫѩµìÏÈµʌуű̑^Ѐ  ǜˤ̇̽ƽοȑħ˭ȐȑҐȀħ^ɕʝ  ɖ  ˾   ˤ Ⱦԩɍ11. Nakamura K, Ago T, Arimura K, Makihara N, Nishimura A, Matsuo R, Kuroda J,
Wakisaka Y, Isomura T, Awano H, Suzuki K, Okada Y, Kamouchi M, Kiyohara Y, Ooboshi
H, Kitazono TQOBasic fibroblast growth factor after ischemic stroke in diabetic patients Research for Biomarkers in Ischemic Stroke (REBIOS) -QOInternational Stroke Conference
2014, 2014 ɖ 2 ˾ San Diego
12. Όԕʊғ^ȀԕЙ^ɣ҇ƗԻ^ӇƫԉĂ °óÌÙ¨¾óʧŸ¡ƫњʣɕ÷χσ 1/<13?

@>63?3 ɮʝёǽƐ_Ѐǜˤ̇οΪȑħ^ ɖ  ˾ ɚɁɍ13. ȀԕЙ^Όԕʊғ^ӇƫԉĂ T ОѐŚνʁЄǩƫњБѢοǽjq¡®Ù­µÅóОѐ÷χҢǂʇ̵̭_Ѐǜˤ̇οΪȑħ^ ɖ  ˾ ɚɁɍ14. թίŀӥ^̦ƟɧôԊ^͕Ϫɯ^ϘɄƚă  Дȷοâ¬¿љЕΩıjq¡̽ƽοƟѻΰ̍LPS ¡ TLR2/4 ĺȎʇ»«Ì±«ðτΨ_ˤ̇ՙɺԡȑħЀ  ǜҪʃȑҐӂ΂ħ^ɖ  ˾ ƕѿɍ15. թίŀӥ^̦ƟɧôԊ^͕Ϫɯ^ϘɄƚă Severe Periodontal Disease exacerbate Diabetic

Nephropathy through Toll-like receptor (TLR) 2 and TLR4. Ѐ  ǜ˭Ȑˤ̇̽ƽοȑħȑҐԽħ^ ɖ  ˾ Ⱦԩɍ16. Sawa Y, Takata S, Ishikawa H, Hatakeyama Y, Tsuruga E. Promotion of nephropathy by

Porphyromonas gingivalis lipopolysaccharide in diabetic kidney. J. Dent. Res. 92(S).
92th International Association of Dental Research, 2014  6 " Cape Town
17. ϫɁϬ˛^ȿ̇ȤǻԻ^ԟ͗ȹͨ^ѨҞѸ͗Ԋ^ȿԌɗư  é×³Çðì²óÂ SCF/β-TRCP^іé×³ÇðƐԐМ CYLD ԖφŸɷ¥ĘwĞӃȑħ^ϛզОѐűƐ¥ĿӸy¡_Ѐǜˤ̇զ ɖ  ˾ ȀԪɍ18. ԎЊȯ^ԟ͗ȹͨ^ɳ҇ƈȪȍ^ǯӏư^ȿԌɗư  å±Ï±í¿Ìî¿¡̝̽ѢРи

¹ëó¸ðέάёƈհ¡ǽƐ_Ѐǜˤ̇զĞӃȑħ^23 ɖ  ˾ ȀԪɍ

19. ԣȿѰϤ^ԟ͗ȹͨ^ȿ̇ȤǻԻ^ϫɁϬ˛^ȿԌɗư  ϺМƸ˿Ö¿ß¿ßÑóÌҙſ

#%¡ϛզОѐҌƲԬȞ¥Ęy¡űƐԬȞĴή_Ѐǜˤ̇զĞӃȑħ^ ɖ  ˾ȀԪɍ20. ϫɁϬ˛^Οǳƚă^ȿ̇ȤǻԻ^ԟ͗ȹͨ^ȿԌɗư  Оѐƽ̃jq¡ SCF/β-TRCP¡ Cdh1 ԖφŸɷ̵̭_Ѐ  ǜˤ̇άΪȑħ^ɖ˾ խśɁɍ

21. Κ̠ƕϮ^ǤӇ˵ă^ȿ̇ȤǻԻ^ȿԌɗư^̏ø̺ă  ӉΛѴОѐjq¡ (&%"τΨҥ̑_Ѐ  ǜˤ̇άΪȑħ^ɖ˾ խśɁɍ

22. ԟ͗ȹͨ^Ȁǫɏмȍ^ȿ̇ȤǻԻ^ȿԌɗư  Ù¨óÑ½íƲʝԐМ¡ϛզОѐ ClնӧӮıҿЈ_Ѐ  ǜˤ̇άΪȑħ^ɖ˾ խśɁɍ

23. Hiroshi Hayakawa  Proteins that recognize oxidative RNA damage_Ѐ  ǜˤ̇άƐȑħȀħ^«ðÅóÎ½êÎí½ðá¾¬ä Gene Expression under Oxidative Stress
03-1IS15a 2013 ɖ  ˾ ̲ͦɍ24. ďƫŞԊ^ĥ̎Ϊüȍ^ԨƫΣ^ԨƫϓȂ  ԑМ¿Ìî¿øԄĨȍτΨ̵̭_ˤ̇ԄĨȑħЀցվǜȀħ^ɖ  ˾ ̲ͦɍ25. ĥ̎Ϊüȍ^ďƫŞԊ^ԨƫΣ^ԨƫϓȂ  Ȁѝѻjq¡ցն°³Ã¶©Ïð¥ƸÐµî°ÇÍˁ԰̵̭_ˤ̇ԄĨȑħЀցվǜȀħ^
26. ˤըϐЙ^įԕwjɖ  ˾ ̲ͦɍ^ǧ÷ϼӒ^ԨƫϓȂ  ©áÌó½¿ҹȱӽϱ MAPO1 ȓȗƐ

FLCN  AMPK Ÿɷu¢¡_Ѐ  ǜȀħˤ̇ԄĨȑħ^ɖ  ˾^̲ͦɍ

27. į`̄öȅ^ԣȿѰϤ^͌͘գи^ȁίł˘^ɞɄ˱Ă^þȽńČ^Ƚøǐɧ^ȀԨʋ ͐ԆǈԊ  ԑƐ¿Ìî¿ȩy¡l¦ʧŸԄĨȍ¥ĘwОѐсƐҹȱĴή_Ѐ  ǜˤ̇ƫњϯȑħȑҐԽħ^ɖ˾ˤ ȒԎȝɍ28. ̒ӾȂ^Ϙ̴ôʝ^̤̟͢ȍ  µïâÇðìæËìð¶ǝȍ¸ÒäȓȗЩʶփCse4¥Ęw Rdh54 ̵ё_Ѐ  ǜˤ̇űȍάΝȑħ^ɖ˾ ϧʡɍ

29. Ϙ̴ôʝ^̒ӾȂ^̤̟͢ȍ  ԑƐ¿Ìî¿¡©áÌó½¿փ¬­íÎóπňнƟǝԄĨȍ̶ˊ¡ǹɬ_Ѐ  ǜˤ̇űȍάΝȑħ^ɖ˾ ϧʡɍ

30. Όԕʊғ^ȀԕЙ^Ƚίǂɯ^Ӈƫȅȃ^ɣ҇ƗԻ  ëÈÌŝӟʇŚνʁЄæËíjq¡̽шΎοʖ_Ѐ ǜˤ̇̽ϯŁȎȑħϮ̃ȑҐȀħ^ɖ˾   ˤ ϫȿɍ31. Όԕʊғ^ȀԕЙ^Ƚίǂɯ^Ӈƫȅȃ^ӇƫԉĂ^ɣ҇ƗԻ  °óÌÙ¨¾ó cancer

sphere ɮʝёԨӶ_Ѐ  ǜϫȿ̽ϯȀȑȑħ^ɖ˾  ˤ ϫȿɍ32. ɀŕϕă^ԙ̄ȅȃ^ЍίԼҗ^Ƚίǂɯ^̢ȶԴĘ^҇̇˶͏^ĥ͞ɗĴ^Όԕʊғ^ɣ҇ƗԻ  ÛïÔ«°Êªµ¿¥ήgƫњξʌĊԫЇΪƨɖ˾Р_̽ϯĖԧɇȑħ^ˤ ƵƬȹɍ

33. Όԕʊғ^ȀԕЙ^Ƚίǂɯ^Ӈƫȅȃ^ɣ҇ƗԻ^ЯƲ̽ϯүςϯjq¡Оѐүșӝ_ЯƲ̽ϯƘӅħ^ɖ˾   ˤ ̎Ĕ

34. ĥ͞ɗĴ^ԙ̄ȅȃ^ЍίԼҗȽίǂɯɀŕϕă̢ȶԴĘ҇̇˶͏Όԕʊғ

24˭ƵôĖ^ȓʂȀ^Ŝ͏Āĵȍ^қƟǈü^ġқȕĘ^ɣ҇ƗԻ  ÖÒ³Ç°óíԏƲ¾­
í¥ήgƫњ·©ƫѩˑǐƊ̓^ЯƲ̽ϯƘӅħ^ɖ˾   ˤ ̎Ĕ

35. ҇̇˶͏^ЍίԼҗ^ԙ̄ȅȃ^Ť҇ɽ^ȽίΆô^ɣ҇ƗԻ  ƫѩʈʄГϧϯοԯƈς¥Ҝwπĸ^ˤ̇̽ϯŁȎȑħ^ɖ˾   ˤ Ϯίɍ36. ˭ƵôĖ^ԙ̄ȅȃ^ЍίԼҗ^ȽίΆô^̢ȶԴĘ^қƟǈü^ġқȕĘ^Ƚίǂɯ^ɀŕϕă^҇̇˶͏^ĥ͞ɗĴ^Όԕʊғ^ȓʂȀ^Ŝ͏Āĵȍ^ɣ҇ƗԻ^S-PRG ΀ŰͭlƫњÔ«°ÙªíäƫѩƣyԬȞĴή_ˤ̇̽ϯŁȎȑħ^ɖ˾   ˤ Ϯίɍ

37. Suzuki N, Yoneda M, Tanabe K, Fujimoto A, Iha K, Seno K, Iwamoto T, Yamada K, Masuo

Y, Haruna K, and Hirofuji T, Improvement of oral malodor using Lactobacillus salivarius
WB21-containing tablets. WCPD, 2013 ɖ 10 ˾ 9-12 ˤ Butapest
38. ҇̇˶͏^ԙ̄ȅȃ^ЍίԼҗ^ĥ͞ɗĴ^Ƚίǂɯ^ɀŕϕă^̢ȶԴĘ^Όԕʊғ^ɣ҇ƗԻ^ƫѩԨӶОѻȩy¡ÖÒ³Ç°óíʩѻĴήÖÒ³Ç°óíԏƲ¾­í¡ƫњ·©ƫѩˑǐƊ̓_Ѐ  ǜˤ̇ƫѩȑħ^ɖ˾  ˤ ̲ͦɍ39. ĥ͞ɗĴ^ԙ̄ȅȃ^ЍίԼҗ^Ƚίǂɯ^ɀŕϕă^̢ȶԴĘ^҇̇˶͏^Όԕʊғ^˭ƵôĖ^ȓ ʂȀ^Ŝ͏Āĵȍ^қƟǈü^ġқȕĘ^ɣ҇ƗԻ  ÖÒ³Ç°óíԏƲ¾­í¥ήgƫњ·©lƫѩƣƫњŤΫǸúi¡ɰՉ^Ѐħ^ ǜˤ̇̽ϯŁȎȑħ˭ȐȑҐȀɖ  ˾   ˤ ϫȿɍ40. ̏ͧ͠ʀ^ЍίԼҗ^ԙ̄ȅȃ^ȿίѲмȍ^҇̇˶͏^ɣ҇ƗԻ  ԣ̃ԧʍu¢ƫњλɑʔlƫњĈΙȩy¡ůкͬȄwπĸ_Ѐg ǜˤ̇̽ϯŁȎȑħ˭ȐȑҐȀħ^ɖ  ˾   ˤ ϫȿɍ
41. Mori N, Washino K, Iwata T, Yoshida T, Fukushima T, Sakagami R, Yamato M, Okano T.

Optimalconditions

forcreating

rat

periodontal

ligament-derived

multipotent

mesenchymal stromal cell (RPDL-MSC) sheets . 12thCELL TRANSPLANT SOCIETY, 
2013 ɖ Milan
42. ̏ͧȵʀ^į`̄м˵ȍ^͋γ̘мΪ^ΚͷöƕЪ^į҇ƚł  ø՗զāҜզǮӕʝűԌĭΞλʇ QǛщզ͇ӣQ_ ˤ̇ƫњ«ðÛëðÌȑħЀɖǜĄɅːԌȑҐȀħ^˾ Ŷɞɍ

43. Nakamura K, Arimura K, Ago T, Makihara N, Isomura T, Watabe W, Awano H, Suzuki K,

Kamouchi M, Kiyohara Y, Ooboshi H, Kitazono T. The expression of pericyte PDGFRβ isregulated by basic FGF after ischemic stroke - Research for Biomarkers in Ischemic Stroke(REBIOS) -.ONeuroscience Meeting 2013, 2013 ɖ 11 ˾ San Diego
44. Yamada S, Tokumoto M, Taniguchi M, Tsuruya K, Ooboshi H, Kitazono T.OPhosphate

overload induces systemic inflammation, malnutrition, and vascular calcification inuremia.OASN Kidney Week 2013, 2013 ɖ 11 ˾ Atlanta
45. Tokumoto M, Yamada S, Fujino T, Tsuruya K, Kitazono T, Ooboshi H. The combined25therapy with calcitriol and a calcimimetic agent, R568, ameliorates phosphorus-induced
calcification with altered expression of SIRT1 and ALP in human vascular smooth muscle
cells. ASN Kidney Week 2013, 2013 ɖ 11 ˾ Atlanta
46. þ̋˲ă^ƺԍǈ́^˿̋şô^ΜƟŢȍ^ВԕϬĖ^ԙ̄ôȂ^ʹƟҗ^լʥ̺ͨ^Ȁ˫ƚ˩^Ƒǣȏʝ  ї̥ǴτπɳДȷοʌуjq¡ basic FGF ÷˨: Research forɖBiomarkers in Ischemic Stroke (REBIOS).ˤ̇їɹΫĞӃȑħЯħ^˾̈ɓɍ

47. єǧоł^ƺԍǈ́^լʥ̺ͨ^ϡ̋ǈ^ВԕϬĖ^ԙ̄ôȂ^ȿίՃ^ʹƟҗ^Ȁ˫ƚ˩^Ƒǣȏʝ  ї̥Ǵɳ 'Ҏ΄ΉɟˮˤĊɳùѰʼЇy¡փResearch for

Biomarkers in Ischemic Stroke. Ѐռ ǜˤ̇їƖþȑħЯħ^ɖ˾ ̎Ĕ

48. Wakisaka Y, Ago T, Kamouchi M, Kuroda J, Matsuo R, Gotoh S, Watanabe W, Isomura T,

Awano H, Suzuki K, Fukuda K, Okada Y, Kiyohara Y, Ooboshi H, Kitazono T.
Extracellular newly identified receptor for advanced glycation endproducts binding protein(EN-RAGE) predicts the outcome in patients with acute ischemic stroke: Research for
Biomarkers in Ischemic Stroke. International Stroke Conference 2013,2013 ɖ 2 ˾

Honolulu
49. Όԕʊғ^ȀԕЙ^ȁίł˘^ɣ҇ƗԻ^ӇƫԉĂ  °óÌÙ¨¾óŸɷ¡ cancer sphereɮʝёЀ  ǜˤ̇ѧɛƫњοΪȑħ^ɖ  ˾ ̎Ĕ

50. ȀԕЙ^Όԕʊғ^ȁίł˘^ӇƫԉĂ  °óÌÙ¨¾óŸɷ¡ƫњʣɕ÷χσОѐƋʖ_Ѐǜˤ̇οΪȑħ^ɖ  ˾ ̈ɓɍ51. ȁίł˘^ȀԕЙ^Όԕʊғ^ӇƫԉĂ  ®Îåí÷χσσќ՚ĬŒ¥Ƹ˿y¡®Îå

í÷χќ

ĸ_Ѐ

ǜˤ̇οΪȑħ^̈ɓ^ɖ  ˾շ

52. ƈǦƕ˴^Ƥȿ¤^θȽԻ̷^˗ӑѸϕ^ȲɁȥ^͕Ϫɯ  ̺ɑâ¬¿¶ì©ОѐlτΨy¡áÍÛëìð±ÍÜìð_Ѐ ǜˤ̇ҥŽȑħЯħòŝǢȑҐԽħ^

ɖ

˾ ը

̏ɍ
53. ըίŀӥ^ŤȽӏҺ^˗ӑѸϕ^θȽԻ̷^ϘɄƚă^͕Ϫɯ  ДȷοΫǸøљЕΩıjq¡ (!&  (!& τΨg_Ѐ ǜˤ̇ҥŽȑħЯħòŝǢȑҐԽħ^

ɖ

˾

ը̏ɍ
54. ŤȽӏҺ^ըίŀӥ^˗ӑѸϕ^θȽԻ̷^ϘɄƚă^͕Ϫɯ  ДȷοæËíâ¬¿љìðÕЇǹάg_Ѐ ǜˤ̇ҥŽȑħЯħòŝǢȑҐԽħ^ɖ˾ ը̏ɍ

55. ըίŀӥ^ŤȽӏҺ^˗ӑѸϕ^θȽԻ̷^ϘɄƚă^͕Ϫɯ " Expression of toll-like receptors

in glomerular endothelial cells under diabetic conditionsNЀ  ǜˤ̇ɺȲɹΫȑħЯħ^ɖ˾ ̎Ĕ

56. ըίŀӥ^ŤȽӏҺ^ϘɄƚă^͕Ϫɯ  ДȷοæËíâ¬¿љЕΩıjq¡ (!&  (!&τΨ_Ѐ  ǜˤ̇ДȷοƲĶπȑħ^ɖ  ˾ ˧Ʉɍ57. ŤȽӏҺ^ըίŀӥ^˗ӑѸϕ^θȽԻ̷^ϘɄƚă^͕Ϫɯ  UǩVǩДȷοæËíâ26

¿jq¡љìðÕЇ˞ά_Ѐ  ǜ̽ϯǮϢƓȑħȑҐȀħòЯħ^ɖ  ˾ ȿȽɍ58. ըίŀӥ^ŤȽӏҺ^˗ӑѸϕ^θȽԻ̷^ϘɄƚă^͕Ϫɯ  ДȷοΫǸøљЕΩıŤχОѐjq¡ (!&  (!& τΨ_Ѐ  ǜ̽ϯǮϢƓȑħȑҐȀħòЯħ^ɖ  ˾ ȿȽɍ
59. ŤȽӏҺ^ըίŀӥ^ϘɄƚă^͕Ϫɯ  UǩVǩДȷοâ¬¿jq¡љìðÕЇǹάg_Ѐ  ǜˤ̇ДȷοȑħĄɅǦ˟ħ^ɖ˾ ͓дɍ

60. ըίŀӥ^ŤȽӏҺ^˗ӑѸϕ^θȽԻ̷^ϘɄƚă^͕Ϫɯ  ДȷοΫǸøљЕΩıjq¡ Toll-like receptor(TLR)2  4 τΨ_Ѐ  ǜˤ̇ДȷοȑħĄɅǦ˟ħ^ɖ˾ ͓дɍ
61. ŤȽӏҺ^ըίŀӥ^ϘɄƚă^͕Ϫɯ  UǩVǩДȷοæËíâ¬¿jq¡љìðÕЇ˞άg_Ѐ  ǜϫȿ̽ϯȀȑȑħЯħ^ɖ˾ ϫȿɍ

62. ըίŀӥ^ŤȽӏҺ^ϘɄƚă^͕Ϫɯ  ДȷοæËíâ¬¿љЕΩıjq¡ TLR2 

TLR4 τΨ_Ѐ  ǜϫȿ̽ϯȀȑȑħЯħ^ɖ˾ ϫȿɍ

63. Ʉәʕ^ȽăŤգ^þŪİգ^þɁôҪ^˗ӑѸϕ^͕Ϫɯ^ϘɄƚă  ÖÌ̝̽ѢаЩѴОѐ¡°³½ÅëðаЩűҥӽϱ_Ѐ  ǜĄɅϗ̺̽ϯȑħȑҐȀħ^

ɖ

˾ Ƒ

ĄɅɍ
64. ȽăŤգ^˗ӑѸϕ^͕Ϫɯ^ϘɄƚă  ̝̽Ѣ°³½ÅëðаЩɮʝjq¡ MAGP-1

̵ё_Ѐ  ǜ˭Ȑˤ̇̽ƽοȑħȑҐȀħ^ɖ  ˾ ̎Ĕ

65. Ʉәʕ^˗ӑѸϕ^͕Ϫɯ^ϘɄƚă  ÖÌ̝̽Ѣ°³½ÅëðаЩűҥ̵̭_Ѐ  ǜ˭Ȑˤ̇̽ƽοȑħȑҐȀħ^ɖ  ˾ ̎Ĕ

66. ҇ίԵȥ^ȽăŤգ^þŪİգ^þɁôҪ^˗ӑѸϕ^͕Ϫɯ^ϘɄƚă  °³½ÅëðаЩɮʝ̵̭jq¡ MAGP-1 ̵ёҥ̑_Ѐ  ǜˤ̇ϗ̺̽ϯȑħȀħ^

ɖ

˾ ԣ

ԕɍ
67. Ʉәʕ^ȽăŤգ^þŪİգ^þɁôҪ^˗ӑѸϕ^͕Ϫɯ^ϘɄƚă  ÖÌ̝̽Ѣ°³½

ÅëðаЩˑӵ̵̭_Ѐ  ǜˤ̇ϗ̺̽ϯȑħȀħ^ɖ˾ ԣԕɍ

68. ȽăŤգ^Ʉәʕ^þŪİգ^þɁôҪ^˗ӑѸϕ^͕Ϫɯ^ϘɄƚă  ÖÌΑѱМ͈̮ı÷χОѐ¡°³½ÅëðаЩɮʝҥ̑_ˤ̇ҥŽȑħЀ  ǜĄɅːԌȑҐԽħ^ɖ˾ խśɁɍ

69. қ̋Кǂ^͕Ϫɯ^ϳίͨȍ^÷ίхôԊ^ϘɄƚă^͋ίϨĞ  Ȳśl¦͗ςɳ̽ϯφԣ̃Ù¯ïó©ÈÛ_Ѐ  ǜˤ̇ȲśҎͭòl¦ȑħȑҐԽħ½ðá¾¬ä^

ɖ

˾ ϫ

ȿɍ
70. Tsutsumi T, Kajiya H, Goto K, Takahashi Y, Okabe K. Expression of C-C chemokine

ligands for osteoclastogenesis induced by hyperocclusion. ©åì±զĞӃȑħò
Խħ^

ɖ

ɖȑҐ

˾ àíÇæ©

71. Kajiya H, Tsutsumi T, Nagaoka Y, Goto K, Fukawa T, Sasaki M, Okamoto F, Okabe K. A

27

novel role of farnesyl diphosphate synthetase (FDPS) on the activity of Cl- extrusion in
osteoclasts. ©åì±զĞӃȑħòɖȑҐԽħ^ɖ˾ àíÇæ©72. ϫɁϬ˛^ԟ͗ȹͨ^ȿ̇ȤǻԻ^ѨҞѸ͗Ԋ^ȿԌɗư  Notch2  Hadju-Cheney πňнǩǽλ SCF/FBW7 ¡ÅðÕµԖφŸɷ¥Ś¢¡_Ѐ  ǜқˤ̇άΪȑħ^ɖ˾ ƑĄɅɍ

73. ԣȿѰϤ^ԟ͗ȹͨ^į`̄öȅ^͌͘գи^ǯӏư^ɞɄ˱Ă^ȿ̇ȤǻԻ^ȿԌɗư  ϺМƸ˿Ö¿ß¿ßÑóÌҙſ(NBP)¡ϛզОѐОѐҌƲԬȞĴή_Ѐ  ǜ̽ϯǮϢƓȑħ^ɖ  ˾ ȿȽɍ74. Tsutsumi T, Kajiya H, Goto K, Nagaoka Y, Okamoto F, Okabe K. The novel roles of CCL2

and CCL3 on osteoclast differentiation and alveolar bone resorption during occlusal
traumatism. ǢԸզĞӃȑħ"'òˤ̇զĞӃȑħ'"&ЀǜƲƴǢԸħӅ^ɖ˾ ϧʡɍ
75. Okamoto F, Kajiya H, Okabe K. The properties of Mg2+-inhibited TRPM7-like channel inmouse osteoclasts. Ѐ  ǜˤ̇άΪȑħ^76. įԕwjɖ˾̎Ĕ^ǧ÷ϼӒ^ԨƫϓȂ^ˤըϐЙ  ©áÌó½¿ҹȱӽϱjq¡ MAPO1 ÅðÕµӕȓȗƐ_Ѐ  ǜˤ̇űȍάΝȑħɖħ^77. ˤըϐЙ^įԕwjɖ˾ ϫȿɍ

^҇ţĕӥ^̒ɻӊ^ǧ÷ϼӒ^þ͢ƭӾ^йӦĂ^ԨƫϓȂ  τl¦¥ʧŸy¡©áÌó½¿ҹȱ̵̭_Ѐ  ǜˤ̇űȍάΝȑħɖ^ɖ˾ ϫȿɍ

78. Fujikane R, Sanada M, Sekiguchi M, Hidaka M. The identification of a novel gene, MAPO2,

that is involved in the induction of apoptosis triggered by O6-methylguanine. The 8th 3R
Symposium, 2012 ɖ 11 ˾ ͯӜɍ
79. ˤըϐЙ^̒ɻӊ^҇ţĕӥ^įԕwj^ǧ÷ϼӒ^þ͢ƭӾ^йӦĂ^ԨƫϓȂ  MAPO1 FLCN ¡ AMPK ͣʇƐ©áÌó½¿¥ҹȱy¡_Ѐ  ǜȀħˤ̇ԄĨȑħ^ɖ  ˾ ϫȿɍ80. þԕǐȂ^ԙ̄ȅȃ^ЍίԼҗ^ɣ҇ƗԻ^̲Όƍм^̡ί˛ɗ ÖÌƫњŤОѻƪ̭ʝȩy¡ĐԚ«°ðɰՉ_Ѐ  ǜˤ̇άƐȑħȀħ^ɖ˾   ˤ ϫȿɍ81. ̉̇ΰЗȍ^ЍίԼҗ^ԙ̄ȅȃ^ɣ҇ƗԻ  ùԂƲńɸΝ԰ơj̽ƽǾϯѩlȔŝͬȄwπĸ_Ѐ  ǜˤ̇̽ƽοȑħȑҐȀħ^ɖ˾

82. ̏ͧ͠ʀ^ЍίԼҗ^ԙ̄ȅȃ^Ť҇ɽ^ɣ҇ƗԻ ƫѩ͗ςgȩӉwҿ̗Т̓P_Ѐ ǜˤ̇̽ϯŁȎȑħϮȐȑҐȀħ^ƫˤ oɍ

ʒӄP̽ϯґάǻ¥
ɖ

˾



ˤ ɚɁ

ɍ
83. ̢ȶԴĘ^ԙ̄ȅȃ^ЍίԼҗ^ȓʂȀ^ġқȕĘ^҇̇˶͏^ĥ͞ɗĴ^Όԕʊғ^Ƚίǂɯ^ɀŕϕă^ɣ҇ƗԻ S-PRG ΀Űͭ S-PRG ԏƲ̽ՆϙϠſƫњÔ«°ÙªíäɰՉ_Ѐ ǜˤ̇̽ϯŁȎȑħϮȐȑҐȀħ^

ɖ

˾



ˤ ɚɁɍ

84. ĥ͞ɗĴ^ԙ̄ȅȃ^҇̇˶͏^ЍίԼҗ^Ƚίǂɯ^ɀŕϕă^̢ȶԴĘ^қƟǈü^ԗȍ28ŕ͊^˭ƵôĖ^ɣ҇ƗԻ^ÖÒ³Ç°óíԏƲƫњ·©ή¾­í¡ƫњʹʿƫѩˑǐƊ̓^Ѐ ǜˤ̇̽ϯŁȎȑħϮȐȑҐȀħ^

ɖ

˾



ˤ ɚɁɍ

85. ̢ȶԴĘ^ԙ̄ȅȃ^ЍίԼҗ^ȓʂȀ^ġқȕĘ^҇̇˶͏^ĥ͞ɗĴ^Όԕʊғ^Ƚίǂɯ^ɀŕϕă^ɣ҇ƗԻ S-PRG «°ð΀Űͭ S-PRG ԏƲ̽ՆϙϠſƫњÔ«°ÙªíäɰՉ_Ѐ  ǜϫȿ̽ϯȀȑȑħЯħ^˾˾  ˤ ϫȿɍ86. ĥ͞ɗĴ^ԙ̄ȅȃ^҇̇˶͏^ЍίԼҗ^Ƚίǂɯ^ɀŕϕă^̢ȶԴĘ^қƟǈü^ԗȍŕ͊^˭ƵôĖ^ɣ҇ƗԻ ÖÒ³Ç°óíԏƲƫњ·©ή¾­í¡ƫѩˑǐƊ̓ѧɛ
ϙϸ_Ѐ  ǜϫȿ̽ϯȀȑȑħЯħ^ɖ˾  ˤ ϫȿɍ87. ƈǵȅ͢ɏ^ЍίԼҗ^ŤίŴм^ԙ̄ȅȃ^Ť҇ɽ^дίǂ̸ȍ^կίмǂȍ^Ɔ̻Кΰм^ɣ҇ƗԻ ƫѩ͗ςԨy¡̽ϯґάǻʒӄҿ̗_Ѐ  ǜϫȿ̽ϯȀȑȑħЯħ^
ɖ

 

˾  ˤ ϫȿɍ88. ЍίԼҗ^ƬӑƕȰ^ԙ̄ȅȃ^Ť҇ɽ^ɣ҇ƗԻ ϫȿ̽ϯȀȑƫњƓςÁðÅóƫѩϯʌуҥ̑jƫѩʈʄπ

πĸ_Ѐ  ǜˤ̇̽ϯɾӟƓȑħЯħòȑҐȀħ^ɖ˾  ˤ Ʉәɍ89. ҇̇˶͏^ԙ̄ȅȃ^ЍίԼҗ^ĥ͞ɗĴ^ίԇôʝ^Ƚίǂɯ^ɀŕϕă^̢ȶԴĘ^ɣ҇ƗԻ ϐʇƫѩπjq¡ Lactobacillus salivarius WB21 ̛ԏƲԜѼ˿ήʇ̩ҩ_Ѐǜˤ̇ƫѩȑħ^ɖ  ˾  ˤ ̎Ĕ

90. ԙ̄ȅȃ^þԕǐȂ^ЍίԼҗ^̲Όƍм^̡ί˛ɗ^ɣ҇ƗԻ ǵƐĐԚ΀ͭ͡ƫ¡ƫњŤОѻƪǽƋ_Ѐǜˤ̇ƫѩȑħ^ɖ  ˾  ˤ ̎Ĕ

91. ԙ̄ȅȃ^þԕǐȂ^ζԕŔȍ^ЍίԼҗ^̲Όƍм^̡ί˛ɗ^ɣ҇ƗԻ ǵƐĐԚ˹Ղ¡ƫњОѻ̭ʝǽƐ_Ѐ ǜˤ̇̽ϯŁȎȑħ˭ȐȀħ^ɖ  ˾   ˤ Șԕͼɍ
92. ҇̇˶͏^ԙ̄ȅȃ^ЍίԼҗ^ίԇôʝ^Ƚίǂɯ^ɀŕϕă^̢ȶԴĘ^ĥ͞ɗĴ^ɣ҇ƗԻ Lactobacillus salivarius WB21 ̛ԏƲԜѼƫѩʧŸƊ̓gÆäƐČԔϋ̩ÛëÁàȩΕµï¿°óÔóҲեe_Ѐѧɛϙϸeëð ǜˤ̇̽ϯŁȎȑħ˭ȐȀħ^ɖ  ˾   ˤ Șԕͼɍ
93. ƈǵȅ͢ɏ^ЍίԼҗ^ŤίŴм^ԙ̄ȅȃ^Ť҇ɽ^̋÷˦Ѷ^ȓ͖Ť^ɣ҇ƗԻ ƫѩ͗ςԨy¡̽ϯґάǻʒӄҿ̗_Ѐ  ǜˤ̇̽ƽοȑħ˭ȐȀħ^ɖ  ˾  ˤ ̈ɓɍ
94. Ohgi K, Kajiya H, Okamoto F, Tsusumi T, Onitsuka T, Nagai A, Sakagami R, Okabe K.

Bisphosphonate as a novel target to the Clcn7 Cl- transporter in osteoclasts. Ѐ  ǜˤ̇άΪȑħȀħ^ɖ˾ ̏̇ɍ

95. ̋÷ɧ^ȿ̋ǂɯ^ǧ÷ϼӒ^ȽձЙ ëÈÌƫњБѢŦ̭ЊЖjq¡ԔȼƐòҤƐ÷χ±¿ÕóÂ  τΨ_Ѐ  ǜˤ̇҅Ϊȑħɖħ^ɖ˾ ĔԎ

96. Murakami H, Okamura K, Sakagami R, Yamazaki J. Expression of caspase-14 in stratified

29and cornified epithelium in a rat oral mucosal reconstruction model. Ѐ  ǜˤ̇҅Ϊȑħɖħ^ɖ˾ ĔԎ

97. ÿȶό̳^ȿ̋ǂɯ^ӇƫԉĂ^ǧ÷ϼӒ â¬¿ø՗Ų̝̽ȴԌǿёʇɘОѐjq¡ Sox2

τΨЀ  ǜϫȿ̽ϯȀȑȑħ^ɖ˾  ˤ ϫȿɍ98. ɣ̏ĕ^ŞίŘü^ǧ÷ϼӒ^ȽձЙ ǭա÷χОѐjq¡ Cl-ÇçÑíҿЈǝȍԄĨȍτΨҥ̑_Ѐ  ǜ̽ϯǮϢƓȑħȑҐȀħ^ɖ  ˾ ԋȽɍ99. Ȁǫɏмȍ^ȿԌɗư^իǳɶą^͌ďͱ^ǧ÷ϼӒ ϺМƸ˿×¿Ù¯¿Ù¯ÑóÌ(NBPs)

ϛզОѐ ClC7 ǩ Cl-ӧӮı (Clcn7) ̵ё¥ʧŸy¡_Ѐ  ǜˤ̇̽ƽοȑħ˭ȐȑҐȀħ^ɖ  ˾ ̈ɓɍ100. ̋÷ɧ^ȿ̋ǂɯ^ȽձЙ^ǧ÷ϼӒ Epigallocatechin-3-gallate (EGCG) ¡ƫњБѢűƐȩy¡ɰՉ_Ѐ  ǜˤ̇̽ƽοȑħ˭ȐȑҐȀħ^ɖ  ˾ ̈ɓɍ101. Sakagami R, Nagai A, Kaneko N. Surface roughness of curettes sharpened by diamonddressers. American academy of periodontology 98th annual meeting, 2012 ɖ 9-10 ˾

LosAngels102. Nagai A, Sakagami R Phylogenetic mapping of chronic periodontitis– associatedmicrobiota

to the human microbiome. American academy of periodontology 98th annual meeting, 2012
ɖ 9-10 ˾ Los Angels
103. ̏ͧȵʀ^į`̄м˵ȍ^ΚͷöƕЪ^ɻȤŋȁԊ^ϘɄмǄ^˞ίʋ^͋γ̘мΪ^į҇ƚł զ¹ëó¸ðl̽ȪǀȢúy¡ƭёʇ_Ѐǜˤ̇ҘЬ̽ϯȑħ^ɖ  ˾ ̲ͦɍ
104. ̏ͧȵʀ^ΚͷöƕЪ^ɻȤŋȁԊ^˞ίʋ^į҇ƚł ÖÌΤıø՗զjq¡զǮӕþ

¹ëó¸ðԖ́Ȏ̽˙Ԩľ_ˤ̇ƫњ«ðÛëðÌȑħЀ  ǜĄɅːԌȑҐȀħ^ɖ˾ ȝɂɍ

105. Ooboshi H. Innate immunity as a novel therapeutic target of brain infarction. TranspacificWorkshop on Stroke, 2012  10 &O New Orleans
106. Ȁ˫ƚ˩ Immune response as a novel therapeutic target of brain infarction. Ѐ  ǜˤ̇ƋѕϝƐȑħ^ɖ  ˾ ϫȿɍ107. ȀԕЙ^ɀ̴Ӧ˩^ӇƫԉĂ ConA ¡ƫњʣɕ÷χσОѐ°óÌÙ¨¾óҹȱ_Ѐǜˤ̇οΪȑħ^ɖ  ˾ ̎Ĕ
108. ƈǦƕ˴^Ƥȿ¤^ȲɁȥ^͕Ϫɯ â¬¿ѕФƪjq¡áÍÛëÏð±Íìðτ

Ψ_Ѐ  ǜˤ̇ɺȲɹΫȑħЯħ^ɖ˾ ψȿɍ

109. θȽԻ̷^θȽЙȍ^ȿ˸ȍ^˗ӑѸϕ^ϳďǈố^͕Ϫɯ ʝԣ̐Ӡզjq¡©åï¾­Ïðj LAMP-1 ŚνРиȑφϙϸ_Ѐ  ǜˤ̇ТƲРиȑħ^ɖ  ˾ ̎Ĕ

110. θȽԻ̷^θȽЙȍ^ȿ˸ȍ^˗ӑѸϕ^ϳďǈố^͕Ϫɯ ̝̽Ѣɮʝjq¡Lysosome-associated membrane protein-1 (LAMP-1)ŚνРиƐȑφȸǥg̽ϯǮϢƓȑħȑҐȀħòЯħ^ɖ  ˾ ԋȽɍ30

Ѐ  ǜ

111. ȽŤΰț^þŪİգ^þɁôҪ^˗ӑѸϕ^͕Ϫɯ^ϘɄƚă Fibulin-4  LOXL-2/®ë¿ÇðҚƲıɮʝ¥ҿЈy¡_Ѐ  ǜˤ̇ТƲРиȑħ^ɖ  ˾ ̎Ĕ

112. ȽăŤգ^Ʉәʕ^þŪİգ^þɁôҪ^˗ӑѸϕ^͕Ϫɯ^ϘɄƚă ͈̮ıɮʝjg

Fibrillin-1  Fibrillin-2 ɿՍf¡_Ѐ  ǜˤ̇ТƲРиȑħ^ɖ  ˾ ̎Ĕ

113. þŪİգ^˗ӑѸϕ^ȽŤΰț^þɁôҪ^͕Ϫɯ^ϘɄƚă EMILIN-1 G Fibrillin-1 ОѐŤТƲw°³½ÅëðаЩɮʝԖ¥ҿЈwg¡_Ѐ  ǜˤ̇ТƲРиȑħ^ɖ  ˾ ̎Ĕ
114. қ̋Кǂ^ϳίͨȍ^͕Ϫɯ^ϘɄƚă Ȳśσʩσſ͗ςlɦmӗsy͌Ă̽ɮʝԹȞg_Ѐ  ǜϫȿ̽ϯȀȑȑħЯħ^ɖ˾ ϫȿɍ

115. Kaji C, Tomooka M, Kojima H, Sawa Y. Distribution of Podoplanin Expressing Cells in theOral Tissue. J. Dent. Res. 90(S) 90th Interbational Association of Dental Research,2012 7  Iguaçu Falls
116. Tomooka M, Kaji C, Kojima H, Sawa Y. Podoplanin expression on the peripheral

nerves and central nervous system. The 60th Annual Meeting of Japanese
Association for Dental Research, 2012 ɖ˾ ˞΅ɍ

117. Uchiyama, T., Kojima, H., Ishikawa, H., Sawa, Y.:Immunohistochemistry for oral tissue by

a novel antibody to podoplanin. The 60th Annual Meeting of Japanese Association for
Dental Research, 2012 ɖ˾ ˞΅ɍ

118. ǯӏư^ԟ͗ȹͨ^ԎЊȯ^̝̇ǈѦ^ը̴җ^ȿԌɗư  ǃƲʇǾŏ˰ϛզОѐҹȱjq¡  ·æ±«ðɱƃ_Ѐ  ǜϫȿ̽ϯȀȑȑħЯħ^ɖ˾ ϫȿɍ

119. ԣȿѰϤ^ԟ͗ȹͨ^ɞɄ˱Ă^į`̄öȅ^̍ͪʙôԊ^Ƚøǐɧ^ȀԨʋ^͐ԇǈԊ^ȿ̇ȤǻԻ^ȿԌɗư ϺМƸ˿×¿ß¿ßÑóÌҙſճNBPմ¡ϛզОѐɮʝԬȞÛîÏíƐĿӸΝӕ¡ǜɸ_Ѐ  ǜϫȿ̽ϯȀȑȑħЯħ^ɖ˾ ϫȿɍ

120. ǯӏư^ԟ͗ȹͨ^ը̴җ^ȿԌɗư CCL2 ½¶Îí̶ˊlӽƂǃƲƆҹτʇ̯̽զƹƧƣyɰՉ_Ѐ  ǜ̽ϯǮϢƓȑħ^ɖ  ˾ ԋȽɍ121. Ȁǫɏмȍ^ԟ͗ȹͨ^ȿ̇ȤǻԻ^ǯӏư^ԣȿѰϤ^į`̄öȅ^ǧ÷ϼӒ^ȿԌɗưϺМƸ˿×¿Ù¯¿Ù¯ÑóÌճNBPsմϛզОѐ Clcn7 ¥Ęw ǜÌëð¿áóÅóϙϸħĄɅԌħ^Cl-ӧӮ¥ʧŸy¡_Ѐɖ  ˾ ϫȿɍ122. ԟ͗ȹͨ^Ȁǫɏмȍ^ȿ̇ȤǻԻ^ȿԌɗư ϛզОѐ ClC7 ǩ Cl-ӧӮı(Clcn7)Ù¨

óÑ½í 2 ìðԑƲʝԐМ(Fdps)
ʧŸy¡_Ѐ

ǜˤ̇զĞӃȑħ^ͣʇƐu¢^ԬȞſÄîðÍïԑs Cl-ű͜ё¥ɖ  ˾ ̎Ĕ

123. ǯӏư^ԟ͗ȹͨ^ɳ҇ƈȪȍ^ȿԌɗư  CCL2 ½¶Îí̶ˊwǃƲʇǾŏæËíâ¬¿¥ήg՗զƹƧ˰·æ±«ðƋʖҥ̑_Ѐǜˤ̇զĞӃȑħ^ɖ  ˾ ̎Ĕ

124. ȿ̇ȤǻԻ^ԟ͗ȹͨ^ȿԌɗư  ϛզОѐkҹȱu¢¡ (&%" ̮Դ«°ðՁͤ}ԑ

ĺȎφͣʇƐ_Ѐ  ǜ TRP ÇçÑíϙϸħ^31

ɖ  ˾ ȿɂɍ125. Okabe K, Kajiya H, Okamoto F, Tsusumi T. Regulation of osteoclastogenesis throughcalcium oscillations. Ѐ  ǜˤ̇άΪȑħ½ðá¾¬ä ^ɖ˾ ̏̇ɍ

126. Okabe K, Okamoto F, Kajiya H, Ohgi K. Cl- transporters as novel therapeutic targets forabnormal osteoclastic bone resorption.

Ѐ  ǜˤ̇άΪȑħ½ðá¾¬ä ^

̏̇ɍ

"
"
f gYЀպǜсƐŸɷ½ðá¾¬ä  “Oxidative Stress and Aging”  ˤ˰ 2013 ɖ 9 ˾ 9 ˤճ˾մ 14:00~17:30
  Ǳʢ ϫȿ̽ϯȀȑ 504 ˕Ȝ  T. Sekiguchi ճKyushu Univ.մElimination of oxidized nucleic acid  J-P. Cai (Beijing Institute of Geriatrics) Translational errors caused by ROS.
"   H. Hayakawa (FDC) Proteins that recognize oxidative RNA damage.
"   M. Hidaka (FDC) Molecular mechanism of the induction of apoptosis to suppress 

mutations and cancer.

"   Stuart LinnճU. C. BerkeleyմThe role of DDB2 (XP-E) in tumor suppression and  apoptosis.
  " http://www.fdcnet.ac.jp/col/facilities/cca/index.html
"

"
"

32

ɖ

˾




¹ ōŕƇƪüéŬFƞÉ½


33

34



ČÜ ĩƸƚ°hphBƔÏńĴ









 # ċƯ ŊŢƸń5TSûª:QVpfhFĝě 

 #

xśƏœûªJFV~l # Ƌ· ƖƸ·Ű5TFƩƘĘĦ ėÏƸ`loa|U`kBcvFÒÓDŧý  

 #Ġƕ ÀƗƸĶÊÄÏFƔŠJFĹ 
  



 # 

 # 

 # 





  

 # 







  

 #





Üƛ æƸ ĸķóªïó  ŤŭSĹ0=ĉ90ŋįŁĢŃùļ  

 #





/·ŰŝŲFŪ°ĝěBń5TBFƟ¡E?0@Fōŕ/  

Ź ³¢Ƹ·ŰF­ưË°F£ÝBƮÈƍFƟ¡ÛƘ ã¸ƸŏťũƊĽàBfarƓġ ŐëƸűłFƏœB¦ņŤŭFòř

  


Íď ³ĎƸŮŻŚƤÕB¤ľƚ°hphÆ ŘƌƸ·ŰņŤŭF©°EBND1cvF[{gZunWm`DË° #   
  









 #  Ŝĺ ƦſƸ­ưE1·ŰĶÊFË°3OH·ŰĶÊFĄÁ

 #  

 # çŹ ²ƥƸ~wX]nW`hB·ŰĿõ







· ¥ƗƸƚ°t`]lqBƔöÉńĴĽà 


35




ϙ ϸ Ҿ ՖԑƐ¿Ìî¿ԄĨȍτΨϙϸĞҔу˦Ʉ ͨճ̵ёάΝƐȑӂɠòάƐȑűԕò˕ˀմƁš ʞ`̇ϙϸԑƐ RNA ΞλφТƲy¡ÅðÕµӕ Auf1/HNRNPD gğøΏ¥˩kw_Y ОѐАʮŰͭþ Auf1 ÅðÕµӕ 8 °³Ã¶©Ïð¥ΞλφТƲy¡Z Гҙu¢РˇiÅðÕµӕ}¢ѨıԑƐ RNA ΞλφТƲwgl^ОѐʮŰͭ¥sГҙÅðÕµӕƈi¡ԑƐ RNA ΞλφТƲёlǜɸy¡_ ssk Auf1 ÅðÕµӕ}¢ğǾÅðÕµӕҚƲı¥ɮʝy¡w
ё¥Υɶw

ΞλφТƲ

g¡тi¢¡_ ōŕňŅ ԑМάǀͣƋùƭ̶f¡l^ô˟άıʝű¥ԑƐwʎɰՉ¥ƣy_þ։֌ֆ֍֌ֆԑƐτl¦сƐ¥ɦmӗsyƟǝ¡тi¢¡_}¢ȩwάıs¢ԑƐ¥ԫpҖк¥ʶ ԑƐ¿Ìî¿g¡_̜ԑԑƐu¢̮`ԑƐńՠǵǮlάx¡l^}þ˽ԔҜ¶©ÏðǵǮԑƐıf¡ց°³Ã¶©Ïðճ8oxoGմɮʝf¡_ց°³Ã¶©Ïð½Ì½ðz©ËÏðǵǮȩƲlŰ̍¡ԄĨʏǰĨӿӽϱ®ëó¥ɦmӗsy_։֌ֆ÷άxǱƲϹΓǽλ¥^uτl¦¥ɦmӗs
yslϕ¢^ϙϸloӸ¢g¡_ô˟^֍֌ֆǱƲһӡŨòһрҭ¥ӳx λɑÅðÕµƲʝ¥ɦmӗsys¥ʞ`x
³Ã¶©Ïð¥Ƹ֍֌ֆсƐԨӶl͟ϊu¢ǰƼwl^˽ӫsց°g¡_ƞ^©íÉÓ«âóʌусƐâ¬¿їϧСОѐց°³Ã¶©Ïð¥Ƹ֍֌ֆl҂ϵwg¡ghċșf¡_ց°³Ã¶©Ïð¥Ƹ֍֌ֆλɑÅðÕµƲʝ¥ӗsyl^s¢ξʌλɑÅðÕµŰΨlΞɼφf¡_^ԑƐu¢֍֌ֆűҥu¢^ȷþ
ց°³Ã¶©Ïð¥ƸÐµî°½Í^ց°³Ã¶©Ò½ðw¡сƐʷ̰w

̃ɲm¡_  ʞ`Ξ֍֌ֆԑƐ͟ϊwԑƐԹȞ¥ԫp̵̭w

ˁ͚u¢¡тi¢ϙϸ¥Ӹg¡l^s¢ϙϸk RNA øҪǠպϣyhջěРlтi¢¡_պմRNA Ʋʝżդı¡ԑƐÐµî°ÇÍ(8oxoGTP, 8oxoGDP)űҥ_
ջմRNA áìåëóÂl 8oxoGTP ¥Ǯӕw
^RNA ό˄ԑƐ

ց°³Ã¶©Ïð¥ RNA þƨάx 8oxoG ¥Ƹ RNA ȩy¡ˁ԰Ж_36Ө¦ ̇ϙϸjg÷ʹrպմ^ջմԨ¤¡ǝȍ¥ƴȗòҥ̑w^ǉćƋΝjq¡ԑƐ¿Ìî¿øԄĨȍτΨǆӕЇΪ̵̭ŝӋ¥˩ky¡s¥ϊφy¡_Ċĥ ԑƐ RNA ¥ΞλφҸӄy¡ÅðÕµӕw

ˣ Auf1 ÅðÕµ¥ƴȗwl^sÅðÕµҵОάƐȑφҥ̑¥Ӹ¡ΐ˞ҟÛïóÚ¥Ĵʝw_s¢ÛïóÚlôԌԐМ¥ŷήw^RNA ×óÀԧl polyA:polyT ©Ïóìð¶f¡ȩw^ėǜŝƐȑƲʝ¡YƧΦl̫

Ŕ¢

ТƲw

g¡_ZŠ˿ТƲ RNA ¥×óÀТƲu{¡skÛïóÚѨӟlȓȗ_ [uƲʝ°ìºÐµî°ÇÍʁήƭё̮`ŷΏlf¡_ŦĕBūÖ
պմԑƐÐµî°ÇÍűҥЖ GMP ¥ GDP ìðԑƐy¡ԐМf¡Ȁѝѻ Guanylate kinase ԑƐǩ GMP¥ӄŶw^8oxoGMP ¥ 8oxoGDP ìðԑƐwgs¥ϞҸw_ô˟ nucleoside
diphosphate kinase  adenylate kinase  8oxoGDP ¥ìðԑƐw¡^ssk Guanylate kinase l¸«Ì³óÕówճӁ˛պմ_37

őg

8oxoGTP ¥άέyg¡sl˩kջ մAuf1 ÅðÕµҥ̑ŤŭĪF Auf1 kx`GƷ]_jaVsS»M RNA EĲĽŅEŦº:Q ց°³Ã¶©Ïð¥Ƹ°ìºâó¥ƐȑƲʝw^s¢-Ċĥ.ӬĴʝ͝¥ήg©²ïó¿×óÀŠ˿ТƲu{_¹ðÌïóíw©ÏðĞ¤¼«ðӳƴôԏų¥ց°³Ã¶ӳɑ¶©Ïð¥Ƹ°ìºâó¥ήg_zs˞ҟÛïóÚlË

Ȕʝwg¡khkg

ց°³Ã¶©ÏðΞλφʩı¥ήg̩Ұw

_Ǡջ A ϣyhΞλʩıց°³Ã¶©Ïð¥Ƹ°ìºâóÛïóÚТƲw^¹ðÌïóíÛïóÚŝoТƲwgskË¼«ðӳÛïóÚlȔʝw_ ̷sÛïóÚ¥ήgԑƐ RNA ТƲÅðÕµwƴȗw Auf1 ÅðÕµlΞλφТƲy¡khk¥ҿ_Ǡջ B ϣu¢¡h Auf1 ÅðÕµց°³Ã¶©
Ïð¥Ƹ°ìºâó¥Š˿ТƲu{©²ïó¿×óÀТƲw^¹ðÌïóí°ìºâó×óÀТƲwk_sskОѐͭþ Auf1 ÅðÕµց°³Ã
¶©Ïð¥Ƹ RNA ΞλφТƲy¡sl˩k_ j Auf1 ÅðÕµ¿Ûë«½ð¶Űu¢¡ 3 ņŝսÔì©ðÌlf¡slϕ¢g¡l^HeLa Оѐ̩lց°³Ã¶©Ïð¥Ƹ°ìºâóΞλφТƲy¡_ 














Şƀ8R=ťĀ2 Auf1 kx`G<RųƎ>7AGƚ° RNA EĲĽŅEŦº¨Ĕ;ŤŭóÄÏF®75ñƁ ս¿Ûë«½ð¶Ôì©ðÌ¥ȀѝѻРˇiÅðÕµwȀԖάέu{Гҙw_s¢Гҙ Auf1 ÅðÕµ}¢ѨӟԑƐ RNA ΞλφТƲё¥ϣugl^s¢ОѐʮŰͭ¥Ͳ|¡ΞλφТƲёlǜɸy¡slŵճǠռմ_38 ssk^Auf1 ÅðÕµ̅ϕОѐʇǝȍҚƲı¥ɮʝy¡k^f¡g̅ϕОѐʇǝȍńՠ¥ƩqΨǥĴ̪ĠҼw^ԑƐ RNA ΞλφТƲё¥Υɶy¡slтi¢¡_^sԑƐ RNA ТƲ ԑƐ RNA űҥ^f¡g^ԑƐRNA ҂ϵwОѐ Apoptosis lҹȱu¢¡gkтiճǠսմ^s̅ϕ
ǝȍƴȗ¥Ӹg¡_                   Å ƶ ƓȑʁήՆg^сƐæËíâ¬¿ÖÌ©íÉÓ«âóʌуΰ̍Ри¥ήgοΪȑφҥ̑gʝ̓l÷lm_ճӁ˛ջ^սմ^сƐwâ¬¿»í(Macaca mulatta) ȷþԑƐ RNA űҥέΝтi¢¡ց°³Ã¶©Ò½ðlǹƈwg¡slӕԖű̑Т̓˩k_sǹƈсƐæËíâ¬¿f¡ SAMP8 ÷˨w
ó±ów

g¡_sskȷþց°³Ã¶©Ò½ðсƐ˿Ɗâėɳ̃ɲm¡_ճӁ˛ռ^վմ

ńžƈć
1.

Elimination and Utilization of Oxidized Guanine Nucleotides in the Synthesis of39RNA and its Precursors. Sekigucgi T, Ito R, Hayakawa H, Sekiguchi M. J. Biol.

Chem. ̗ҽ˿^288, 8128-35 (2013)2.

Age-dependent accumulation of 8-oxoguanine in the DNA and RNA in various rat
tissues. Nie, B., Gan, W., Shi, F., Hu, GX., Chen, LG., Hayakawa, H., Sekiguchi,
M., Cai, JP.

Oxidative Medicine and Cellular Longevity. ̗ҽ˿^ID 303181,

http://dx.doi.org/10.1155/2013/303181 (2013)
3.

Oxidative damage of DNA, RNA and their metabolites in leukocytes, plasma andurine of Macaca mulatta: 8-oxoguanosine in urine is a useful marker for aging. Shi,F., Nie, B., Gan, W., Zhou, XY., Takagi, Y., Hayakawa, H., Sekiguchi, M., Cai, JP.

Free Radic Res. ̗ҽ˿^46, 1093-98ճ2012մ
4. Greater nucleic acids oxidation in the temporal lobe than the frontal lobe in       
SAMP8. Shi F, Gan, W., Nie, B., Takagi, Y., Hayakawa, H., Sekiguchi, M., Cai, JP.

Neuroreport. ̗ҽ˿^23, 508-512 (2012)
5. Age-dependent increases in the oxidative damage of DNA, RNA and their
metabolites in normal and senescence-accelerated mice analyzed by
LC-MS/MS: urinary 8-oxoguannosine as a novel biomarker of aging. Gan, W.,
Nie, B., Shi, F., Xu, X. , Jianchang Qian, J. , Takagi, Y., Hayakawa, H.,
Sekiguchi, M., Cai, JP. Free Radical Biology & Medicine ̗ҽ˿^52,
1700-1707 (2012)6.

Lowered Nudix type 5 (NUDT5) expression leads to cell cycle retardation in
HeLa cells. Zhang, LQ., Dai, DP., Gan, W., Takagi, Y., Hayakawa, H.,
Sekiguchi, M., Cai, JP. Mol. Cell. Biochem. ̗ҽ˿^363, 377-384 (2012)

1. Proteins that recognize oxidative RNA damage.

Hiroshi Hayakawa.

Ѐ 86 ǜˤ̇άƐȑħȀħ^«ðÅóÎ½êÎí½ðá¾¬ä: Gene Expression under
Oxidative Stress 03-1IS15a ̲ͦ^2013 ɖ^ւ˾40ϙ ϸ Ҿ Ֆτl¦¥ʧi¡©áÌó½¿̵̭ϙϸĞҔуˤըϐЙճОѐűȍάΝȑӂɠòűȍ̵ёŸɷȑűԕò˕ˀմƁš DNA ÷άxńՠǵǮ O6-åÇí¶©Ïð DNA ҚҙӽϱǵǮһȩƲ¥ɮʝw^ϹΓǽλuτl¦¥mӗsyƟǝ¡_wkw^ըЂάΝsˊŏ¥ʶОѐ©áÌó½¿¥ҹȱwņıkˁ԰y¡sǽλОѐŰΨ¥ʧŸwg¡_ʞ`

¾óðÌëÈÛ͝¥ήg ^s©áÌó½¿ҹȱԨ¤¡˞ҟǝȍw

MAPO1 ¥

ƴȗw_MAPO1 Оѐӕȸǥw^τl¦ʧŸǝȍôf¡ FLCN ОѐŤ®
Ñí´óʔϕ³ÎóÂf¡ AMPK ύčĴήy¡_siRNA ¥ήg Ampkα f¡gFlcn ԄĨȍÒÈµÆ¬ðОѐ^©í³íƐſůΪɳ»Ú G1 ОѐŰΨlՙҀʧŸu¢sk^AMPK  FLCN  MAPO1 ƴ̮©áÌó½¿ҹȱɿҜf¡slϣu¢_^AMPK-MAPO1-FLCN ҚƲı©áÌó½¿ҹȱӽϱƋʖ¥Śν͒ԭ͝j«äÒÚïÈÌ͝ҥ̑ws£^AMPKα ©áÌó½¿ҹȱɳ MAPO1-FLCN ҚƲıkҥԿw^}¢ĩg MAPO1 lÅðÕµӕîÝíȓȗƐy¡sl˩k_MG132 ¥ήgșե

^MAPO1 ÅðÕµӕȓȗʇÛïÊ©ÃóäĺȎwÅðÕµűҥЖlͰoԨ¤j^}űҥ¥ƩqzȓȗƐy¡s^MAPO1 ©áÌó½¿ҹȱё¥ͣʇƐy¡̵̭lϣǊu¢_ōŕňŅ ΫǸþԑМƐȑΝӕάǀͣƋùƭ̶f¡l^}skάx¡ͣʇԑМǽλƟΝӕ¸Òä DNA ¥ŏq^l¦сƐ¥mӗsyƟǝ¡_DNA
ˊŏf¡ńՠǵǮ O6-åÇí¶©Ïð^DNA ҚҙӽϱǵǮã¿ȩƲ¥ɮʝwϹΓǽλƟǝ¡^Оѐ©áÌó½¿¥ҹȱy¡slϕ¢g¡_s©áÌó½¿ҹȱã¿âÈÇńɸճğø MMR ιҪմÅðÕµӕlɿҜf¡lճHidaka et al., Nucl. Acids Res., 33, 5703-5712, 2005մ^MMR ÅðÕµӕ¥̶ˊw
ОѐjgϹΓǽλ҂ϵlӗs¡s^^MMR ԄĨȍlùͣƐu¢ÒÈµ©¬Ìâ¬¿τl¦Փɟ÷˨lӗs¡sk^s̵̭ҥ˩ϹΓǽλτl¦ʧŸ̵̭ҥ˩зl¡тi¢¡ճǠպմ_}sʞ`^̇©áÌó½¿ͣʇƐ̵̭ҥ˩¥ϊφw^©áÌó½¿ҹȱŴ̃Ʀʁ¥άƐȑφҥ̑w^ÖÌОѐµïâÇð÷jg

MMR ÅðÕµӕlҚƲı¥ɮʝw

 DNA ˊŏ¥Ҹӄw

O6-åÇí¶©Ïð¥Ƹg¡s¥˩kw_}¢ƴ˰^MMR ÅðÕµӕl

Proliferating Cell Nuclear Antigen (PCNA)ύčĴή¥ӳw
41

DNA ҚҙƦʁþDNA ˊŏ¥Ҹӄwg¡sϣw_}ɳ^DNA ˊŏҸӄɳ̵ёy¡˞ҟ©á

Ìó½¿ҹȱǝȍЫлφƴȗ¥ϊʷw^ԄĨȑφ¿µìóÏð¶¥ҏϸ^άƐȑφԄĨȑφҥ̑m_̇ϙ©áÌó½¿ҹȱǝȍ¥˞ҟƴȗw^Оѐ̿ҹȱСӜűȍ̵ɜ¥˩ky¡s¥ϊφy¡_lk\fcj_`
 


(MNU)
 



 
 

 

TXZSYVTP[U" 

  
 

 

 

 



!

P









  



"Ċĥ ԄĨȑφҥ̑jq¡ȡāОѐ O6-åÇí¶©Ïð¥Ξλφńɸy¡ԐМ MGMT
¥̶ˊwОѐ¥ήg_sОѐ©í³íƐſȩwըgʔƩʇ¥ϣyl^MMR

ÅðÕµӕh©áÌó½¿ҹȱ̵ёy¡ÅðÕµӕ¥ƴ˰̶ˊwОѐ^©
áÌó½¿¥ҹȱmo©í³íƐſȩwʭʩʇ¥Υɶy¡_ʞ`^sҔΨЖ¥©áÌó½¿ҹȱ̶ˊОѐ¿µìóÏð¶͝ŷήwճǠջմ_z^Ûïæó
ÅóՎǬ¥̶gÓ«¶ïâ«½ðфʇԄĨȍ¥îÌï¬«í¿ÝµÅó¥ήgԄĨȍÌëÈÛ͝^©í³íƐſ N-åÇí-N-ÏÌïÃ¬î©ճMNUմȩwʔƩʇ

f¡ Mgmt ̶ˊОѐΰ̍y¡ԄĨȍϛǺ̛ë«ÚëìóճÓ«¶ïâ«½ðфʇմ¥̭Њy¡_̷^}þk©í³íƐſ MNU ʭʩʇ¥ϣyǽλОѐ̛¥ƙԿy¡_s¢Оѐ̛©áÌó½¿ҹȱԄĨȍlϛǺu¢Ĩȍ҅ſфʇԄĨȍ DNA ԏųʏǰ¥ʤlk42g¡ƭёʇlըo^ϛǺu¢Ԅw PCR ͝Ƞ˪ƴȗm¡_ÅƵ,gpm~ĥEOQVpfhƆØĞĂŤŭFh`saĥŦ ĕպշ©áÌó½¿ҹȱӽϱ MAPO1 ÅðÕµӕȓȗƐ ʞ`^ǠջϣwԄĨȑφ¿µìóÏð¶˞ҟ©áÌó½¿ҹȱǝȍ

MAPO1 (O6-methylguanine-induced apoptosis 1)¥ƴȗwճKomori et al., Oncogene,28, 1142-1150, 2009 մ_ MAPO1  О ѐ ӕ  ȸ ǥ w ^ FLCN (Follicuin)  AMPK(AMP-activated protein kinase)ύčĴήy¡_FLCN  BHDճBirt-Hogg-Dubeմπňнճχѡ^ь^љѥЂѥǗըՓɟќρ¥άx¡մƟǝǝȍfǹ͂Ÿɷjg^AMPK ОѐԔҜ̵ё¥ʯhìðԑƐԐМf¡_siRNA ¥ήg Ampkαf¡g Flcn ԄĨȍÒÈµÆ¬ðОѐ^©í³íƐſůΪɳ»Ú G1 ОѐŰΨlՙҀʧŸu¢sk^AMPK  FLCN  MAPO1 ƴ̮©áÌó½¿ҹȱɿҜf¡slϣu¢ճLim et al., DNA Repair, 11, 259-266, 2012մ_ ©áÌó½¿ҹȱӽϱ MAPO1 τΨîÝí¥«äÒÚïÈÌ͝ҥ̑ws£^MAPO1 ÅðÕµӕОѐ©í³íƐſճMNUմůΪɳС˰φ÷˨w^72˰ԧɳ̅ůΪ˰͇И 2.1 Ňǹƈy¡slűkճǠռֆմ_sÅðÕµӕîÝíǽƋҿЈwo¥ҿ¡^FLAG-MAPO1 ¥ȓȗτΨy¡ОѐÛïÊ©ÃóäԬȞſ MG132 ¡ůΪ¥ҏ_Ǡռևϣyh^MAPO1 ÅðÕµӕîÝí MG132 ůΪտ˰ԧɳպջ˰ԧɳ˿ʒǹƈw_ƴ̮ǹƈ^
é×³ÇðոÛïÊ©ÃóäĺȎwÅðÕµӕjgʉɑφűҥu¢ңȧu¢_s¢ȩw43g¡slϕ¢g¡ p53^FLCN  AMPKαÅðÕµӕîÝí MG132 ůΪɳǽƋwk_sТ̓^MAPO1 ÛïÊ©ÃóäĺȎφȗɑφűҥu¢g¡l^©áÌó½¿ҹȱ˰ȓȗƐu¢¡s¥ϣǊwg¡

ճSano et al., Biochem. Biophys. Res. Commu., 430, 810-815, 2013մ_A

MNU(-)
0

24

48

MNU(+)
72

24

48

B

72 ()MAPO1

FLAGMAPO1

FLCN

FLCN

AMPKα

MG132(-)

MG132(+)

0

0

6

12

6

12 ()AMPKα

GAPDH

p53
GAPDH

"mM\fcj_`TOQZ 81;:( U"ջշFLCN  AMPK  MAPO1 ÅðÕµӕȓȗƐɰՉ
 MAPO1  FLCN  AMPK ύčĴήy¡slűkg¡^s¢ύčĴήǝȍ MAPO1 ȓȗƐԨúy¡slтi¢¡_}s^s¢ԄĨȍΞλφ siRNA ¥ОѐŤȱŜw^FLCN  AMPKαԄĨȍτΨʧŸ˰ MAPO1 ÅðÕµӕîÝí¥«äÒÚïÈÌ͝ҥ̑wճǠսմ_¹ðÌïóí siRNA ¥ȱŜwОѐճsiCONTմȗɑ˰ MAPO1 îÝí¥պy¡^MNU ůΪրջ˰ԧɳ}îÝíǠռֆТ̓ƴxoИջŇ÷˨w_ FLCN ÒÈµÆ¬ðОѐճsiFLCNմ^MNU ̅ůΪ˰ MAPO1 îÝíl¹ðÌïóí͇Иսպղ͸

ȳwճ*P<0.01մ^MNU ůΪɳ}ǹƈ¦ңȧu¢k_}¢ȩw^

AMPKαÒÈµÆ¬ðОѐճsiAMPKαմ^MNU ̅ůΪ˰jg ¹ðÌïóíî
ÝíИջŇǹƈwճ*P<0.01մ^MNU ůΪɳîÝíu÷˨w_s¢Т̓^FLCN  MAPO1 ȓȗƐԨww

g¡s¥ϣǊw

á¾ÊªÚ^AMPK ӰÑ²ÊªÚԨú

g¡_

44

MAPO1 

6


4



2
0

-

MNU

+

-

siCONT+-

siFLCN+siAMPKαnM81;:( hegWU 4729%R 8;6α%db^a]iU!"       ռշ©áÌó½¿ҹȱӽϱ AMPK-MAPO1-FLCN ҚƲıǽƋ ©áÌó½¿ҹȱӽϱjq¡ MAPO1  FLCN  AMPK ΝΪφύčĴήǽƋ¥ҥ̑y¡^FLAG-MAPO1 ¥ȓȗτΨy¡Оѐ¥ MNU ůΪw^}ɳրջ
˰ԧОѐʮŰͭճInputմ¥ήg

ʩ FLAG ʩı×óÀ¡Śν͒ԭșե¥ҏ_Ǡվϣyh^ėǰƼӳ

MNU ̅ůΪ̌Ģճչ˰ԧմ MAPO1 

FLCN  AMPKαýу˿ʒύčĴή¥ɮʝw_MNU ůΪɳ MAPO1  FLCNȓȗύčĴήŁ¢l^AMPKαMAPO1koҥԿw^րջ˰ԧɳ

}ύčĴήҀwoĮøy¡slҞŰu¢_AMPK  MAPO1 kҥԿl©á
Ìó½¿ҹȱͣʇƐȣ˄ԨӶwg¡ƭёʇlтi¢¡_

Input
0

24

48

IP (FLAG)
72

0

24

72 ()48

FLAGMAPO1
FLCN
AMPKα
GAPDH
oM\fcj_`TOQZ 81;:( U 4729 R 18;6αRUU""" ʞ`îÌï¬«í¿ÝµÅó¥ήg¾óðÌëÈÛ͝˞ҟ©áÌó½¿ҹ

ȱǝȍ MAPO1 ¥ƴȗw_sǝȍėŝoҥ̑u¢zmÅðÕµӕf¡l^ѬƾͰgssÅðÕµӕάΝϲ¥ӳw
45ըɟŁȎu¢j^}̵ёάΝȑφԔҜʇlīi¡_̇ϙϸjg ^ОѐŤ MAPO1 ȗɑΠʖĮîÝíʧi¢g¡l^©áÌó½¿ҹȱĩgǹƈy¡sl˩k_sÅðÕµӕîÝíǽƋ MAPO1 ύčĴήǝȍf¡ AMPK  FLCN  ҿЈu¢
AMPK  MAPO1 ÛïÊ©ÃóäĺȎφűҥ^}wg¡ƭёʇlϣǊu¢_}w^

FLCN }ȓȗƐ¥ĿӸw^ÛïÊ©ÃóäĺȎφűҥ½¿Êä¥ӯ¢Ɛw MAPO1-FLCN ҚƲıl©áÌó½¿ҹȱ½¶ÎíĨӿjg


j

ȓȗ

ԔҜ̵ё¥ʯg¡ϣǊu¢¡_ėɳ^MAPO1 ÅðÕµӕҚƲıǽƋԨӶw©áÌó½¿ҹȱͣʇŸɷ̵̭¥űȍîÝí˩kw

gmgтi

g¡_

"
ńžƈć
1.

Stabilization of MAPO1 by specific binding with folliculin and AMP-activatedprotein kinase in O6-methylguanine-induced apoptosis. Sano S., Sakagami R.,
Sekiguchi M., Hidaka M. Biochemical and Biophysical Research Communications,̗ҽ˿^430, 2, 810-815 (2013)

2. The identification of a novel gene, MAPO2, that is involved in the induction of
apoptosis triggered by O6-methylguanine. Fujikane R, Sanada M, Sekiguchi M,
Hidaka M. PLoS ONE, ̗ҽ˿^7, 9, e44817 (2012)3.

Activation of AMP-activated protein kinase by MAPO1 and FLCN induces
apoptosis triggered by alkylated base mismatch in DNA. Lim TH., Fujikane R.,
Sano S., Sakagami R., Nakatsu Y., Tsuzuki T., Sekiguchi M., Hidaka M. DNA

Repair, ̗ҽ˿^11, 259-266 (2012)
A novel protein, MAPO1, that functions in apoptosis triggered by O6-methyl

4.

guanine mispair in DNA. Komori, K., Takagi, Y., Sanada, M., Lim, TH., Nakatsu,
Y., Tsuzuki, T., Sekiguchi, M., Hidaka, M. Oncogene, ̗ҽ˿^28, 1142-1150 (2009)""
1. ǽλОѐ¥ˁ԰y¡©áÌó½¿ҹȱ̵̭. ˤըϐЙ. ˓ȭаάΝϙϸ^̗ҽ˿^49, 1, 73-84 (2014)"
1. ©áÌó½¿ҹȱӽϱ MAPO1 ȓȗƐ FLCN  AMPK 46

Ÿɷu¢¡. ˤըϐЙ^įԕwj^ǧ÷ϼӒ^ԨƫϓȂ. Ѐ 85 ǜȀħˤ̇ԄĨȑħ^ʙʁоǷȀȑ^2013 ɖ 9 ˾.
2. ©áÌó½¿ҹȱӽϱjq¡ "%$ ÅðÕµӕȓȗƐ. įԕwj^ǧ÷ϼӒ^

ԨƫϓȂ^ˤըϐЙ. Ѐ 35 ǜˤ̇űȍάΝȑħɖħ^ϫȿ^2012 ɖ 12 ˾.
3.

τl¦¥ʧŸy¡©áÌó½¿ҹȱ̵̭. ˤըϐЙ^įԕwj^҇ţĕӥ^̒ɻӊ^ǧ÷ϼӒ^þ͢ƭӾ^йӦĂ^ԨƫϓȂ. Ѐ 35 ǜˤ̇űȍάΝȑħɖħ^ϫȿ^
2012 ɖ 12 ˾.
4. The identification of a novel gene, MAPO2, that is involved in the induction of
apoptosis triggered by O6-methylguanine. Fujikane R., Sanada M., Sekiguchi M.,
Hidaka M. The 8th 3R Symposium, Awaji, Japan, November 2012.
5. MAPO1  FLCN ¡ AMPK ͣʇƐ©áÌó½¿¥ҹȱy¡. ˤըϐЙ^̒ɻӊ^҇ţĕӥ^įԕwj^ǧ÷ϼӒ^þ͢ƭӾ^йӦĂ^ԨƫϓȂ. Ѐ 84 ǜȀħˤ̇ԄĨȑħ^ĄɅȀȑ^2012 ɖ 9 ˾.
6. MAPO1/FLCN/AMPK protein complex is involved in apoptosis induced by DNA
damage. Hidaka M., Fujikane R., Sano S., Sakagami R., Sekiguchi M.
Birt-Hogg-Dube Syndrome 3rd International Symposium 2011. Maastricht,
Netherland, May 2011.

47ϙ ϸ Ҿ Ֆƫњl¦ՒԌìðÕЈӡϰʧŸ©ÛïóÇϙϸĞҔуӇƫ ԉĂճάı̭ӵȑӂɠòοʖ̭ӵȑűԕò˕ˀմƁš ̇ ϙ ϸ   ^ճ պ մ 1/<13?7<7A7/A7<5 13::@ @  â ó ± ó  f ¡ /:236F23
236F2?=53</@37@=4=?; ! ƫњʣɕ÷χσРиűɎ̮ɥl^ѧɛφŦτԨӶy¡s¥ѧɛοΪȑφ̩Нϣw_ճջմ^ƫњʣɕ÷χσОѐ¥ήg

7<C7A?= șեk^½¿ÛëÇðʭʩʇσОѐ^! ԴʇОѐǹƈl˩k_ճռմ½¿ÛëÇðʭʩʇ ! ԴʇОѐʇΠ¥̩НwТ̓^ƴОѐYʩσſˁṶ̵̋Ԩúy¡  τΨ÷˨^ZͫΆёĒӸj[ѨɌҚҙёĒӸlҸ¢_ğ÷Т̓k^! Դʇƫњʣɕ÷χσОѐ^@ w

ʇΠ¥slϣǊu¢_u^ѧɛφƴОѐȎǥf¡g́Ȏ^ŦτԨӶy¡sl˅ͻu¢_ōŕňŅ ƫњl¦ճāƫњʣɕ÷χσմʢȻìðÕЈճՒԌìðÕЈմӡϰ˿Α^ʌуĊɳɰՉy¡ԔҜǝȍf¡_wl^l¦ОѐӡϰʧŸ̵ɜҥ˩l¦͗ςƊ̓Ʒ÷όТy¡ҾՖf¡_l¦Риǿ̮űƐ̓Էl¦Оѐнk̭ʝu¢¡ heterogenous ԽǞf¡sl˩

m_ӫɖ^s¢l¦ОѐԽǞþ^l¦ɘОѐճcancer stem cell, CSCմf¡g cancer initiating cell (CIC)lȳ˙lƸ˿wg¡slǰƼu¢g¡_CIC ^ɘОѐΞɼf¡ѨɌҚҙёjǿűƐ̵ё¥˿wl¦Оѐǹ͂jͫΆԔҜОѐf¡_u^CIC
ĮԑМ^Į̘աΠʖάȎf¡g͗ςʭʩʇ̵ё¥Łʶwg¡sl˅ͻu¢g¡_
 Aldehyde dehydrogenase (ALDH)©«ÃÙ¯óäf¡ ALDH1 ͣʇ^ҎͭjϧСɘОѐ÷˨lǰƼu¢^}ɳ^ǿoʎʇќρРиճǿτʇզէќ^ʆʇզէʇυҎο^їќρ^ьσ^ćσ^ѤѥσjƫњσմƸ˿u¢g¡ɘОѐjgըgͣʇ¥ϣysl¤k_y¤^ALDH1 ^̺ɑjl¦jq¡ɘОѐâó±ówƭёʇl˅ͻu¢g¡_u^f¡ϲʎʇќρjg

ALDH1 τΨѧɛφĊɳύԨʇǰƼu¢ wl

^g¡_^ALDH1 τΨƫњʣɕ÷χσάΝȑφʇΠԨúy¡sl˅ͻu¢¡_u^ALDH1 τΨσОѐ^CIC w͗ςʭʩʇԨӶwg¡gk^тi_}s^̇ϙϸ^պմƫњʣɕ÷χσРи ALDH1 τΨ¥ѧɛοΪȑφ̩Нw^ջմin vitro șեjg^ʩσſf¡½¿ÛëÇðʭʩʇʣɕ÷χσ48Оѐ ALDH1 τΨjτΨОѐ CIC w̵ё¥̩ҩw_ō ŕťũÍƛ Ţ Ʊŀ÷ěƒÑ©ƛƉßƲÎĺ¢Ć Ʊ·ŰűłÑ©ƛÍÑƢķ,Ĵ®ąƲĭƛôŽ ƱŨºğŒÑ©ƛÍÑƢƲĊĥ zȉ^90 πĸƫњʣɕ÷χσճOSCCմРи ALDH1 τΨ¥ŚνРиƐȑφ̩Нw^ѧɛʖɟύԨʇ¥̩ҩw_̷^ÖÌƫњʣɕ÷χσОѐ(HSC-3)¥ήg^½¿ÛëÇðź·нՅź·н HSC-3 ОѐОѐǹ͂©ÈÁ«^ALDH1 τΨj
 CIC ̵ёԨy¡Ʊϲ©ÈÁ«¥ҏ_ŦĕBūÖ
պշ$' Ри ! τΨŦτύԨy¡ 90 πĸ OSCC РиŚνРиƐȑφ ALDH1 τΨ̮ɥ^Բʇ^Ԯȸʇճ<20%̕ѱΦմ΃ʇճ>20%̕ѱΦմ 3 ¶íóÛűqճǠպմ_Ǡպ OSCC Риjq¡ ALDH1 ̕ѱ̮ɥ_(A) ՅσԌƫњБѢԴʇОѐ¢
g_(B)OSCC РиԮȸʇ ALDH1 τΨ_(C)OSCC Ри΃ʇ ALDH1 τΨ_
ALDH1 ԴʇΦg^Բʇճ7 ĸ^7.8%; scorre 0մ
ք1-5%ճ20 πĸ^22.8%; score 0մք

6-20%ճ16 πĸ^17.8%; score1մք21-50%ճ37 πĸ^41.1%; score 2մ
ք>50%ճ10 πĸ^11.1%;score 3մf_ALDH1 ըτΨнճ>20%մ^ɖհճp=0.464մ
^ʇŶճp=0.876մ^τάԌĭճ=0.392մ^ќρȀmuճp=0.239մ^T ű՚ճp=0.574մ
^ìðÕЈӡϰճp=0.577մ^pTNM¿¹©ճp=0.694մύԨʇ¥Ҹk_wkwl^ALDH1 ըτΨнճ>20%մȸʢŦτճp=0.006մ^̺ύԨʇ¥Ҹ_
ջշOSCC Оѐ ALDH1 τΨ OSCC Оѐ ALDH1 τΨ^ŚνОѐƐȑφjԐМРиƐȑφ̩Н¥ҏ_ŚνРиƐȑφjԐМРиƐȑφ^ALDH1  HSC-3 Оѐнȳ˙l^Ȏǥw
49

_Ùïó»«ÌåóÅó̩Нjg^ALDH1 τΨОѐ 0.62 %f_ Ǡջ HSC-3 Оѐ ALDH1 τΨОѐ_(A) ŚνРиƐȑφ̩Н_(B)ԐМРиƐȑφ̩Н_(C)Ùïó»«ÌåóÅóԴʇОѐűɎ_ALDH1 ͣʇԬȞſf¡ DEAB 

ͬ

Ȅw_
ռշOSCC Оѐ ALDH1 τΨȩy¡½¿ÛëÇðɰՉ ôѯφʩσſw

ķήu¢g¡½¿ÛëÇðȩy¡ ALDH1 ԴʇОѐʭʩʇg ̩ҩw_z^½¿ÛëÇðʨújq¡ OSCC Оѐǹ͂ͣʇ¥ CCK-8 assay ̩Нw_0.1 j 1μM ½¿ÛëÇð^Оѐǹ͂ɰՉ¥úik_w
kwl^5 μM ğ÷ΉɟОѐǹ͂͸ȳ¥Ҹ_½¿ÛëÇðʭʩʇ OSCC
ОѐճCisSCsմ ALDH1 ԴʇОѐ¥Ùïó»«ÌåóÅó 1.81%, 5 μM  7.70%ȩw̩Нy¡^1 μM 

^10 μM  14.8%÷˨w_sТ̓^½¿ÛëÇðՅʨúճ¹ðÌïóíմ͇ӣy¡^24 Ň÷˨wðʭʩʇ OSCC Оѐн^ALDH1 ԴʇОѐlǹƈwg_y¤^½¿ÛëÇg¡s¥ϣwg¡_ s¢ CiSCs ^½¿ÛëÇðˁ͚áðÛԨúy¡ ABCG2 τΨlĒӸw
sl western blotting ͝
̵ё¥˿w

g¡

˩k_sТ̓^CiSCs ОѐнʩσſˁŰg¡ƭёʇ¥ϣǊwg¡_50

Ǡռ HSC-3 Оѐ½¿ÛëÇðɰՉ_(A) CCK-8 ͝¡Оѐǹ͂ё_(B) ½¿ÛëÇðʨúΉɟ¡ ALDH1 ԴʇОѐ percentage_(C) Western blotting ͝ ABCG2
τΨ_PTCs,½¿ÛëÇðՅʨúճ¹ðÌïóíнմ
քCiSCs, ½¿ÛëÇð 10 μM ʨúн_
սշCiSCs ͫΆё
 CiSCs  PTCs  ALDH1 ԴʇОѐȣɟԀglÙïó»«ÌåóÅó̩Н˩k^̷ýуͫΆёg̩ҩw_˟͝^Matrigel invasion assay ¥ʁήw_ͫΆОѐ˙^CiSCs l 134H12.1 ȩw^PTCs  54H   7'@ нl˿ʒըgŉ¥ϣw_sТ̓^½¿ÛëÇðʭʩʇσОѐըgͫΆʇ¥Łʶwg¡sl˩k_Ǡս 7'@ j %(@ jq¡ "/A?753:7<C/@7=</@@/F_51վշCiSCs  cancer sphere formation σɘОѐΞɼô^ѨɌҚҙё¥Łʶwg¡slϕ¢g¡_CiSCs ѨɌҚҙё¥̩ҩy¡^ΑҎʹø cancer sphere formation assay ¥ҏ_PTCs ͇ӣw^CiSCs Ȁm sphere ɮʝlҸ¢_y¤^CiSC ¥̭ʝy¡Оѐн^σɘОѐl PTCs нǿoƸ˿u¢g¡slϣǊu¢_Ǡվ CiSCs j PTCs  cancer sphere formation assay_ ğ÷Т̓k^ALDH1 τΨʣɕ÷χσОѐlȸʢŦτԨúy¡sl˩k
_ǭաОѐșեk^ALDH1 ͣʇ¥˿y¡σОѐн^ʩσſʭʩʇ^ͫΆёĒӸjѨɌҚҙё CIC wʇΠ¥ɬoϣysl˩k_ń žƈć
1. Dynamic changes in cell-surface expression of mannose in the oral epithelium
during the development of graft-versus-host disease of the oral mucosa in rats.
Hanada H, Ohno J, Seno K, Ota N, Taniguchi K. BMC Oral Health ̗ҽ˿^15, 5(2014).
2. In vitro and in vivo expression of aldehyde dehydrogenase 1 in oral squamous cell
carcinoma. Ota N, Ohno J, Seno K, Taniguchi K, Ozeki S. Int J Oncol. ̗ҽ˿^44,
435-442 (2014).
3. Lupus-like oral mucosal lesions in mercury-induced autoimmune response in
Brown Norway rats. Seno K, Ohno J, Ota N, Hirofuji T, Taniguchi K. BMC

Immunol. ̗ҽ˿^14, 47 (2013).
4. Tumor-induced lymphangiogenesis in cervical lymph nodes in oral
melanoma-bearing mice. Ozasa R, Ohno J, Iwahashi T, Taniguchi K.
. J Exp Clin Cancer Res ̗ҽ˿^31, 83 (2012).
52


1.

°óÌÙ¨¾óʧŸ¡ƫњʣɕ÷χσ cancer sphere ɮʝёǽƐ. Όԕʊғ^ȀԕЙ^ɣ҇ƗԻ^ӇƫԉĂ. Ѐ 103 ǜˤ̇οΪȑħ^ɚɁ^2014 ɖ 4 ˾.

2. T ОѐŚνʁЄǩƫњБѢοǽjq¡®Ù­µÅóОѐ÷χҢǂʇ̵̭.  ȀԕЙ^Όԕʊғ^ӇƫԉĂ. Ѐ 103 ǜˤ̇οΪȑħ^ɚɁ^2014 ɖ 4 ˾.
3. °óÌÙ¨¾óŸɷ¡ cancer sphere ɮʝё. Όԕʊғ^ȀԕЙ^ȁίł˘^ɣ҇ƗԻ^ӇƫԉĂ. Ѐ 24 ǜˤ̇ѧɛƫњοΪȑħ^̎Ĕ^2013 ɖ 8 ˾շ
4. °óÌÙ¨¾óŸɷ¡ƫњʣɕ÷χσОѐƋʖշ ȀԕЙ^Όԕʊғ^ȁίł˘^ӇƫԉĂշЀ 102 ǜˤ̇οΪȑħ^̈ɓ^2013 ɖ 6 ˾շ
5. ®Îåí÷χσσќ՚ĬŒ¥Ƹ˿y¡®Îåí÷χќ 2 ĸ. ȁίł˘^ȀԕЙ^Όԕʊғ^ӇƫԉĂ. Ѐ 102 ǜˤ̇οΪȑħ^̈ɓ^2013 ɖ 6 ˾շ
6. ConA ¡ƫњʣɕ÷χσОѐ°óÌÙ¨¾óҹȱշȀԕЙ^ɀ̴Ӧ˩^ӇƫԉĂշЀ 101 ǜˤ̇οΪȑħ^̎Ĕ^2012 ɖ 4 ˾.

53


ϙϸҾՖ

µïâÇðìæËìð¶Ù¨µÅó¸ÒäȓȗЩʶϙϸĞҔу̤͢ ̟ȍճ̵ёάΝƐȑӂɠòάƐȑűԕò˕ˀմƁš ԐͅµïâÇðìæËìð¶Ù¨µÅóRdh54 ^ɵ̍тi¢ёz^ÁðÌïå©ՎǬ¥Ęw
̵ёg

ҥ̑¥Ӹ

gύƴРˇijq¡̵¸ÒäȓȗƐȢúy¡ϕҞ¥ɶ^s˞ҟ

g¡_̇ϙϸ^Rdh54 lό˄ÁðÌïå©ΞλφÅðÕµӕ Cse4ύčĴήy¡ċ¥˩kw^u^}¢~¢ÅðÕµӕjq¡ТƲՎǬ¥Ξȗw_
Rdh54 ßæï¶ Rad54  Cse4 ύčĴήy¡l^Cse4 ¥˝ΚƐwҥ̑y¡ Rdh54 ΞλφТƲy¡ՎǬlɶ¢^˽Пφ Cse4 þȃԌ 21 ©ãÒԑ́ǮΞȗu¢_©
ãÒԑкˇ

^ТƲՎǬŤҚ˙ Lys ́Ǯ̺ѺՁlԨúwô˟^Rdh54  Cse4 ТƲՎǬþȃԌИ 300 ©ãÒԑ́Ǯg¡slϣǊu¢_^Ö¿Ìð H3 ТƲՎǬλ¡slűk_ğ÷Т̓¥^ԐͅОѐŤ Rdh54  Cse4 ԧύčĴή¸ÒäȓȗƐ̵̭Ԩ¤gҥ̑¥Ӹ¡Ċȗf¡_ōŕňŅ ӡŨ DNA ńɸ^ҚҙЂ̕ѱı÷άΝ̵ёlǕ¢¡Ը_µïâÇð̭ӵ¥ҥͬy¡ɿҜlf¡_Ö¿Ìð}Ĝ DNA ТƲÅðÕµӕ¥¸Òä DNA kǾys¥µïâÇðìæËìð¶ƿ^άΝ̵ё͆ΞλφµïâÇðìæËìð¶Ù¨µÅólϕ¢g¡_

Ԑͅ Rad54  Rdh54  Swi/Snf Ù¨ãìóµïâÇðìæËìð¶Ù¨µÅófŠύƴРˇiԨúwg¡_Rad54 g^ҲեЇŤÐµî°ÃóäìæËìð¶ͣʇƈi^Ö¿Ìð H3 ό˄ύčĴήy¡sűkg¡_ʞ`ϙϸȜ^ԐͅČŇıОѐ¥ήg¸Òäȓȗʇҥ̑k^ύƴРˇil̶ˊwg¡ Rad52 ̶Ȅ̛jg^Rdh54 ¥u̶ˊu{¡̕ѱıǓȄl÷˨y¡s¥ҞŰw_us̛^ÁðÌïå©ԏųĺȎwÛë¿ãÍǓȄl÷˨w^Rdh54 ÁðÌïå©ՎǬ¥Ęw̕ѱıȓȗƐȢúy¡slϣǊu¢_Rdh54 ³ÑÌ¹©ÅðÕµӕŠȸǥy¡ǰƼlf¡sk^
Rdh54 ˞ҟ̵ёg^Rdh54 lÁðÌïå©ΞλφÖ¿Ìð H3 Ôì©ðÌf¡ Cse4ύčĴήy¡sĴήwg¡Ĵ̪ĠҼ¥ϻճǠպմ_

^Cse4 ¥ƸÁðÌïå©ΞλφÐµî°Ãóä̭ӵµïâÇðìæËìð¶ Rdh54 lɿҜu¢¡gkĠҼf¡_}sz^Rdh54  Cse4 lΞλφύčĴήy¡kg

54

̩Ұw_

Ǡպ Ĵ̪ĠҼĊĥ
A. ОѐŤȸǥҥ̑ ԐͅОѐŤ^Rdh54  C ̆Ͻ YFPճYellow Fluorescence Proteinմ¥ҌƲu{ Rdh54-YFP^^Cse4  C ̆Ͻ CFPճCyan Fluorescence Proteinմ¥ҌƲu{ Cse4-CFP ¥ƴ˰τΨu{^ҊŘՙɺԡ}ȸǥ¥ңȧw_
B. ҲեЇŤύčĴήҥ̑ Ԑͅ Rad54  Rdh54^ƣ}¢~¢¥˝ΚƐwԌűáìÞÛÇÍgwo MBP Å¶¥ N ̆ϽĝƈwáìÞÛÇÍw©ãïó¿×óÀ¥ήgìÞÛÇÍgȀѝѻӽƂτΨw^Ni2+×óÀwo

Гҙw_Ö¿Ìð H3  Cse4^ƣ}¢~¢¥˝ΚƐwԌűá^GST Å¶¥ N ̆ϽĝƈwáìÞÛÇÍw¶íÅÇ°ð×óÀ¥ήg

^His Å¶ȀѝѻӽƂτΨw^

Гҙw_Гҙ̰ǆ¥Ͳǂɳ^¶íÅÇ°ð×óÀÛíÆ¬ðw^

SDS-PAGE  CBB ̕ѱύčĴή¥ңȧw_ɿҜʁxÅ¶ȩy¡ʩı¡¬­¿ÅðÚïÈÊªð¶¥ήgճǠվ^ʴɩŤմ_ŦĕBūÖ
A. ОѐŤȸǥҥ̑ Rdh54 ԐͅОѐŤ Rdh54 ³ÑÌ¹©ÅðÕµӕf¡ Mtw1 Šȸǥy¡slϕ¢g¡_}s^Rdh54 lԐͅОѐŤÁðÌïå©ΞλφÖ¿Ìð H3 Ôì©ðÌf¡ Cse4Šȸǥy¡k̩ҩw_Rdh54  C ̆Ͻ YFPճYellow Fluorescence Proteinմ¥ҌƲu{Rdh54-YFP ¥τΨu{^ƴ˰ Cse4  C ̆Ͻ CFPճCyan Fluorescence Proteinմ¥ҌƲu{ Cse4-CFP ¥τΨu{^ҊŘՙɺԡ}ȸǥ¥ңȧw_ԐͅОѐŤÁðÌïå©̜ŤþȃĝӫôԌűԽ¡ճÁðÌïå©µë¿Åìð¶մ_Ǡջϣyh^Rdh54  Cse4Šȸǥlңȧu¢_55Ǡջ Rdh54  Cse4 ŠȸǥB. ȔŝԣÅðÕµӕԧύčĴήҥ̑µïâÇðìæËìð¶Ù¨µÅóRdh54 ÁðÌïå©Ԩľ¥˩ky¡^Rdh54
ÁðÌïå©ΞλφÖ¿Ìð H3 Ôì©ðÌ Cse4 ύčĴή¥̩ҩy¡^ȩӉșեw}¢~¢ßæï¶ Rad54 Ö¿Ìð H3 ¥ƈiҥ̑¥ҏ_ˣǰƼu¢g¡

Rad54 Ö¿Ìð H3 ύčĴήƈi^Rdh54 Ö¿Ìð H3^Rad54  Cse4^Rdh54  Cse4ԧύčĴήl˩k_ֈ. Cse4  Rdh54 ΞλφТƲՎǬΞȗ
Rdh54  Cse4 ԧύčĴήg^Cse4ճŝԣ 229 ©ãÒԑ́Ǯմ¥˝ΚƐw Rdh54 ΞλφТƲy¡ՎǬ¥ƴȗwճǠռ^սմ+ Cse4  109 κϊk 129 κϊ©ãÒԑ́Ǯ Rdh54 ɬgύčĴή¥ϣw_+ ÷Ҫ 21 ©ãÒԑ́Ǯþսì½ð́Ǯ¥©ëÏð́Ǯǽˇy¡ Rdh54 ύčĴήȄ¤¢¡l^©í´Ïð́Ǯǽˇŕƴ̮ύčĴή¥ϣw^̺ѺՁlԔҜf¡slϣǊu¢_+ Ξȗu¢ Rdh54 ύčĴήՎǬáìÞÛÇÍȩwՎǬ Rdh54 ȩw

Rad54 ύčĴή¥ϣuz^s

ΞλφύčĴήy¡slűk_+ Rdh54 ύčĴήՎǬÖ¿Ìð H3 Ҵɭy¡ՎǬlΑo^^ɿՍԄĨȍ CSE4 þɿՍՎǬҴɭwg_+ Rad54  Cse4 ύčĴήg^Ö¿Ìð H3 ßæï¶ՎǬ¥ƸՎǬlɿҜf

Rad54 Ö¿Ìð H3 ύčĴή¥Ʀˬwf¡ƭёʇlf¡_





56

^

Ǡռ Cse4  Rdh54 ΞλφТƲՎǬƴȗ

















Ǡս Cse4  Rdh54 ΞλφТƲՎǬ©ãÒԑкˇҥ̑
















57

D. Rdh54  Cse4 ΞλφТƲՎǬΞȗ÷Ҫ C Ξȗu¢ Cse4  21 ©ãÒԑ́Ǯk¡áìÞÛÇÍ¥ήg^Rdh54ճŝԣ 924 ©
ãÒԑ́Ǯմ¥˝ΚƐw Cse4 ΞλφТƲy¡ՎǬ¥ƴȗwճǠվմ_+ Rdh54  301 κϊk 600 κϊ©ãÒԑ́Ǯ Cse4 ˝ΚύčĴή¥ϣw_w^ȔŝԣύčĴήɪg_+ ÷Ҫ 300 ©ãÒԑ́ǮáìÞÛÇÍg^Ξԑʇ©ãÒԑ́ǮȎǥϒϊw˝ΚƐҥ̑¥ҏl^ƴЂύčĴή¥ϣy˝ΚΞȗmk_+ ÷ҪύčĴήՎǬ Rdh54 Ö¿Ìð H3 ύčĴήՎǬλ

g_


ğ÷

^Rdh54  Cse4 čgΞλφՎǬύčĴήy¡slϣu¢_Ψǥ^ԐͅАʮŰͭjq¡ Rdh54  Cse4 ύčĴήǝȍgÆ¬ð͝ϞҸþf¡_^ɿՍԄĨȍ CSE4 g÷Ҫƴ̮Å¶¡Ûí

Rdh54 ύčĴή¥ΞλφȄ̵ёűԿǽλ̛lĴʝm¡ƭёʇlϣu¢sk^sǽλ̛Ĵҙòҥ̑¥ӳx
Rdh54-Cse4 ύčĴή¸ÒäȓȗʇԨľ¥ΞȗwǠվ Rdh54  Cse4 ΞλφТƲՎǬƴȗ


















58

goĊȗf¡_Ñńž
µïâÇðìæËìð¶ǝȍ¸ÒäȓȗЩʶփ Cse4 ¥Ęw Rdh54 ̵ёշ̒ ӾȂ^Ϙ̴ ôʝ^̤͢ ̟ȍ^Ѐ 36 ǜˤ̇űȍάΝȑħ^ϧʡ^2013 ɖ 12 ˾շԑƐ¿Ìî¿¡©áÌó½¿փ¬­íÎóπňнƟǝԄĨȍ̶ˊ¡ǹɬշϘ̴ ôʝ^̒ ӾȂ^̤͢ ̟ȍ^Ѐ 36 ǜˤ̇űȍάΝȑħ^ϧʡ^2013 ɖ 12 ˾շ59ϙ ϸ Ҿ ՖΫǸǝȍԄĨЖĴήƫњБѢсƐ̵̭τl¦Ԩľg ϙϸϙϸĞҔу͐Ԇ ǈԊճƫњò՗՘ՆǾϯȑӂɠòƫњǾϯȑűԕò˕ˀմƁš ƫњБѢτl¦^ΎπЂτάwͣʇԑМճ&$'մƫњБѢ÷χОѐճ·ëÇÒ»«Ìմ # lԑƐu¢^# Қҙã¿âÈÇlԨúy¡l^̺ɑОѐ &$'ȩy¡̮`ԫɷƦʁ¥˿y¡_}ԫɷƦʁպlОѐсƐf¡тi¢¡_ОѐсƐǿ̮ΞɼlƸ¢¡l^˽ԔҜΞɼùƭӰφОѐƽ̃Ŋ̹f¡_̺ɑОѐ &$' # Æåó¾¥ƩqОѐсƐy¡sԫgg¡ҧi¡_Ӱҧh^l¦ОѐОѐсƐ¥ǜԅwl¦Ɛ¥g¡f£h_}s^̺ɑ·ëÇÒ»«Ìƫњʣɕ÷χσОѐ¥ǭաw^&$'ճӽԑƐ͋МմůΪw
ѐсƐ̵̭Ԁg¥͇ӣw_}Т̓^̺ɑ·ëÇÒ»«Ì &$' ó±óf¡ % # / %

^О

ОѐсƐâ

1:7> τΨlĒӸwl^ƫњʣɕ÷χσОѐ% 1:7> ĒӸw^% # /ǽƐlk_̺ɑ·ëÇÒ»«Ìƫњʣɕ÷χσОѐԀg % # /τΨf¡slϣǊu¢^% # /τΨ¥ҿЈy¡®Ø¾­ÑÊªÈµΠʖ¥ҿ¡^̺ɑ·ëÇÒ»«Ì &$' % # /ÛïæóÅóՎǬåÇíƐîÝílĮøw

g_åÇíƐʧŸ% # /τΨlǹƈy¡slтi¢_ƴ˰̺ɑ·ëÇÒ»«Ì &$' åÇíƐԐМ "#( τΨlʧŸu¢g^#"( τΨĒӸlåÇíƐʧŸƟǝтi¢_ô˟^ƫњʣɕ÷χσОѐåÇíƐʧŸ "#( τΨĒӸҞ¢k_ōŕňŅ Оѐȩy¡ԑƐ¿Ìî¿f¡ &$' ȩy¡̺ɑƫњБѢճ̺ɑ·ëÇÒ»«Ìմ¿Ìî¿ԫɷ̵̭τl¦å±ÏÀä¥˩ky¡^̺ɑ·ëÇÒ»«ÌОѐсƐ̵̭®Ø¾­ÑÊªÈµńՠ¥̩ҩy¡_̺ɑ·ëÇÒ»«Ìƫњʣɕ÷χσОѐ¥ǭաw^&$'ճӽԑƐ͋МմůΪw^ОѐсƐ̵̭^ΞОѐсƐâó±óτΨԀg¥͇ӣw^}ԀgƟǝ¥˃Нy¡_^ƫњʣɕ÷χσОѐűƐϱɟ®Ø¾­ÑÊªÈµńՠԨľ¥̩ҩw^τl¦ĊͻԨľ¥ҿ¡_Ċĥ պմӽԑƐ͋МճROSմůΪu¢̺ɑ·ëÇÒ»«ÌճNHEKմƫњʣɕ÷χσОѐk mRNA ¥űԿw^DNA â«µï©î«τΨԄĨȍύԀ¥͇ӣy¡_ջմ̺ɑ·ëÇÒ»«ÌճNHEKմƫњʣɕ÷χσОѐ¥ӽԑƐ͋МůΪw^Оѐ
60сƐâó±óSA-M-galactosidase τΨ¥ҿ¡_ռմ̺ɑ·ëÇÒ»«ÌճNHEKմƫњʣɕ÷χσОѐ¥ӽԑƐ͋МůΪw^p53TP53^p21cip1^p16INK4a τΨ¥ RTPCR j Western blotting ҥ̑y¡_սմ̺ɑ·ëÇÒ»«ÌճNHEKմƫњʣɕ÷χσОѐ¥ӽԑƐ͋МůΪw^DNAåÇíƐԐМ DNMT1 τΨ¥ RT-PCR j Western blotting ҥ̑y¡_վմ̺ɑ·ëÇÒ»«ÌճNHEKմƫњʣɕ÷χσОѐ¥åÇíƐ«ðÖ×Åó5-AzacůΪw^p53TP53^p21cip1^p16INK4a τΨ¥ RT-PCR j Western blotting ҥ̑y¡_տմ̺ɑ·ëÇÒ»«ÌճNHEKմƫњʣɕ÷χσОѐ¥ӽԑƐ͋МůΪw^p16INK4aԄĨȍÛïæóÅóåÇíƐîÝí¥ҥ̑y¡_րմűƐϱɟλ¡ƫњʣɕ÷χσОѐ·ëÇð 13 ԄĨȍτΨƴԄĨȍµïâÇðńՠճÖ¿Ìðńՠմ¥͇ӣy¡_ŦĕBūÖ
ò̺ɑ·ëÇÒ»«ÌճNHEKմƫњʣɕ÷χσОѐճSCCմ͇ӣ
ճպմDNA â«µï©î«փӽԑƐ͋МůΪ
 NHEK ˟lĒӸw

p21cip1  p16INK4a τΨ SCC g_ճջմSA-M-galactosidaseճSA-M-galմτΨփӽԑƐ͋МůΪ

NHEK  SA-M

-gal τΨlҞ¢ȩw SCC  SA-M-gal τΨlҞ¢k_NHEK  ROSОѐсƐy¡l^l¦ОѐОѐсƐwgslϣu¢_  
ճռմp53TP53^p21cip1^p16INK4a τΨփӽԑƐ͋МůΪ^NHEK  SCC  p53TP53 τΨǽƐk_wkw^p21cip1  p16INK4a τΨ NHEK ÷˨61w^SCC ǽƐlk_p21cip1  p16INK4a ŠОѐсƐ¡Оѐƽ̃Ŋ̹Ԩúwg¡slǰƼu¢ОѐсƐwgs¥Ʀˬwg¡ NHEK  ROS ОѐсƐlάx^SCC g¡_ճսմDNMT1 τΨփӽԑƐ͋МůΪ

NHEK  DNMT1 τΨlʧŸu¢l^

SCC  DNMT1 τΨǽƐlk_NHEK  ROS ԄĨȍåÇíƐîÝ

íl͸ȳy¡slϣǊu¢_ճվմåÇíƐ«ðÖ×Åó5-Azac Ɗ̓փ5-Azac Оѐ¥ůΪy¡^NHEK 
p21cip1  p16INK4a τΨl÷˨wl^SCC ǽƐlk_ROS ¡ p21cip1 
p16INK4a τΨ^ОѐсƐԄĨȍåÇíƐlԨúwg¡slтi¢_ճտմp16INK4a ÛïæóÅóՎǬåÇíƐփӽԑƐ͋МůΪ^NHEK p16INK4a ÛïæóÅóՎǬåÇíƐîÝíĮølҞ¢l^SCC ǽƐlҞ¢62k_ń žƈć
1. Okamoto Y, Ohkubo T, Ikebe T, Yamazaki J. Blockade of TRPM8 activity reduces theinvasion potential of oral squamous carcinoma cell lines. Int J Oncol 40: 1431-1440, 2012.
2. Ikebe T, Yamasaki K, Takamune Y, Nakayama H, Shinohara M.

Reduced expression of

nuclear factor kB in oral mucosa undergoing preoperative chemoradiotherapy. Oral Science Int
9: 33-37, 2012.
3. Fukawa T, Kajiya H, Ozeki S, Ikebe T, Okabe K. Reactive oxygen species stimulates epithelial
mesenchymal transition in normal human epithelial keratinocytes via TGF-beta secretion. Exp
Cell Res 318: 1926-1932, 2012.
4. Tanaka T, Nakayama H, Yoshitake Y, Irie A, Nagata M, Kawahara K, Takamune Y, Yoshida R,  Nakagawa Y, Ogi H, Shinriki S, Ota K, Hiraki A, Ikebe T, Nishimura Y, Shinohara M.
Selective inhibition of nuclear factor-κB by nuclear factor-κB essential modulator-binding
domain peptide suppresses the metastasis of highly metastatic oral squamous cell carcinoma.
Cancer Sci 103: 455-463, 2012.
5. Ota N, Izumi K, Okamoto Y, Toshitani K, Nakayama K, Fukuzawa H, Ozeki S, Ikebe T.
Tapia’s syndrome following the orthoghathic surgery under general anaesthesia. Journal of
Oral and Maxillofacial Surgery, Medicine, and Pathology 25:52-54, 2013.


1. į`̄öȅ^ԣȿѰϤ^͌͘գи^ȁίł˘^ɞɄ˱Ă^þȽńČ^Ƚøǐɧ^ȀԨ63ʋ^͐ԆǈԊ  ԑƐ¿Ìî¿ȩy¡l¦ʧŸԄĨȍ¥ĘwОѐсƐҹȱĴή  Ѐ 67 ǜˤ̇ƫњϯȑħȑҐԽħ 2013 ɖ 5 ˾ 23 ˤ ȒԎȝɍ
2. į`̄öȅ^̧ ЛôԊ^͌Ƀƍă^ίþ˛ʊ^ԣȿѰϤ^͌͘գи^ƍŃΰԓ^ȁίł˘^ɞɄ˱Ă^ŷӇɗ͗^̴̇ʛôԊ^͛ ǒǂȍ^Ťίϼư^͐ԆǈԊ^ȀԨʋ ̺ɑҤƐ÷χОѐ÷χԧѿϰҏjq¡ IKKalpha ½¶ÎíԨú  Ѐ 68 ǜˤ̇ƫњϯȑħȑҐԽħ 2014 ɖ 5 ˾ 8 ˤ ̎ĔԎ
3. į`̄öȅ^͌͘գи^ϿȽՙȍ^ƍŃΰԓ^ȁίł˘^ɞɄ˱Ă^ȿ̇ʓɯ^̴̇ʛôԊ^͐ԆǈԊ^ȀԨ ʋ  ԑƐ¿Ìî¿ȩy¡l¦ʧŸԄĨȍ p16 τΨҿЈ¥Ęy¡ОѐсƐҹȱĴή  Ѐ 32 ǜˤ̇ƫњќρȑħȑҐԽħ 2014 ɖ 1 ˾ 24 ˤ ̈ɓɍ64ϙ ϸ Ҿ ՖƫњƈհǽƐņıɋզǮӕԨľϙϸĞҔуį҇ ƚłճǃƲńɸȑӂɠòũ̴о̽ȑűԕò˕ˀմƁš ǁǚ̵ё¡Ξ˿ƆȑφΫǸf¡՗զ^ìæËìð¶¿ØóÍlӴgΞ˿ĞӃ¥Ǖ¦g¡_}ĞӃ˽ПέΝf¡¹ëó¸ðզ̖Ӡʇ¥úi^¹ëó¸ðрҭɳńՠf¡ì¾ð͋ԑƐϱɟզӕφʇΠ¥ɈƮy¡_ÖÌΤıø՗զ^÷ћզjȀѠզ¹ëó¸ðԖճI5 ;5 ĈΙզմì¾ð͋ԑƐϱɟճ͋ԑƐì¾ðԖփ;=: ;=: ¹ëó¸ðմ¥ȗԖű̑ws£^ø՗զΞ˿¹ëó¸ðʇΠ¥˿y¡sl¤k_gz¢զjg¹ëó¸ðԖ͋ԑƐì¾ðԖƈհǽƐʇɋҸ¢k_ø՗զ¹ëó¸ðԖǿoյƦȩ͋ԑƐì¾
ðԖȳk_¹ëó¸ðԖ͋ԑƐì¾ðԖȀmņĖɋlfl^ø՗զ͋ԑƐì¾ðԖņĖɋlȲuk_¹ëó¸ðԖǿgø՗զǁǚȩy¡̖Ӡʇ¥˿wg¡ƭёʇlf^ø՗զΞ˿ƆȑφΫǸlАՆȲѐıрҭɳńՠǝȍ¹ëó¸ð½çÞïðɰՉw^ì¾ð͋ԑƐ¥Įøu{^¹ëó¸ðаЩɮʝɰՉwg¡ƭёʇl˅ͻu¢¡_ōŕňŅ ՗զĜŝӟզƴ̮^զԖ}ƈհǽƐȀmņıɋ¥ϣy_զԌĭΞλʇlf¡slϕ¢jƈ¤¡Ɔ¦̽¥Ęw^}ΞλʇƆȑφǝȍlȀmoȢúy¡_՗զj^ǁǚƆ Ň^µîðÇð¶ƈ¤¡Ɔ̼ҏ˰øщզƈ¤¡Փж^kҚԾ˟ƷƆlƈ¤¡sk^՗զƆȑφǛщզλΫǸøf¡gi¡_՗զǛщզËìð¶¿ØóÍlӴoճ«Ð^ø՗զ  Ň^÷՗զ
13:: զɮʝёlըgslǰƼu¢¡тi¢

j

ìæ

ŇӴgմ
^;3@3<16F;/:@A3;

^}¢՗զΞ˿ΫǸǝȍlԨľw

g

g¡_

զĞӃ˽ПέΝf¡¹ëó¸ðզզ̞¥ʯhǮӕÅðÕµf^ãÑëílϝu¥úi¡ȩw^¹ëó¸ð̖Ӡʇ¥úi¡_¹ëó¸ð}Ԗz¹ëó¸ðӕφʇΠզɬɟȀmoɰՉy¡_¹ëó¸ðрҭɳńՠϱɟ¹ëó¸ðűȍԽƲʇɰՉ¥úi^ɦmШmӗs¡űȍԧ̴̔¹ëó¸ðаЩɮʝɰՉy¡_ãÑëí¹ëó¸ðűȍ^}͒ϒʝԣɰՉ¥Ʃq¡^Т̓w̭Њu¢ÊðÛîóÌʇΠզɬɟlɈƮu¢¡_¹ëó¸ðрҭɳńՠôf¡ì¾ð́Ǯ͋ԑƐ :F@F:6F2?=EF:/@3ճ!մԐМͣʇ65 Ξλφӗs^ɮʝu¢͋ԑƐì¾ðuԐМΞλφДԠͳƈlu¢^}Т̓¹ëó¸ðаЩɮʝlŸɷu¢¡_զlѓɪƐy¡զАժπզɮʝùŝπզsì¾ð́Ǯ͋ԑƐϱɟlȀmo¡slÖÌϕҞ˩ku¢j^ʞ`զАժπæËíâ¬¿ø՗զì¾ð́Ǯ͋ԑƐĒӸƴ˰¹ëó¸ðаЩl΢ȲƐw
&3@3/?16g¡s¥˩kwճ(=9BA=;73A/:=<<31A7C3(7@@B3   մ_ğ÷h^¹ëó¸ð}Ԗì¾ð́Ǯ͋ԑƐϱɟlզǮӕʇΠɰՉ¥úi¡sk^Ǜщզλ¡ΫǸøf¡՗զl}ΫǸԂƲwΞ˿¹ëó¸ðʇΠ¥˿wg¡˅ͻu¢¡_}Ξ˿ʇΠ¥Ϊҥy¡s®×Ëð¿¥Ýó¿w̽ϯƓςτȺȀmʒƾ¥ʶ_̇ϙϸϊφ^ÖÌΤıø՗զ¹ëó¸ðԖ¹ëó¸ðì¾ð́Ǯ͋ԑƐϱɟ¥©ãÒԑű̑զȀѠզ}¢͇ӣy¡sȗԖw^÷ћ

^՗զ¹ëó¸ðΞλʇ¥˩ky¡s

f¡_
Ċĥ
 ϫȿ̽ϯȀȑ˕ыϙϸˆĹu¢Τı 49 ıճβʇ 28 ı^Ȇʇ 21 ıմø
՗զճn=48մ^÷ћզճn=48մjȀѠզճn=46մ¥ϙϸĹw_}¢~¢ϙϸȩӉԌĭwՓήu¢^kχӕզͪЮզƃƲlӫĬy¡ø՗զ°Ì²«Ԍ^÷ћզȀѠզӫĭզϽՒԌχӕզ¥ϙϸȩӉԌĭw_˂ƨwχӕզ¥ͭıϺМøɺЏȍЎϚw^ŭТĈΙu{_ĈΙҲ˜¥©ãÒԑű̑ήg^Ó«Íï³½Ûï
ìðճHypմԖk¹ëó¸ðԖճµg/mg ĈΙզմ¥ІŰw^Ó«Íï³½ì¾ðճHylմԖk¹ëó¸ð 1 űȍɭ

ì¾ð́Ǯ͋ԑƐϱɟճHyl mol/mol ¹ëó¸ðմ¥ІŰw_Ʊզjq¡¹ëó¸ðԖì¾ð́Ǯ͋ԑƐϱɟņĖɋϱɟƈհǽƐ¥ҿ^ռզԧԖφ͇ӣջզԧύԨԨľ¥ҿ_Ԗφ͇ӣ
Kruskal-Wallis ̩ȗ¥^ύԨԨľ̩̗ Pearson ύԨľ˙¥ήg̩ȗ¥ҏ_ŦĕBūÖ
պշø՗զ^÷ћզjȀѠզ¹ëó¸ðԖ ¹ëó¸ðԖgz¢զjgȀmņĖɋlҸ¢^ʇɋƈհǽƐҸ¢kճǠպմ_¹ëó¸ðԖø՗զ^÷ћզ^ȀѠզՌǿo^ø՗զȀѠզԧ˿ʒɋlҸ¢_ø՗զ^}ӈȤ¹ëó¸ðԖƆ¥ҬȠy¡̖Ӡʇlĝúu¢g¡ƭёʇlϣǊu¢_

66

̽¥Ęw

Ǡպշø՗զ^÷ћզjȀѠզ¹ëó¸ðԖ^ջզԧύԨԨľgz¢РƲ¤{ύԨľ˙lĮo^˩kԨӶҸ¢kճǠջմ_sՅύԨʇø՗զ^÷ћզjȀѠզ}¢~¢λƆȑφΫǸ¥Ʀˬwg¡ƭёʇlf^ø՗զ¹ëó¸ðԖlǿq¢^ȀѠզǿgghhƙЙ˅ͻlɿzwmgslϣu¢_Ǡջշ¹ëó¸ðԖջզԧύԨԨľջշø՗զ^÷ћզjȀѠզì¾ð́Ǯ͋ԑƐϱɟ ì¾ð́Ǯ͋ԑƐϱɟgz¢զjg÷ћզȀѠզjgʇɋƈհǽƐlҸ¢k_ȀmņĖɋlҸ¢l^ø՗զņĖɋՅɑȲukճǠռմ_^ì¾ð́Ǯ͋ԑƐϱɟ^÷ћզȀѠզlƴîÝífȩw^ø՗զ˿ʒĮgîÝíf_
67Ǡռշø՗զ^÷ћզjȀѠզì¾ð́Ǯ͋ԑƐϱɟջզԧύԨԨľø՗զ÷ћզ^ø՗զȀѠզԧĮgύԨľ˙¥ϣwl^÷ћզȀѠզԧύԨʇ¥ʅ¤{¡ύԨľ˙ճr=0.20^p=0.19մf^Ξβʇ˿ʒύԨʇlϣu¢ճǠս^r=0.46^p=0.02մ_ssk^÷ћզȀѠզȀmņĖɋ¥ϣyì¾ð́Ǯ͋ԑƐϱɟ^ø՗զ˿ʒĮgîÝí^ņĖɋlȲuo¡̮ύl˩k_Ǡսշì¾ð́Ǯ͋ԑƐϱɟջզԧύԨԨľ ì¾ð́Ǯ͋ԑƐ^¹ëó¸ðԠlАՆȲѐıɮʝu¢ȉlɮʝu¢¡ԧ^:F@F:6F2?=EF:/@3 ԐМőm¥ĘwkռԔҍˢ̭ӵu¢¡_ɵ

^ø՗զĮgì¾ð́Ǯ͋ԑƐϱɟ^
ճպմ:F@F:6F2?=EF:/@3 τΨĮøf¡gԐМͣʇʧŸ^f¡gճջմռԔҍˢ̭ӵɮʝ¿ØóÍĿӸ
68

^u¢

g¡ƭёʇl˅ͻu¢¡_ ì¾ð́Ǯ͋ԑƐϱɟlȀmo¡^¹ëó¸ðаЩОo¡slϲ`ϙϸϕҞw˩k

g¡_ø՗զì¾ð́Ǯ͋ԑƐϱɟĮø¹ëó¸ðаЩlȁgƭёʇ¥˷ϣw

j^¹ëó¸ðԖǹƈтʘy¡}ƭёʇl

ϣǊu¢¡_ø՗զìæËìð¶¿ØóÍ¥тʘy¡^ôҞϔώw
Ҟi¡l^ø՗զ¹ëó¸ð̴̔ȀѠզ͇ճ(=9BA=;73A/:=<<31A7C3(7@@B3&3@3/?16
̅Ηǩ
lȁo

g¡h

̅Ηǩlǿo^ʝΗǩlȳg   մ_¹ëó¸ðűҥԐМʝΗǩǿg¹ëó¸ðаЩ¥űҥwog^i¹ëó¸ðаЩ̅Ηǩǿgø՗զ¹ëó¸ðаЩűҥwygтi¡slm¡_ ğ÷^Ξ̀ƆȑφΫǸøf¡ø՗զ¹ëó¸ð^Ǜщզ}¢͇^Ԗlǿo^ì¾ð́Ǯ͋ԑƐϱɟlȲugsl˩k_s¢ϕҞ^ՓжkҚԾƆ¥Ʃq¡ø՗զƆȑφΫǸhoԂƲwʇΠ¥ϣw

g¡gi

¡_
ń žƈć
1. Distinct characteristics of mandibular bone collagen relative to long bone collagen:relevance to clinical dentistry. Matsuura T., Tokutomi K., Sasaki M., Katafuchi M.,
Mizumachi E., Sato H. BioMed Res. Int. ̗ҽ˿^DOI: 10.1155/2014/769414, (2014)(in press)
2. Characterization of the bone matrix and its contribution to tooth loss in humancadaveric mandibles. Matsuura T., Sasaki M., Katafuchi M., Tokutomi K.,
Mizumachi E., Makino M., Naito T., Sato H. Acta Odontol. Scan. ̗ҽ˿^DOI:
10.3109/00016357.2014.903517, (2014) (in press)
3. Sex-related differences in cortical and trabecular bone quantities at themandibular molar. Matsuura T., Mizumachi E., Katafuchi M., Tokutomi K., Kido
H., Matsuura M., Sato H. J. Hard Tissue Biol. ̗ҽ˿^23, 267-274 (2014)
4. A multi-centered epidemiological study evaluating the reliability of the treatment
difficulty indices developed by the Japan Prosthodontic Society. Kuboki T.,
Ichikawa T., Baba K., Hideshima M., Sato Y., Wake H., Nagao K., Ueda Y., Ono Y.,
Tamaki K., Tsuga K., Sakurai K., Sato H., Ishibashi K., Yatani H., Ohyama T.,
Akagawa Y., Hirai T., Sasaki K., Koyano K. J. Prosthodont. Res. ̗ҽ˿^56, 71-86(2012)69
1. ø՗զāҜզǮӕʝűԌĭΞλʇ QǛщզ͇ӣQ.

̏ͧȵʀ^į`̄м˵ȍ^͋γ̘мΪ^Κͷ öƕЪ^į҇ƚł. ˤ̇ƫњ«ðÛëðÌȑħЀ 30 ǜĄɅːԌȑҐȀħ^Ŷɞ^2013 ɖ 1 ˾.
2. զ¹ëó¸ðl̽ȪǀȢúy¡ƭёʇ.

̏ͧȵʀ^į`̄м˵ȍ^Κͷ öƕЪ^ɻȤŋȁԊ^ϘɄмǄ^˞ίʋ^͋γ̘мΪ^į҇ƚł. Ѐ 121 ǜˤ̇ҘЬ̽ϯȑħ^̲ͦ^2012 ɖ 5 ˾.
3. ÖÌΤıø՗զjq¡զǮӕþ¹ëó¸ðԖ́Ȏ̽˙Ԩľ. ̏ͧȵʀ^ΚͷöƕЪ^ɻȤŋȁԊ^˞ίʋ^į҇ƚł. ˤ̇ƫњ«ðÛëðÌȑħЀ 29 ǜĄɅːԌȑҐȀħ^ȝɂ^2012 ɖ 1 ˾."70ϙ ϸ Ҿ ՖϝРиĞӃλɑ½¶ÎíĨӿϙϸĞҔуȿԌ ɗưճОѐűȍάΝȑӂɠòОѐάΪȑűԕò˕ˀմƁš ʞ`^ϲ`զϛǺʇξʌþɾφɱƃ¥yϛզОѐ«°ðӧӮ̵̭զƹƧ̵ёҿЈ̵̭̽ΛãÑëíӧӮϘ΍Ɛ̵̭ԨwğøռҾՖƨР¦_cҾՖպdϛզОѐ ˓ŰզƹƧԨ¤¡ԔҜ :ӧӮűȍf¡ : ǩ :ӧӮıճ:1<մȩwСӜ¥Ęw^զАժπ͗ς҅f¡ϺМƸ˿ʇ×¿ß¿ßÑóÌlåÔïðԑĞӃ} :ӧӮ¥ʨúɳϖ˰ԧʧŸ¥ϣys¥ǰƼw_cҾՖջdϛզОѐűƐҹȱɵτΨ÷˨y¡ / ӱӽʇǩԴ«°ðÇçÑíf¡ (&%" ̵ё¥ҥ̑w_(&%" ³ÎóÂͣʇ¥˿y¡éÏóµ«°ðÇçÑíűȍf^ϛզОѐ (&%" ¥Ęy¡Դ«°ðӧӮlŔĭȎǥw^s¢ԑʇΫǸͣʇƐu¢ "5 ʨúÚïÈµu¢¡ʇӕ¥ϣyslűk_s¢ϛզОѐűƐզƹƧ̵ёɿҜ / ½¶ÎíɮʝãÑëíĞӃԔҜ̵ёűȍf¡ƭёʇlf¡l^Ψǥ^ϛզОѐΞλφ (&%" ̶ˊâ¬¿¥Ĵʝw 7<C7C= șեЖ̩ҩwg¡_cҾՖռdżӬ(&%" άıτΨűɎ¥ҿs£^ΞӉΛѴОѐ®ÎåíѴОѐ̫ըτΨy¡sl˩k_}s^(&%" űȍ̽Ϙ΍Ɛjq¡ãÑëíӧӮϘ΍ƐҿЈ̵̭Ԩú¥̩ҩw_Риȑφҥ̑^űȍάΝȑφҥ̑jgâ¬¿̽ΛӉΛѴОѐ®ÎåíѴОѐ (&%" l̫(&%" ̮«°ðӧӮlȎǥy^ըτΨw^7<C7A?= șեЖÅ  ŎƮŤŭFƚƱ!Ʋ©Ĥĝě¡sϞҸm_ėɳ^(&%"Ԅ Ĩ ȍ ˑ ǽ â ¬ ¿ ¥ ή g  7<
C7C= șեЖȱŜwu̩ҩ¥Ӹ¡_ōŕňŅcҾՖպd զƹƧjg¡ɱƃ¥̓wāg¡lҎͭ

ɘОѐΰ̍ϛզОѐ^ƹƧ¥ҏhԸ^zǮӕՆɬo˄ϒy¡sΞɼφ͞Πг¥ɮʝwզƹƧlӗs¡_զǮӕãÑëíʝűϛզОѐű͜y¡ԑճǵԑփ:մɬԑʇΫǸ¥ɮʝy¡s΀ҥw^˿̵ʝűìÃÄóä71ű͜u¢ǿoìÃÄóä͋ҥԐМlԑʇΫǸþͣʇƐu¢űҥ¥Ʃq¡_sԑճ:մű͜ÛïÌðáðÛճ*(%/@3մ¥Ęy¡ ӧӮ : ǩ :ӧӮıճ:1<մ¥Ęy¡ :ӧӮl«°ð±ÈÛìð¶y¡s  :«°ðӧӮ¥ʯg¡ճǠպƢΕմ_^s: ԄĨȍ̶ˊâ¬¿ :1< Ώǽλlοǝf¡ɑ̕ѱıŔʇȀΪϘզοVǩճ$Vմʌу^:1< ¥Ęy¡ϛզОѐ :ű͜ёlĮøw^զƹƧԹȞlάx¡_u :ӧӮıϝРиƹƧāıf¥yοǝ¡_ɵ^s̶ˊ̵ёùŝզƹƧ̽ΛēˇԹȞ^shgӧӮıΞʇ̵ё¥ϕ¡sοφզƹƧ¥Ÿɷy¡˿ήƄ҅¥̩ҩy¡÷ԔҜʒоlf¡_ӫɖ^ϛզОѐզƹƧ¥ɬƆʧŸy¡҅ſf¡ϺМƸ˿ʇ×¿Ù¯¿Ù¯ÑóÌճ#%մl^զАժπl¦զӡϰ͗ςՓжήg¢g¡_ô˟^՗զǺ̿ЂƁĴήǏՖlͩm÷l̽ϯՎǬͰŻǏՖ¥ʬi̵ɜ¥ŖűΪҥw^

g¡_shgǏՖ¥ҥ͑y¡^#% ĴήjoɿҜlf¡_s #% ʧŸĴήåÔïðԑĞӃjq¡Ù¨óÑ½íČìðԑƲʝԐМճ2>@մʧŸ©áÌó½¿¥ҹȱy¡ǰƼu¢^ϛզОѐОѐŤզ̞ɮʝԬȞg¡l^ԑű̵͜ёȩy¡Ɗ̓gù˩f¡_̇ϙϸ^shg #% ̅ϕĴή̵̭¥ҥ˩y¡s¥ϊφ^:1< ¥Ęy¡ :ӧӮȩy¡ #% Ĵή¥ҥ̑y¡sf¡_shgƨР #% ƁĴήĊԫ͗ςqo^˿ήզĞӃ͗ςƄ҅¥̩ҩy¡÷ʒоlf¡_cҾՖջds¢ʞ`ϛզОѐ«°ðӧӮզƹƧ̵ёҿЈԨy¡ǿoϙϸ¥ҏg^ϛզżդОѐ&# ! ʨú/ ӱӽʇԴ

«°ðÇçÑíôϲf¡A?/<@73<A?313>A=?>=A3<A7/:
(&%Ù¨ãìóȻy¡(&%* τΨlĿӸu¢^(&%* ¥Ęy¡ / ͤŜl / °½îó½êð¥ɮʝw

Å  Ŗţ»đózh|\h|\upƱƲFƮ¼µûªĝä

1/:17<3B?7< ƣ #(1 ͣʇƐ¥Сճ /87F/3A/:ϛզОѐűƐlҹȱu¢¡s¥ǰƼw

մ_ô˟^sϙϸ # â«µï©î«ҥ̑jg

ìóճ"3:/@A/A7<ƩȠıմȻy¡ (&%"Ǡ^(&%" Ù¨ãƢΕl (&%* ƴ̮ &# ! ʨúϛզżդОѐŔĭҹȱu¢^űƐŠτΨԖlǹƈy¡s^(&%" ԬȞſϛզОѐɮʝlʧŸu¢¡s¥τҞwl^}̵ёù˩f¡_(&%"րɚЉτΨy¡ՅԃʫʇԴ«°ðÇçÑí "5 Ђȩy¡ӱӽʇlΞ̓ըgsk^Оѐ72ŤãÑëíʉɑʇ¥ʯhӧӮűȍw͟ϊu¢g¡_^}  ̆ŌL³ÎóÂÍå«ð¥ʶԐМͣʇ¥˿y¡éÏóµ«°ðÇçÑíf^Оѐǹ͂^Оѐ˄ϒӼƋ^Оѐ̿^τ²ðЂǿȾάǀΨӉԨ¤¡ɿՍűȍf^(&%" ̶ˊL³ÎóÂÍå«ðǽλâ¬¿юάѫ̿¡_̇ϙϸ^ʞ`lϛզżդОѐτҞwãÑëíӧӮ«°ðÇçÑíf¡ (&%" ͟ϊw^sűȍϛզОѐűƐզƹƧ̵ёɿҜ / ½¶ÎíɮʝãÑëíĞӃjq¡̵ё¥ҥ˩y¡sf¡_s¢ƨР^ãÑëíӧӮűȍ¥̰φw˞ҟզƹƧʧŸς͝ȺԦǮω¡тig¡_cҾՖռd̽÷χPԧѿЖύčĴήāӉΛѴОѐ®ÎåíѴОѐkɮÅʝu¢¡l^}¢~¢Ϙ΍Ɛӽϱ}
Щʶ̵̭¥ʯhűȍƴȗù˩f¡_żӬ (&%" άıτΨűɎ¥ҿs£^ΞӉΛѴОѐ®ÎåíѴОѐ̫ ըτΨy¡slҸ¢_}s^̇ϙϸ̽ΛϘ΍ƐԨ¤¡˞ҟűȍw^ʞ`lάıþΞӉΛѴОѐ®ÎåíѴОѐ̫ըτΨy¡ (&% űȍw

τҞw³ÎóÂͣʇ¥˿y¡éÏóµ / ӱӽǩԴ«°ðÇçÑíf¡ (&%" ͟ϊw^sűȍãÑëíӧӮ̵̭s¢Шo̽Ϙ΍ƐҿЈ̵̭Ԩú¥ 7<C7A?= șեЖ 7<C7C= șեЖƥ˟ҥ˩y¡sf¡_s¢ƨР^̽ΛτыԹȞοʖҥ˩̽ΛŦάϙϸ˞w
gʷԘ¥ˆĹy¡тi¢¡_ Ċ ĥcҾՖպdâµïÙ¨ó¾Оѐ̛f¡ &+  Оѐ^ƣâ¬¿զէâµïÙ¨ó¾
&# ! ¥Ĵήu{ϛզОѐ¥ҹȱw_:1< űȍϛզОѐűƐӽϱĩhτΨԖǽƐ¥ &(%& ƣ +3@A3?<0:=A ͝^Śν̕ѱ͝¥ήgßóíÁíÕÈÇµëðÛ͝¥ήgҿ_:1< ¥Ęy¡ :ű͜ё^: «°ðՁͤw

ҪԞw^×¿Ù¯¿Ù¯ÑóÌƊ̓¥ҥ̑w_^åÔïðԑĞӃjq¡Ù¨óÑ½íČìðԑƲʝԐМճ2>@մԨú¥̩ҩy¡^ÊÌë»«µìðҹȱʇ 2>@@6&# ¥τΨu{Оѐ̛¥ήg^:1< «°ðӧӮȩy¡ 2>@ »«îð½ð¶Ɗ̓¥̩ҩw_cҾՖջdâ¬¿զէâµïÙ¨ó¾¥ &# ! ź·ϛզОѐҹȱw_}w^&# ! ź·żź·  ˰ԧɳjq¡ / ӧӮıτΨǽƐ¥ # â«µï©î«͝73

͇ӣy¡Š^(&%" ϛզОѐűƐӽϱĩhτΨԖǽƐ¥ &(%& ƣ +3@A3?<
0:=A ͝¥ήg ҿ_^&# ! ź·wОѐՅź·ОѐßóíÁíÕÈÇµëðÛ͝¥Ԃήw^(&%" ԬȞſОѐŤǾ«°ðΫǸǽƐӧӮ¥«°ðՁͤw^(&%" ¥Ęy¡«°ðҪԞw^}ʇӕҿЈ̵̭¥ҥ̑w_cҾՖռd<@7AB6F0?727G/A7=< ͝^&(%& ͝^РиŚν̕ѱ͝Оѐjq¡^(&%" τΨűɎ¥ҥ̑w_^̛ƐОѐΛѴОѐ®ÎåíѴОѐ¥ήg^ŝӟРи^ҹȱwԕάǩӉ^(&%" τΨ¥ @6&# »«îð½ð¶wОѐ̛¥̳ϻw^(&%" ̵ё¥ҥ̑w_&(%& ͝ +3@A3?<:=A7<5 ͝^ОѐűƐΞλφÅðÕµτΨ¥ҥ̑w_©í±ìÙ¯¿Ù¨ÅóÂ̕ѱ *=<9=@@/ ̕ѱ^Ϙ΍ƐͣʇϘ΍Ɛ͒ϒҥ̑¥ҏ_ßóíÁí
ÕÈÇµëðÛ͝¥Ԃήw^(&%" ԬȞſОѐŤǾ«°ðΫǸǽƐ^(&%" ¥Ęy¡«°ðӧӮ¥«°ðՁͤw

ҪԞw^}ʇӕҿЈ̵̭¥ҥ̑w_ Ŧ ĕBūÖcҾՖպdϺМƸ˿ʇ×¿ß¿ßÑóÌճ#%մʧŸĴÅ  Ŗţ»đózh|\h|\upF !ƐƑûªĹήåÔïðԑĞӃjq¡Ù¨óÑ½íČìðԑƲʝԐМճ2>@մʧŸ^ϛզОѐОѐŤզ̞ɮʝԬȞ©áÌó½¿¥ҹȱy¡ǰƼu¢g¡l^ԑű̵͜ёȩy¡Ɗ̓gù˩f¡_}s^ԑͣʇƐ :Ձͤȩy¡×¿ß¿ßÑóÌƊ̓g̩ҩwТ̓^Å  #$ FeXfaEOQ !ƐƑƠÕĹ

74ϺМƸ˿ʇ×¿ß¿ßÑóÌճ#%մf¡ÄîÍïԑ©îðÍïÑóÌԑͣʇƐ :ՁͤȩwʆʇφkΉɟĺȎφʧŸĴή¥ϣwl^ϺМՅƸ˿ʇ×¿ß¿ßÑóÌf¡®ÇÍïԑĴή¥ϣukճǠ  ƢΕմ_^2>@
 @6&# ¥ήg»«îð½ð¶ճǠ  ƢΕմ¸ëÏí¸ëÏíӡˇԐМԬȞÅ   F !ƐƑûªĹE×:Q  FÃð¯ĕſճ(մ :Ձͤ¥ʧŸwl^åÔïðԑĞӃέΝ¸ëÏí¸ëÏíԑճ$մʨúÄîÍïԑ¡ʧŸĴή¥͸ɪwճǠ  ƢΕմ_ɵ^ϺМƸ˿ʇ×¿ß¿ßÑóÌϛզОѐОѐŤզ̞ɮʝʧŸqo^2>@ ԬȞ¥Ęw˦̃ϛզОѐ :1< Ђ¥Ęy¡ԑű̵͜ё¥ʧŸy¡sl˩k ճǠ  ƢΕմ^s¢Т̓¥ǰƼwճτҔӁ˛#/B<F<'16;732303?5R@?16%6/?;/1=:ƢΕփ

մ_s̮ϛզОѐ :1< ¥Ęy¡ԑṷ̵̋͜Ξʇ¥ҥ˩y¡s^:1< űȍ¥̰φwզńɸ¥ĿӸy¡˞ҟ҅ſ͗ς͝Ԧτ¿ÌëÊ¾ów
 Ψǥ^զАժπ͗ς҅w

ʒоlf¡тi¢¡_͎ήu¢¡ϺМƸ˿ʇ×¿ß¿ßÑóÌ^ɬƆզƹƧʧŸĴή¥˿y¡l^ô˟ϛզОѐ˙¥͸ȳu{^ԣ̃ķήǏՖ¥ʬig¡s՗զǺ̿ЂƁĴή^ϛզОѐ¥̈́uzλɑզƹƧ̵ё¥ԂȘ¹ðÌïóím¡ȓŝʇըg҅ſl͍¢g¡_Ψǥ^*(%/@3 :1< ýӧӮıűȍԧ^sýуҚƲı¥ɮʝw̵ёҿЈ¥ҏhŠӳűȍȎǥl˩kj^ėɳ^shgýӧӮı±ÈÛìð¶űȍ¥̰φw^ƊΦѰgƄ҅Ԧτ̃ɲwg_Å   G #$ ûªS9@    ƚ©Ĥ !ƐƑƱ!" ƲSûª:QcҾՖջd&# ! ź·wϛզОѐ^(&%* qo (&%" τΨlŔĭ÷˨w
j ճǠ  ƢΕմ^(&%* ͣʇ¥ʧŸw̌ĢøԴ«°ðՁͤ¥ҹȱy¡^Ѣӽű̫ОѐŤԴ«°ðӧӮl϶kͣʇƐu¢^іű̫75

ОѐǾԴ

«°ðӧӮlɬoͣʇƐu¢_sԴ«°ðӧӮ &# ! ź·ɳ^˰ԧĺȎφǹȀ w ^ (&%" ¥ Ԭ Ȟ y ¡ 1/?C/1?=: 

2.0

2.0

u¢

1.6

lű_
^> ĮøĺȎw (&%"0ͣʇƐ^ϛզОѐlɮʝy¡ԑʇΫǸ

"5 ¥āw-100-50¡éÏóµűȍf^ėɳ (&%" űȍ¹ðËª½êÎí $â¬¿Ĵʝƨ

20
10

0

50
100
m.p. (mV)

0

50
100
m.p. (mV)

0 Ca2+
-100

-50

50

40
20
0
0

-20

50
100
m.p. (mV)

*

30
20
10

*

*

*

*

0

10
0

*

40

20

-10

0 Mg2+

50
100
m.p. (mV)B

pHo 5.3

outward current

current (pA/pF)

ӧӮy0

24 48 72 96
RANKL (h)0current (pA/pF)

pHo 5.3

00 Mg2+ 0 Ca2+

_(&%"  / 0-5

0 Mg2+

0.5

10μM AA861¡sl˩k

1.0

100 μM carvacrolτΨlŔĭ÷˨y

-50

48
72
24
RANKL (h)2.01.550 μM 2APB

-100

0

2.5

1 mM Mg2+

50 μM 2APB

48
72
24
RANKL (h)

3.0

TRPM7

0 Mg2+

0 Mg2+

current (pA/pF)(&% űȍ &# ! ĺȎʇ10

0

current (pA/pF)

  o (&%"  g h

20-5

inward current0Å  ŎƮŤŭE37Q
      F   ÐóńĴčø /  "5 ЂОѐŤӧӮs¢-50

024 48 72 96
RANKL (h)

0.8
0.4

-100

0

1.2

̵ёy¡s

̇ϙϸk (&%* q

0.5

outward current (pA/pF)^ϛզОѐűƐӽϱτΨy¡

2.0
1.5
1.0

ratioCtșեjg ϣwԴ«°ðӧӮ^ǰƼ
ratioCt°ðӧӮ¦ңȧu¢k_̇0g¡ (&%" ʇӕôѫy¡_ɵ

ratioCt

0.8
0.4

wʇӕтi¢_

0 24 48 72

2.5

1.2

Յź·ОѐkshʇӕԴ«

1 mM Mg2+

GAPDH

3.0

TRPV2

1.6
ratioCt«°ðӧӮlͣʇƐu¢_ô˟^&# !

A

TRPM7

0 24 48 72 0 24 48 72

ʧŸ¥  ğøĮøu{¡^ОѐŤԴӗǝw̵ёҿЈԂTRPV2

RANKL 0 24 48 72 0 24 48 72 0 24 48 72(h)u¢ճǠ  ƢΕմ_^ОѐǾͭ >

(&%" Դ«°ðӧӮıw

BMMs

TRPM7 GAPDH

inward current (pA/pF)

/;7<=3A6=EF27>63<F:0=?/A3 

Raw264.7 cells
TRPV2

0
-5

*

-20
-30

* P< 0.05 vs. 0 Mg

2+*

Å  ƚAħó°8RQ  ĜX]ƧĨB<FŸĵÑŅóƍР^}̵ёҥ̑ӸgoĊȗf¡_ğ÷ϙϸíӧӮı̵ёɱƃl˩k^ϛզżդОѐτΨy¡ (&% űȍghãÑëm_ɵ^s¢̵ёűȍϛզОѐզƹƧ̵ёԨӶ¥ҥ˩y¡s^̽ƽοìè¬âÇЂjq¡οφզƹƧ¥Ÿɷy¡˿ή©«Ë©¥ˆĹw^ϛզОѐ (&% űȍ¥Åó¸ÈÌwΞλφkЌĽŸɷλɑզƹƧȩy¡˞wg҅ſ͗ς͝ԦτȺԦl̃ɲu¢^ϥħφ76Ȁǽʒоlf¡тi¢¡_cҾՖռdԕάǩâ¬¿¥<@7AB6F0?727G/A7=< ͝^Lower First MolarРиŚν̕ѱ͝ +3@A3?<
:=A7<5 ͝

TRIPM7

DAPI

Mergeҥ̑wТ̓^ŝӟþ (&%" ӉΛѴОѐ®ÎåíѴОѐΞɬoτΨwjճǠƢΕմ^(&%" τΨÔë
Abð¿^̽τάҾϱ̽ΛԌĭ

ǽƐw

Ob

g

¡slűk_^̛ƐОѐҹȱwԕάǩÅ  ğİEè6ńĴ:Q  ©ÏƱYhƫÍŵğƘƲӉΛѴОѐ®ÎåíѴОѐ¥ήgșե^(&%" τΨ¥ @6&# »«îð½ð¶y¡̽Ϙ΍Ɛjq¡
/ «°ð̑ŰlʧŸu¢¡s^̽Ϙ΍ƐҿЈ̵̭Ԩ¤¡slϣǊu¢_u (&%" ըτΨ (&%" ¥Ęy¡«°ðӧӮȎǥϞҸm^(&%" űȍlըτΨw«°ðӧӮıw

̵ёw

g¡s˩k_ô˟^ŝӟφ (&%" ԄĨȍ̶ˊâ¬¿юάѫ̿ 7<C7C= ҥ̑mg^ėɳ̽ΛɮʝϘ΍Ɛӽϱjq¡ (&%" «°ðӧӮѨıɱƃ¥ 7<C7C= șեЖҥ˩y¡^ʞ`lĴʝw(&%"4:=E â¬¿¥Ŧҿ˚w^s¢ήgµ ?3 â¬¿ēԏӉΛѴОѐƣ®ÎåíѴОѐΞλφÅðÕ^ӉΛѴОѐƣ®ÎåíѴОѐΞλφ (&%" ¹ðËª½

êÎí̶ˊâ¬¿¥ΨǥĴҙþf¡_^(&%" ³ÎóÂǽλâ¬¿ճ³ÎóÂ̵ё̶ǩմ¥ŠƴϙϸуkŜʤw̽Λ¥ҥ̑y¡Ċȗf¡_s¢ƨР^̽ΛϘ΍ƐҿЈϘ΍ƐЩʶ̵̭ҥ˩зl^̽ΛϘ΍ƐԹȞοʖҥ˩̽ΛϝРиŦάϙϸ˞wgʷԘ¥ˆĹy¡тi¢¡_


ń žƈć
1.

SCFβ-TRCP regulates osteoclastogenesis via promoting CYLD ubiquitination.
Wu X, Fukushima H, North BJ, Nagaoka Y, Nagashima K, Deng F, Okabe K,
Inuzuka H, Wei W.

Oncotarget. ̗ҽ˿^30, 4211-21 (2014)77

2. The potential role of transient receptor potential type A1 as a mechanoreceptor inhuman periodontal ligament cells.

Tsutsumi T, Kajiya H, Fukawa T, Sasaki M,

Nemoto T, Tsuzuki T, Takahashi Y, Fujii S, Maeda H, Okabe K.
Eur J Oral Sci. ̗ҽ˿^121, 538-44 (2013)3.

A novel inhibitory mechanism of nitrogen-containing bisphosphonate on theactivity of Cl- extrusion in osteoclasts. Ohgi K, Kajiya H, Okamoto F, Nagaoka Y,
Onitsuka T, Nagai A, Sakagami R, Okabe K.
Naunyn Schmiedebergs Arch Pharmacol. ̗ҽ˿^386, 589-98 (2013)

4. Hyperocclusion up-regulates CCL3 expression in CCL2- and CCR2-deficient mice.
Tsutsumi T, Kajiya H, Goto KT, Takahashi Y, Okabe K.
J Dent Res. ̗ҽ˿^92, 65-70 (2013)
5. Reactive oxygen species stimulates epithelial mesenchymal transition in normal
human epidermal keratinocytes via TGF-beta secretion.
Ozeki S, Ikebe T, Okabe K.

Fukawa T, Kajiya H,

Exp Cell Res. ̗ҽ˿^10, 1926-32 (2012)

6. Odontoclasts and calcitonin
Okabe K, Okamoto F, Kajiya H.
7.

Clin Calcium. 22, 19-26 (2012)

Calcium/calmodulin-signaling supports TRPV4 activation in osteoclasts andregulates bone mass.

Masuyama R, Mizuno A, Komori H, Kajiya H, Uekawa A,

Kitaura H, Okabe K, Ohyama K, Komori T.
J Bone Miner Res. ̗ҽ˿^27, 1708-21 (2012)
1. é×³Çðì²óÂ SCF/β-TRCP ^іé×³ÇðƐԐМ CYLD ԖφŸɷ¥ĘwϛզОѐűƐ¥ĿӸy¡.

ϫɁϬ˛^ȿ̇ȤǻԻ^ԟ͗ȹ ͨ^ѨҞѸ͗Ԋ^ȿԌɗư. Ѐ 32 ǜˤ̇զĞӃȑħ^ȀԪ^2014 ɖ 7 ˾.
"
2. å±Ï±í¿Ìî¿¡̝̽ѢРи¹ëó¸ðέάёƈհ¡ǽƐ.  ԎЊȯ^ԟ͗ȹ ͨ^ɳ҇ƈȪȍ^ǯ ӏư^ȿԌɗư. Ѐ 32 ǜˤ̇զĞӃȑħ^ȀԪ^78

2014 ɖ 7 ˾.
3. ϺМƸ˿×¿ß¿ßÑóÌҙſ(NBP)¡ϛզОѐҌƲԬȞ¥Ęy¡űƐԬȞĴή. ԣȿѰϤ^ԟ͗ȹ ͨ^ȿ̇ȤǻԻ^ϫɁϬ˛^ȿԌɗư.

Ѐ 32 ǜˤ̇զĞӃȑħ^ȀԪ^2014 ɖ 7 ˾.
4. Оѐƽ̃jq¡ SCF/β-TRCP ¡ Cdh1 ԖφŸɷ̵̭. ϫɁϬ˛^Οǳƚă^ȿ̇ȤǻԻ^ԟ͗ȹ ͨ^ȿԌɗư. Ѐ 91 ǜˤ̇άΪȑħ^խśɁ^2014 ɖ 3 ˾.
"
5. ӉΛѴОѐjq¡ TRPM7 τΨҥ̑.

Κ̠ƕϮ^ǤӇ˵ă^ȿ̇ȤǻԻ^ȿԌɗư^̏ø̺ă. Ѐ 91 ǜˤ̇άΪȑħ^խśɁ^2014 ɖ 3 ˾.
6. Ù¨óÑ½íƲʝԐМ¡ϛզОѐ ClնӧӮıҿЈ. ԟ͗ȹ ͨ^Ȁǫɏмȍ^ȿ̇ȤǻԻ^ȿԌɗư.  Ѐ 91 ǜˤ̇άΪȑħ^խśɁ^2014 ɖ 3 ˾.
7.

Expression of C-C chemokine ligands for osteoclastogenesis induced byhyperocclusion. Tsutsumi T, Kajiya H, Goto K, Takahashi Y, Okabe K. ©åì±զĞӃȑħò2013 ɖȑҐԽħ^àíÇæ©^2013 ɖ 10 ˾.

8.

A novel role of farnesyl diphosphate synthetase (FDPS) on the activity of Clextrusion in osteoclasts.   Kajiya H, Tsutsumi T, Nagaoka Y, Goto K, Fukawa T,
Sasaki M, Okamoto F, Okabe K.  ©åì±զĞӃȑħò2013 ɖȑҐԽħ^àíÇæ©^2013 ɖ 10 ˾.

9. Notch2  Hadju-Cheney πňнǩǽλ SCF/FBW7 ¡ÅðÕµԖφŸɷ¥Ś¢¡. ϫɁϬ˛^ԟ͗ȹ ͨ^ȿ̇ȤǻԻ^ѨҞѸ͗Ԋ^ȿԌɗư.
Ѐ 64 ǜқˤ̇άΪȑħ^ƑĄɅ^2013 ɖ 10 ˾.
10. ϺМƸ˿×¿ß¿ßÑóÌҙſ(NBP)¡ϛզОѐОѐҌƲԬȞĴή.

ԣȿѰϤ^ԟ͗ȹ ͨ^į`̄öȅ^͌͘գи^ǯ ӏư^ɞɄ˱Ă^ȿ̇ȤǻԻ^ȿԌɗư.
Ѐ 55 ǜ̽ϯǮϢƓȑħ^ȿȽ^2013 ɖ 9 ˾.
11. The novel roles of CCL2 and CCL3 on osteoclast differentiation and alveolar bone
resorption during occlusal traumatism.

Tsutsumi T, Kajiya H, Goto K, Nagaoka Y,

Okamoto F, Okabe K. ǢԸզĞӃȑħ(IBMS)òˤ̇զĞӃȑħ(JSBMR)Ѐ 2 ǜƲƴ79ǢԸħӅ^ϧʡ^2013 ɖ 5 ˾.
12. The properties of Mg2+-inhibited TRPM7-like channel in mouse osteoclasts.
Okamoto F, Kajiya H, Okabe K. Ѐ 90 ǜˤ̇άΪȑħ^̎Ĕ^2013 ɖ 3 ˾.
13. ǃƲʇǾŏ˰ϛզОѐҹȱjq¡ C-C ·æ±«ðɱƃ. ǯ ӏư^ԟ͗ȹ ͨ^ԎЊ ȯ^̝̇ǈѦ^ը̴ җ^ȿԌɗưЀ 39 ǜϫȿ̽ϯȀȑȑħЯħ^ϫȿ^2012ɖ 12 ˾.
14. ϺМƸ˿×¿ß¿ßÑóÌҙſճNBPմ¡ϛզОѐɮʝԬȞÛîÏíƐĿӸΝӕ¡ǜɸ. ԣȿѰϤ^ԟ͗ȹ ͨ^ɞɄ˱Ă^į`̄öȅ^̍ͪʙôԊ^Ƚøǐɧ^ȀԨ ʋ^͐ԇǈԊ^ȿ̇ȤǻԻ^ȿԌɗưЀ 39 ǜϫȿ̽ϯȀȑȑħЯħ^ϫȿ^

2012 ɖ 12 ˾.
15. CCL2 ½¶Îí̶ˊlӽƂǃƲƆҹτʇ̯̽զƹƧƣyɰՉ. ǯ ӏư^ԟ͗ȹͨ^ը̴ җ^ȿԌɗưЀ 55 ǜ̽ϯǮϢƓȑħ^ԋȽ^2012 ɖ 9 ˾.

16. ϺМƸ˿×¿Ù¯¿Ù¯ÑóÌճNBPsմϛզОѐ Clcn7 ¥Ęwy¡.

Cl-ӧӮ¥ʧŸȀǫɏмȍ^ԟ͗ȹ ͨ^ȿ̇ȤǻԻ^ǯ ӏư^ԣȿѰϤ^į`̄öȅ^ǧ÷ϼӒ^ȿԌɗư  Ѐ 6 ǜÌëð¿áóÅóϙϸħĄɅԌħ^ϫȿ^2012 ɖ 9 ˾.
17. ϛզОѐ ClC7 ǩ Cl-ӧӮı(Clcn7)Ù¨óÑ½í 2 ìðԑƲʝԐМ(Fdps)

ͣʇƐu¢^ԬȞſÄîðÍïԑs Cl-ű͜ё¥ʧŸy¡. ԟ͗ȹ ͨ^Ȁǫɏмȍ^ȿ̇ȤǻԻ^ȿԌɗư  Ѐ 30 ǜˤ̇զĞӃȑħ^̎Ĕ^2012 ɖ 7 ˾.

18. CCL2 ½¶Îí̶ˊwǃƲʇǾŏæËíâ¬¿¥ήg՗զƹƧ˰·æ±«ðƋʖҥ̑. ǯ ӏư^ԟ͗ȹ ͨ^ɳ҇ƈȪȍ^ȿԌɗưЀ 30 ǜˤ̇զĞӃȑħ^̎Ĕ^2012 ɖ 7 ˾.
19. ϛզОѐkҹȱu¢¡ TRPM7 ̮Դ«°ðՁͤ}ԑĺȎφͣʇƐ. ȿ̇ȤǻԻ^ԟ͗ȹ ͨ^ȿԌɗư

Ѐ 8 ǜ TRP ÇçÑíϙϸħ^ȿɂ^2012 ɖ 6 ˾.

20. Regulation of osteoclastogenesis through calcium oscillations.
Okamoto F, Tsusumi T.

Okabe K, Kajiya H,

Ѐ 89 ǜˤ̇άΪȑħ½ðá¾¬ä 6^̏̇^2012 ɖ 3 ˾.

80

21. Cl- transporters as novel therapeutic targets for abnormal osteoclastic bone
resorption.

Okabe K, Okamoto F, Kajiya H, Ohgi K.

Ѐ 89 ǜˤ̇άΪȑħ½ðá

¾¬ä 27^̏̇^2012 ɖ 3 ˾.
22. Bisphosphonate as a novel target to the Clcn7 Cl- transporter in osteoclasts. Ohgi
K, Kajiya H, Okamoto F, Tsusumi T, Onitsuka T, Nagai A, Sakagami R, Okabe K.
Ѐ 89 ǜˤ̇άΪȑħ^̏̇^2012 ɖ 3 ˾.


81


ϙ ϸ Ҿ ՖE3uI9t4>Au;ϙϸĞҔу͕ Ϫɯճάı̭ӵȑӂɠò̵ё̭ӵȑűԕò˕ˀմƁš ̇ϙϸ^ʩâ¬¿áÍÛëÏðʩıճ%"/0 մʩÖÌáÍÛëÏðʩıճ#.  մ¥Ԧτw
ճ"!"7::7>=?3 ӍǼմ_ƫњσ̩НìðÕЇќρ˄ϒԌĭҎȲ̐lĘǥy¡sl˩k^ҎȲ̐lƫњʣɕ÷χσìðÕҏʇӡϰԨúy¡ƭёʇlϣǊu¢_áÍÛëÏðτΨʇƫњσОѐìðÕЇŤχОѐȩy¡˄ϒáÍÛëÏðՅτΨОѐɬo^˄ϒ #.  ԬȞu¢^áÍÛëÏðʩılӡϰԬ̹˿ήf¡ƭёlϣu¢_ōŕňŅպշϙϸԦȉɭŴэ˳պմìðÕЇŤχОѐjq¡Śν̵ёűȍτΨg αӀуs¢^ìðÕЇl A=:::793?313>A=? Оѻʝű¥ҸӄwυҎΩ˄ϒǝȍӎ՝ОѐΞλφ·
æ±«ð¥τΨy¡sìðÕЈ͍ɾʇŚνȑφʁЄ¥ĿӸy¡ƭёʇ¥ϣw_ջմáÍÛëÏðűȍάΝȑφҥ̑ Šƴϙϸуƈ҇^ѣѴќьʣɕ÷χσlτΨy¡äÇðǩ҉υáÍÛëÏðűȍ̭ӵ¥˩kw^
ҎȲ̐ТƲy¡s¥ϣw_ջշϙϸϊφáÍÛëÏðƫњʣɕ÷χσͫΆՎǬɬoτΨw^ìðÕЈӡϰύԨy¡_̇ϙϸ^ʣɕ÷χσlҎȲ̐¥ĘwìðÕЇŤχОѐТƲy¡ƭёʇ^áÍÛëÏðlʣɕ÷χσŤχОѐ˄ϒ¥ĿӸu{¡ƭёʇ^áÍÛëÏðlќρОѐσɘОѐɮӕ¥ҹȱy¡ƭёʇ¥̩ҩw_Ċĥպշʣɕ÷χσìðÕЇŤχОѐ ! %! ҚƲı¥Ęw˄ϒҥ˩պմɍӍƫњʣɕ÷χσОѐ̛ ' áÍÛëÏðԄĨȍ¥ȱŜw ' %%# ¥ήg_ջմâÌì¸íǭաwÖÌìðÕЇŤχОѐȩy¡ ' %%# ͫΆҲեáÍÛëÏðԄĨȍΞλʩı¡˄ϒԬȞҲե¥ҏ_82ռմâ¬¿áÍÛëÏðԄĨȍΨy¡â¬¿åëÒóâ  ĴҙwÌëð¿¾­ÏÈµâ¬¿ՐБѢøáÍÛëÏð¥ɬoτ¥ϰ̨^РиŲΚ¥Ĵҙw^ìðÕЇϰ̨Оѐ¥ČԔŚν̕ѱw_ջշìðÕЇŤχОѐ ! %! ¥Ęw˄ϒwќρОѐσʇɮӕτΨҥ̑ÖÌìðÕЇŤχОѐ ' %%# ¥Šǭաwǹ͂òͫΆё¥̩ҩw_' %%# ¥ÐóÍâ¬¿ՐБѢøϰ̨^ьӡϰОѐ¥űԿǭաw^σɮӕτΨ¥ű̑w_Ŧ ĕBūÖպմáÍÛëÏð¥Ęw˄ϒ ' %%# ˄ϒͫΆl ' ˿ʒǹȀw^áÍÛëÏðΞλʩıԬȞu¢ճʨϴͿōþմ_ջմáÍÛëÏðĺȎʇìðÕҏʇӡϰ ÐóÍâ¬¿ՐБѢøϰ̨w ' %%# g^ʞ`l˞woԦτwʩÖÌáÍÛëÏðʩı¡ьӡϰԬ̹Ɗ̓lҞ¢ճʨϴͿōþմ_ռմìðÕЈӡϰwϰ̨Оѐ >=2=>:/<7< ĺȎʇσʇɮӕτΨҥ̑ ÐóÍâ¬¿ՐБѢøϰ̨w^՗øìðÕЈ¥ˍŰwϰ̨Оѐ¥űԿǭաwТ̓^ǹ͂òͫΆё^ ""%  ""% έάl՜ӞφǹȀy¡sl˩k^áÍÛëÏðτΨОѐǮɝѢűҥ¥ĿӸu{¡sӡϰёlըo¡ƭёʇlтi¢_սմŋɑņıՑՏԌ̺ɑРиjq¡ >=2=>:/<7< τΨ
 ʩ podoplanin ʩı¡͗ς¥тi˰^ŋɑņıjq¡ podoplanin τΨРи¥Г̗y¡ɿҜlf¡_ÖÌâ¬¿Ри̩НТ̓^ǍͭџЃ÷χ^̽я÷χӉΛӕɮʝ̃ӉΛѴОѐ^ϧСƽχОѐjѕФƪ÷χӠѢjq¡ podoplanin τΨl˞ҞŰu¢_վմ˞ҟʩ >=2=>:/<7< ʩıԦτ â¬¿ÖÌ >=2=>:/<7< ҎȲ̐ТƲʇ %! ՎǬ¥ΞλφҸӄy¡˞wgʩı¥ԦτwփYëÈÌʩâ¬¿áÍÛëÏðʩıճ%"/0 մ^ZëÈÌʩÖÌáÍÛëÏðʩıճ#.  մ^%( %;53<3E'75;/"7::7>=?3ӍǼմ_83

  մ
ճ"!

 



 



 









ń žƈć


/87 /A=-'/D/-(633E>?3@@7=<=4>=2=>:/<7</<21:/@@711/263?7<@7<A63;=B@30?/7<</A 

-/;/<=B167 (@B?B5/$9/ '/D/-70?7::7< /<2470?7::7< /?33@@3<A7/:4=?4=?;/A7=<=4A6719=EFA/:/<4703?@7<6B;/<<=<>75;3<A3217:7/?F3>7A63:7/:13::@7<C7A?==<<31A(7@@B3
&3@  



#/9/A=;7-(@B?B5/'/D/-<A?/13::B:/?7<A3?/1A7=<=4"!# D7A6470?7::7< 7<6B;/<84

>3?7=2=<A/::75/;3<A13::@$?A6=2=<A71+/C3@ 

(@B?B5/$9/ /A/93F/;/-'/D/-!/A3<AA?/<@4=?;7<55?=DA64/1A=?007<27<5>?=A37< <35/A7C3:F?35B:/A3@1=/:3@13<13=4=EFA/:/<4703?@7<2B1320F@A?3A167<5@A?3@@=<<31A(7@@
&3@



 

 

/87(@B87;=A=- /<39="  /A=-/<2'/D/-;;B<=67@A=163;71/:3E/;7</A7=<=4<=C3:
?/A ;=<=1:=</: /<A70=273@ /5/7<@A ;=B@3 /<2 6B;/< >=2=>:/<7< 1A/ 7@A=163; FA=163;








/<39=" '/D/- /A=-167;3?71/<A7>=2=>:/<7</<A70=2F@B>>?3@@3@AB;=?;3A/@A/@7@C7/
<3BA?/:7G/A7=</<2/<A70=2F23>3<23<A13::B:/?1FA=A=E717AF/<13?'17





 

  

$9/ (@B?B5/(/A/93F/;/-'/D/-&=:3@=41=::/53</<2>3?7=@A7<3E>?3@@7=<0F1?/<7/:
<3B?/:1?3@A13::@2B?7<5@=4A>/:/A323C3:=>;3<A7@A=163;FA=163; 

$9/ '/D/-3::B:/?AB?<=C3?7<3>7A63:7/:?3@A@=4"/:/@@3G7<A63>3?7=2=<A/::75/;3<A=4A63;=B@3;=:/?B?$?/:'17

 #7@67;B?/ ' '/D/ - &7@9 4/1A=?@ A= 1/B@3 A==A6 4=?;/A7=< /<=;/:73@ 7<163;=A63?/>F=4>/327/A?711/<13?@B?/<13?/?3     (/9/A/''/D/-E>?3@@7=<=4(=::!793&313>A=?7<:=;3?B:/?<2=A63:7/:
3::@B<23?7/03A71=<27A7=<@1A/7@A=163;FA=163;  )167F/;/'/D/-:A3?322F</;71@7<A63?3</::F;>6/A7117?1B:/A7=<=4AF>3
/<2AF>3 27/03A71;7131A/7@A=163;FA=163; 

 '/D/-(/9/A/'/A/93F/;/-@679/D/(@B?B5/E>?3@@7=<=4A=:::793?313>A=? 7<
5:=;3?B:/?3<2=A63:7/:13::@/<2>?=;=A7=<=427/03A71<3>6?=>/A6F0F%=?>6F?=;=</@57<57C/:7@
:7>=>=:F@/116/?723%!='$<33 Ñńž 
ƈǦƕ˴Ƥȿ¤ȲɁȥ͕Ϫɯâ¬¿ѕФƪjq¡áÍÛëÏð±ÍìðτΨЀ  ǜˤ̇ɺȲɹΫȑħЯħψȿ θȽԻ̷θȽЙȍȿ˸ȍ˗ӑѸϕϳďǈố͕Ϫɯʝԣ̐Ӡզjq¡©åï¾­Ïðj !"% ŚνРиȑφϙϸЀ  ǜˤ̇ТƲРиȑħ̎Ĕθ Ƚ Ի ̷  θ Ƚ Й ȍ  ȿ ˸ ȍ  ˗ ӑ Ѹ ϕ  ϳ ď ǈ ô ́  ͕ Ϫ ɯ  ̽ ̝ Ѣ ɮ ʝ  j q ¡!F@=@=;3/@@=17/A32;3;0?/<3>?=A37< !"% ŚνРиƐȑφȸǥgϯǮϢƓȑħȑҐȀħòЯħԋȽЀ  ǜ̽ȽŤΰțþŪİգþɁôҪ˗ӑѸϕ͕ϪɯϘɄƚă70B:7< !$,!

85®ë¿ÇðҚ

Ʋıɮʝ¥ҿЈy¡Ѐ  ǜˤ̇ТƲРиȑħ̎ĔȽăŤգɄәʕþŪİգþɁôҪ˗ӑѸϕ͕ϪɯϘɄƚă͈̮ıɮʝjg
70?7::7<  70?7::7< ɿՍf¡Ѐ  ǜˤ̇ТƲРиȑħ̎Ĕ

6.

þŪİգ˗ӑѸϕȽŤΰțþɁôҪ͕ϪɯϘɄƚă"!#  70?7::7< ОѐŤТƲw
ħ̎Ĕ





°³½ÅëðаЩɮʝԖ¥ҿЈwg¡Ѐ  ǜˤ̇ТƲРиȑқ̋Кǂϳίͨȍ͕ϪɯϘɄƚăȲśσʩσſ͗ςlɦmӗsy͌Ă̽ɮʝԹȞgЀ  ǜϫȿ̽ϯȀȑȑħЯħϫȿƈǦƕ˴Ƥȿ¤θȽԻ̷˗ӑѸϕȲɁȥ͕Ϫɯ̺ɑâ¬¿¶ì©ОѐlτΨy¡áÍÛëìð±ÍÜìðЀŽȑħЯħòŝǢȑҐԽħը̏ ըίŀӥŤȽӏҺ˗ӑѸϕθȽԻ̷ϘɄƚă͕ϪɯДȷοΫǸøљЕΩıjq¡(!&  (!& τΨg ǜˤ̇ҥЀ ǜˤ̇ҥŽȑħЯħòŝǢȑҐԽħը̏ ŤȽӏҺըίŀӥ˗ӑѸϕθȽԻ̷ϘɄƚă͕ϪɯДȷοæËíâ¬¿љìðÕЇ
ǹάg

Ѐ

 ǜˤ̇ҥŽȑħЯħòŝǢȑҐԽħը̏  ը ί ŀ ӥ  Ť Ƚ ӏ Һ  ˗ ӑ Ѹ ϕ  θ Ƚ Ի ̷  Ϙ Ʉ ƚ ă  ͕ Ϫ ɯ E>?3@@7=< =4 A=:::793
?313>A=?@7<5:=;3?B:/?3<2=A63:7/:13::@B<23?27/03A711=<27A7=<@Ѐ  ǜˤ̇ɺȲɹΫȑħЯħ̎Ĕ  ըίŀӥŤȽӏҺϘɄƚă͕ϪɯДȷοæËíâ¬¿љЕΩıjq¡ (!&  (!& τΨЀ  ǜˤ̇ДȷοƲĶπȑħ˧Ʉ ŤȽӏҺ^ըίŀӥ^˗ӑѸϕ^θȽԻ̷^ϘɄƚă^͕ϪɯփUǩVǩДȷοæËíâ¬¿jq¡љìðÕЇ˞άЀ  ǜ̽ϯǮϢƓȑħȑҐȀħòЯħȿȽ ըίŀӥŤȽӏҺ˗ӑѸϕθȽԻ̷ϘɄƚă͕ϪɯДȷοΫǸøљЕΩıŤχОѐjq¡ (!&  (!& τΨЀ  ǜ̽ϯǮϢƓȑħȑҐȀħòЯħȿȽ ŤȽӏҺ^ըίŀӥ^ϘɄƚă^͕ϪɯփUǩVǩДȷοâ¬¿jq¡љìðÕЇǹάgЀ  ǜˤ̇ДȷοȑħĄɅǦ˟ħ͓д ըίŀӥŤȽӏҺ˗ӑѸϕθȽԻ̷ϘɄƚă͕ϪɯДȷοΫǸøљЕΩıjq¡(=:::793?313>A=?(!&   τΨЀ  ǜˤ̇ДȷοȑħĄɅǦ˟ħ͓д ŤȽӏҺ^ըίŀӥ^ϘɄƚă^͕ϪɯփUǩVǩДȷοæËíâ¬¿jq¡љìðÕЇ˞άgЀ  ǜϫȿ̽ϯȀȑȑħЯħϫȿ ըίŀӥ^ŤȽӏҺ^ϘɄƚă^͕ϪɯДȷοæËíâ¬¿љЕΩıjq¡ (!&  (!&τΨЀ  ǜϫȿ̽ϯȀȑȑħЯħϫȿ Ʉәʕ^ȽăŤգ^þŪİգ^þɁôҪ^˗ӑѸϕ^͕Ϫɯ^ϘɄƚăÖÌ̝̽ѢаЩѴО
ѐ¡°³½ÅëðаЩűҥӽϱЀ  ǜĄɅϗ̺̽ϯȑħȑҐȀħȲŅ  ȽăŤգ^˗ӑѸϕ^͕Ϫɯ^ϘɄƚă̝̽Ѣ°³½ÅëðаЩɮʝjq¡ "% ̵ёЀ  ǜ˭Ȑˤ̇̽ƽοȑħȑҐȀħ̎Ĕ

86



 Ʉәʕ^˗ӑѸϕ^͕Ϫɯ^ϘɄƚăÖÌ̝̽Ѣ°³½ÅëðаЩűҥ̵̭Ѐ  ǜ˭Ȑˤ̇̽ƽοȑħȑҐȀħ̎Ĕ ҇ίԵȥ^ȽăŤգ^þŪİգ^þɁôҪ^˗ӑѸϕ^͕ϪɯϘɄƚă°³½ÅëðаЩɮʝ̵̭jq¡ "% ̵ёҥ̑Ѐ  ǜˤ̇ϗ̺̽ϯȑħȀħԣԕ Ʉәʕ^ȽăŤգ^þŪİգ^þɁôҪ^˗ӑѸϕ^͕Ϫɯ^ϘɄƚăÖÌ̝̽Ѣ°³½ÅëðаЩˑӵ̵̭Ѐ  ǜˤ̇ϗ̺̽ϯȑħȀħԣԕ ȽăŤգɄәʕþŪİգþɁôҪ˗ӑѸϕ͕ϪɯϘɄƚăÖÌΑѱМ͈̮ı÷χОѐ¡°³½ÅëðаЩɮʝҥ̑ˤ̇ҥŽȑħЀ  ǜĄɅːԌȑҐԽħխś
Ɂ





 қ̋Кǂ^͕Ϫɯ^ϳίͨȍ^÷ίхôԊ^ϘɄƚă^͋ίϨĞȲśl¦͗ςɳ̽ϯφԣ̃Ù¯ïó©ÈÛЀ  ǜˤ̇ȲśҎͭòl¦ȑħȑҐԽħ½ðá¾¬äϫ
ȿ





25. թίŀӥ^̦ƟɧôԊ^͕ Ϫɯ^ϘɄƚăДȷοâ¬¿љЕΩıjq¡̽ƽοƟѻΰ̍LPS ¡ TLR2/4 ĺȎʇ»«Ì±«ðτΨˤ̇ՙɺԡȑħЀ 70 ǜҪʃȑҐӂ΂ħ.

ƕѿ. 2014, 5
26. թίŀӥ^̦ƟɧôԊ^͕ Ϫɯ^ϘɄƚăSevere Periodontal Disease exacerbate
Diabetic Nephropathy through Toll-like receptor (TLR) 2 and TLR4. Ѐ 57 ǜ˭Ȑˤ̇̽ƽοȑħȑҐԽħ. Ⱦԩ. 2014, 5/87(=;==9/" =87;//<2'/D/-7@A?70BA7=<=4%=2=>:/<7<E>?3@@7<53::@7<A63$?/:(7@@B33<A&3@ ' A6<A3?0/A7=</:@@=17/A7=<=43<A/:
&3@3/?165B/KB/::@ (=;==9/ " /87  =87;/  '/D/ -%=2=>:/<7< 3E>?3@@7=< =< A63

>3?7>63?/:<3?C3@/<213<A?/:<3?C=B@@F@A3;(63 A6<<B/:"33A7<5=4/>/<3@3
@@=17/A7=<4=?3<A/:&3@3/?16#775/A/ 29. )167F/;/( =87;/@679/D/'/D/-;;B<=67@A=163;7@A?F4=?=?/:A7@@B3
0F/<=C3:/<A70=2FA=>=2=>:/<7<(63 A6<<B/:"33A7<5=4/>/<3@3@@=17/A7=<4=?
3<A/:&3@3/?16#775/A/



30. '/D/-(/9/A/'@679/D//A/93F/;/-(@B?B5/%?=;=A7=<=4<3>6?=>/A6F0F     :7>=>=:F@/116/?7237<27/03A71972<3F3<A&3@ ' A6<A3?</A7=</:@@=17/A7=<=43<A/:&3@3/?16/>3(=D<




87




ϙ ϸ Ҿ ՖїҎЇԹȞŚνòԑƐ¿Ìî¿ϙϸĞҔуȀ˫ ƚ˩ճЯƲƓȑӂɠòŤϯȑűԕò˕ˀմƁš ї҈ҎτπɳїҎͤğǾǝȍlї̥Ǵ¥ǹʎu{¡slϣǊu¢g¡_ʞ`

˽ӫ^ї̥Ǵǹʎӽϱjq¡«ðÅóï«³ð(IL) 23-17 axis ԔҜʇ¥˩kw
j^̇ϙϸ^uї̥Ǵjq¡ŚνʁЄҎͭїԨԤϛЭЂΎπƦʁ̵̭ҥ˩¥ϊφwg¡_Ξ^ї҈Ҏ˦̃jq¡ѨΓŚν̵̭ɱƃgҥ˩¥Ҳ^Toll ̮ƩȠı TLR2  TLR4 j}øͤ½¶Îí MyD88 l IL23 έάȢúy¡s¥˩kw_^ŏȞїРиk˓Űu¢

TLR2/4 ¥ź·y¡Νӕl^ɵ̍ʩԑƐΝӕҸӄu¢^˞ҟ damage-associatedm peroxiredoxin family fmolecular patterns (DAMPs)w^ї҈ҎɳΎπʑӗΝӕwőos¥˩kw_uї̥Ǵ innate immunity jq¡ãµï¶ì©òâµïÙ¨ó¾ɱƃj pericyte ҎͭїԨԤɱƃg

ҥ̑¥ҏ

g¡_


ōŕňŅ
 їҎЇԹȞ^ʞlǢāҜ̿ǝf¡z^ȦmƟǝf^Ǣ͉οwըհƐϥħ¥ӪiҜĘӆ¡ЀպĭyyѧɛφԔҜʇ¥ǹwkwl^}ɳԄπ¥Ӣ͸y¡δ̃φ͗ς͝̅Ԧτu¢րƃ¥ƛg¡_w

gg_їҎЇԹȞg¡ї̥Ǵ^ʆʇ̃ʳȀòǹʎw^˰ѫ̿φΠʖ¥yl^ӫɖʆʇ̃ї̥Ǵjq¡űȍ̵̭ò½¶ÎíĨӿlɴ`˩kїҎͤğǾǝȍlї̥Ǵ¥ʳȀòǹʎu{¡slϣǊu¢q¡ŚνʁЄɱƃl͟ϊu¢m^ї҈Ҏτπɳg¡_^ї̥Ǵjg¡l^ʞ`˽ӫ^ї̥Ǵǹʎӽϱjq¡«ðÅóï«³ð 23-17 axis ԔҜʇ¥˩kw

g¡(Nat Med 2009)_̇ϙϸ^ԄĨȍˑǽƋΝ in vivo ԄĨȍȱŜ͝Ђ¥ήg^ї̥Ǵjq¡ŚνʁЄҎͭїԨԤϛЭЂΎπƦʁ̵̭¥ҥ˩w^˞͗ς̰φ¥˃ϸy¡s¥ϊφw

g¡_

Ċĥ
 s¢ϙϸ^ї̥Ǵǹʎ̵̭jq¡ŚνʁЄ^Ξ IL23-IL17 axis ͣʇƐ¥yΎπ½¶Îí¥̩ҩwm_y¤^Ŵ̃ŚνʁЄԨӶy¡½¶ÎíԄĨȍˑǽƋΝ¥ήg^ї҈Ҏ˦̃̓Էjq¡ѨΓŚν̵̭ɱƃ¥˃͍wm_̇ϙϸΞ Toll ̮ƩȠı(TLR)}øͤ½¶ÎíԄĨȍˑǽƋΝ}ŚνʯɭОѐ¥ήg^IL-23 τΨҹȱ¥yź·g88̩ҩw_ї҈ҎĴҙ^̙ЕԥǴæËí¥ήg^їҎͤԖάΪȑφÕëåóÅó¥ͻȗw^ŦΨʇŔ¢ї҈Ҏ¥Ĵҙw_͗ςƊ̓¥ŵȗy¡^РиŏȞz^ϧС̵ёɰՉұĻw_ ӫɖ^ϲ`ΎπʇξʌԔҜʇl͟ϊu¢g¡!  f¡l^ʞ` !  ¥έάy¡Оѐl҈Ҏїǹƈw^}ͫΆ !

ź·lɿҜf¡s^!  έάОѐlɭŴʐȗu¢  Դʇ (6  Оѐo^NO( Оѐf¡s^wk^}ͫΆlї҈Ҏɳռˤ¥Øóµy¡s^u^ї҈ҎȱŜպˤɳk͗ςԦȉ¡ !  ʧŸfї̥Ǵ¥еȲm¡s¥ǰƼwg¡#/A"32_̇ϙϸ^s !  τΨ¥y÷ͤ½¶Îí¥ҥ˩y¡^ԄĨȍˑǽƋΝ¥ήg^' ҥ̑¥դķw̩ҩ¥ҏ_^ǭա̳ΠОѐ¥ήgź·șե¡ҥ̑ҏ_ŦĕBūÖ(!& ї̥ǴǹʎɰՉ

 (!&  (!& ԄĨȍ̶ˊâ¬¿^ї҈Ҏ¡РиԹȞjϧСȑφλɑlԕάǩ͇ӣw˿ʒӢ͸wg_s¢ԄĨȍˑǽâ¬¿҈ҎїͫΆwΎπОѐΎπʇ»«Ì±«ðτΨ¥̩ҩy¡^!
Èµ©¬Ìâ¬¿Ҁ˩Įøwέά (!& j (!& Ò

gճǠպմ_      Ǡպ ҈ҎїΎπОѐ !

ҹȱ (!&  ĺȎy¡









˞ҟ "%@ ƴȗ ԄĨȍˑǽâ¬¿զէΰ̳̍ΠОѐ¥ήg҈ҎїʮŰͭź·y¡^!

έά¥ҹȱm¡s^їʮŰͭ¥ΘůΪ҉υűҥԐМůΪy¡sҹȱͣʇͬȄy¡sk^ e 9/ ÅðÕµlͣʇƐΝӕf¡slŵ˩w_uӕԖű̑¡ҥ̑
w

^!

¥ҹȱy¡Νӕl^ʩԑƐĴή¥˿y¡ÅðÕµϕ¢¡Þí°³îÍ³½ð>3?=E7?32=E7<%?EÙ¨ãìóf¡s¥ƴȗw

_%?E Ç°îÍ³½ðӽԑƐ͋М¥þǂw^ğżÇ°îÍ³½ðÞí°³89

½ÆóÂƿ¢j^Ƹ˿ԖΞїРиǿo^ОѐŤάxͣʇԑМϲf¡ӽԑƐ͋М¥űҥy¡s ї҈ҎτπОѐ¥Łӆy¡тi¢m_˰ԧɳ̥ǴɆ %?E lɬoτΨҹȱu¢¡l^ėǜʞ`˞^ї҈ҎɳԹȞϧСОѐŤτΨw %?E l^ОѐǾӻԿy¡s^ӻԿw %?E ͫΆâµïÙ¨ó¾Ҹӄu¢¡s^%?E l (!& ĺȎʇОѐԹȞ¥ɦmӗsys¥ϣw^%?E l 2/<53?@75</:^y¤^2/;/53/@@=17/A32;=:31B:/?>/AA3?<@"%@w
̵ёw^ͫΆҎͭОѐͣʇƐΎπ¥ʑmӗsys¥˩kwճǠǠ ջմ_   Ǡջ ї҈ҎɳŏȞϧСОѐ()#! Դʇ˓Űu¢ peroxiredoxin (Prx)âµïÙ¨ó¾  Ҹӄu¢¡

















%?E ԬȞ¡ї̥Ǵ͗ςƊ̓
 %?E Ù¨ãìókտȎǥw^%?E  %?E Ξ̭ӵύƴʇlըg_їʮŰͭ̩ҩk %?E  %?E l˽ź·ͣʇlըgslҸ¢^%?E  ź·w
lĊʐu¢_^LռÜìÈµ¿Ԍű̭ӵl¢ҹȱԔҜf¡sŵ˩wճǠռմ

90

j

g¡s

^ƴԌűl !
  Ǡռ Peroxiredoxin family ύƴʇ












}ss¢ʩı¥Ĵҙw͗ςƊ̓¥̩ҩy¡^Ҁ˩ї̥ǴеȲƊ̓lҸ¢

ճǠսմ
_ 

 Ǡս Peroxiredoxin ԬȞ¡ї̥Ǵ͗ςƊ̓












^ї҈Ҏɳ˰ԧɳʨú %?E ʩı¡ї̥ǴеȲƊ̓lҸ¢_ ėǜ^їŤͫΆwâµïÙ¨ó¾l^҈ҎԹȞԱїϧСОѐk˓Űu¢
%?E 

(!& ĺȎφͣʇƐu¢^u¡РиŏȞȢúy¡s¥˩kw_҈ҎїͫΆwâµïÙ¨ó¾lέάy¡ !
Άy¡NO( ОѐĴήw^âµïÙ¨ó¾Ӻ¢!  έά¥ҹȱy¡s
91

їŤͫ

^Đʆʇ̃ŚνʁЄ¥Ÿɷy¡s¥¤¢¤¢ˣ˩kw
÷ĭ½¶Îíw%?E l "%@ wg¡#/A"32l^ėǜ̩ҩ^}Ĵήy¡s¥˩kw_ճǠվմ_  Ǡվ Damage-associated molecular patterns (DAMPs)w

 peroxiredoxin Ĵ

ή












shΎπʇŚνʁЄå±ÏÀä¥uҥ˩w^Ξλφ͗ς̰φ¥˩ky¡s^ї̥Ǵ˿Ɔ͗ς͝ԦτТoтi¢¡_^ėɳuї̥Ǵ 7<</A37;;B<7AF jq¡ãµï¶ì©òâµïÙ¨ó¾ɱƃj >3?71FA3 ҎͭїԨԤɱƃg

̩ҩ¥Ӹ

go_


ńžƈć
1. Yamada S, Tokumoto M, Tatsumoto N, Taniguchi M, Noguchi H, Nakano T,
Masutani K, Ooboshi H, Tsuruya K, Kitazono T. Phosphate overload directly
induces systemic inflammation and malnutrition as well as vascular calcification inuremia. Am J Physiol Renal Physiol. ̗ҽ˿^306, F1418-1428 (2014)
2. Wakisaka Y, Ago T, Kamouchi M, Kuroda J, Matsuo R, Hata J, Gotoh S, Isomura T,
Awano H, Suzuki K, Fukuda K, Okada Y, Kiyohara Y, Ooboshi H, Kitazono T;
REBIOS Investigators. Plasma S100A12 is associated with functional outcome
after ischemic stroke: Research for Biomarkers in Ischemic Stroke. J Neurol Sci ̗ҽ˿^340, 75-79 (2014)
3. Kiyohara T, Kamouchi M, Kumai Y, Ninomiya T, Hata J, Yoshimura S, Ago T,
92

Okada Y, Kitazono T; Fukuoka Stroke Registry Investigators (Ooboshi H). ABCD3and ABCD3-I scores are superior to ABCD2 score in the prediction of short- andlong-term risks of stroke after transient ischemic attack. Stroke ̗ҽ˿^45,
418-425 (2014)
4. Ishitsuka K, Kamouchi M, Hata J, Fukuda K, Matsuo R, Kuroda J, Ago T,
Kuwashiro T, Sugimori H, Nakane H, Kitazono T; FSR Investigators (Ooboshi H).
High blood pressure after acute ischemic stroke is associated with poor clinicaloutcomes: Fukuoka Stroke Registry. Hypertension ̗ҽ˿^63, 54-60 (2014)
5. Namura S, Ooboshi H, Liu J, Yenari MA. Neuroprotection after cerebral ischemia.
Ann N Y Acad Sci ̗ҽ˿^1278, 25-32 (2013)
6. Abe K, Uchiyama S, Matsubara E, Muramatsu S, Atsuta N, Kitagawa K, Iguchi Y,
Ooboshi H, Kaji R, Terao Y. IT network establishment for neuropatients. Rinsho
Shinkeigaku ̗ҽ˿^53, 1155-1158 (2013)
7. Shichita T, Ago T, Kamouchi M, Kitazono T, Yoshimura A, Ooboshi H. Noveltherapeutic strategies targeting innate immune responses and early inflammation
after stroke. J Neurochem ̗ҽ˿^123S2, 29-38, (2012)8.

Shichita T, Hasegawa E, Kimura A, Morita R, Sakaguchi R, Takada I, Sekiya T,
Ooboshi H, Kitazono T, Yanagawa T, Ishii T, Takahashi H, Mori S, Nishibori M,
Kuroda K, Akira S, Miyake K, Yoshimura A. Peroxiredoxin family proteins are key
initiators of post-ischemic inflammation in the brain. Nat Med ̗ҽ˿^18, 911-917(2012)

9. Arimura K, Ago T, Kamouchi M, Nakamura K, Ishitsuka K, Kuroda J, Sugimori H,
Ooboshi H, Sasaki T, Kitazono T. PDGF receptor ß signaling in pericytes following
ischemic brain injury. Curr Neurovasc Res ̗ҽ˿^9, 1-9 (2012)10. Kuwashiro T, Sugimori H, Ago T, Kamouchi M, Kitazono T; FSR Investigators(Ooboshi H). Risk factors predisposing to stroke recurrence within one year of
non-cardioembolic stroke onset: the Fukuoka Stroke Registry. Cerebrovasc Dis ̗ҽ˿^33, 141-149 (2012)93
1. Basic fibroblast growth factor after ischemic stroke in diabetic patients - Researchfor Biomarkers in Ischemic Stroke (REBIOS) -QONakamura K, Ago T, Arimura K,
Makihara N, Nishimura A, Matsuo R, Kuroda J, Wakisaka Y, Isomura T, Awano H,
Suzuki K, Okada Y, Kamouchi M, Kiyohara Y, Ooboshi H, Kitazono TQOInternational Stroke Conference 2014, San Diego, February 2014.
2. The expression of pericyte PDGFRβ is regulated by basic FGF after ischemic stroke- Research for Biomarkers in Ischemic Stroke (REBIOS) -.ONakamura K, Arimura
K, Ago T, Makihara N, Isomura T, Watabe W, Awano H, Suzuki K, Kamouchi M,
Kiyohara Y, Ooboshi H, Kitazono T.ONeuroscience Meeting 2013, San Diego,
November 2013.
3. Phosphate overload induces systemic inflammation, malnutrition, and vascular
calcification in uremia.OYamada S, Tokumoto M, Taniguchi M, Tsuruya K, Ooboshi
H, and Kitazono T.OASN Kidney Week 2013, Atlanta, November 2013շ
4. The combined therapy with calcitriol and a calcimimetic agent, R568, ameliorates
phosphorus-induced calcification with altered expression of SIRT1 and ALP in
human vascular smooth muscle cells. Tokumoto M, Yamada S, Fujino T, Tsuruya
K, Kitazono T, Ooboshi H. ASN Kidney Week 2013, Atlanta, November 2013շ
5. ї̥ǴτπɳДȷοʌуjq¡ 0/@71 ÷˨&3@3/?164=?7=;/?93?@7<@163;71'A?=93&$'QO þ̋˲ă^ƺԍǈ́^˿̋şô^ΜƟŢȍ^ВԕϬĖ^ԙ̄ôȂ^ʹƟҗ^լʥ̺ͨ^Ȁ˫ƚ˩^ƑǣȏʝQO ˤ̇їɹΫĞӃȑħЯħ^̈ɓ^ɖ˾շ

6. D,u ^SRRZST G01v%"Ft!<swy]bnb_maeOckmO[fki_mgbmnOfjO\naebifaO^omkgbQO B@PO J'PO N -.PO 6*PO =K8PO L(PO 2MPO/HPO $#POQO :xX ")D?r+rTRSU  U &Q

7. Extracellular newly identified receptor for advanced glycation endproducts binding
protein (EN-RAGE) predicts the outcome in patients with acute ischemic stroke:
Research for Biomarkers in Ischemic Stroke. Wakisaka Y, Ago T, Kamouchi M,
Kuroda J, Matsuo R, Gotoh S, Watanabe W, Isomura T, Awano H, Suzuki K,
94

Fukuda K, Okada Y, Kiyohara Y, Ooboshi H, Kitazono T. International Stroke
Conference 2013, Honolulu, February 2013.
8.

Innate immunity as a novel therapeutic target of brain infarction. Ooboshi H.
Transpacific Workshop on Stroke. New Orleans, October 2012.

9.

$#YO\iipjbOmbnlkjnbO_nO_OjkqbhOoebm_lbpofaOo_mdboOkcO`m_fjOfjc_maofkjQO : VV ")
C5

r7rTRST  W &Q"95ϙ ϸ Ҿ ՖϙϸĞҔуIL-10έάʇŸɷʇTОѐ¥ήg˞wgϑΎπ͗ςʠιɄԕɢôճϑϯմƁš^

IL-12»«Ì±«ðÙ¨ãìóȻy¡IL-27jIL-35ϑΎπƣyƊ̓gșեφѨɌŚνʇhѢΎ(EAU)¥ήgҥ̑¥ҏ_EAUjgΎπɳ̃͒

Մ̃Ʒk IL27IL10τΨlǹƈw g_rIL-27ΎπŴ̃Th1ҹȱòΎπɳ̃Th17ʧŸ^IL-35ΎπŴ̃Th1ʧŸòΎπƱ̃jg Th17ʧŸĴήlf^ý»«Ì±«ðϑΎπ¥ʧŸy¡ƭёʇlϣu¢_ōŕňŅ ŤǝʇhѢΎѨɌŚνʇξʌ^ϲ`ӡɐȄ˩Ѫ¡sf¡ԔҜՀ͗ʇϑξʌfo¡_ΞҠƆĊɳlùѰ^Ȳś¢ƈհĩfÝóÇ­ÈÌο¡hѢΎȩwτπw^ӫɖ»«Ì±«ð1f¡

TNF(ќρǺ̿ǝȍ)-α¥̰φwάΝҙſճ«ðÙì³½âÚմlȱŜu¢s^}Ċɳƅφˑǐw_ϑΎπŸɷshάΝҙſl˿ήf¡slϣu¢^ėɳ˞͗ςÅó¸ÈÌ¥˃¡s¥ϊφw

ϑΎπjq¡»«Ì±«ðƋm¥˃¡s¥ҾՖw_IL-12ԨӶ»«Ì±«ðf¡IL-23, IL-27ͣʇƐw̳ΠОѐkέάu¢^CD4Դʇ
TОѐűƐͰoԨ¤¡slϕ¢¡_IL-12, IL-23, IL-27}¢~¢IFN-γ¥έάwОѐʇŚν(Th1)ҹȱԨúy¡_IL-23IL-17¥έάwΎπʇξʌοʖɮʝԨúy¡
Th17ƿ¢¡ОѐԽǞűƐ¥ĿӸw^ΎπҹȱԨ¤¡_ŠƴϙϸуƳ̋^șեφѨɌŚνʇhѢΎճExperimental autoimmune uveoretinitis,
EAUմæËí¥ήg^hѢΎjq¡Th17Ԩúg

ҥ̑w

m

(Rheumatology (Oxford). 2009 Apr;48(4):347–54.Int Immunol. 2008 Feb;20(2):209–14)_
IL-27Ŵ̃Th1¥ҹȱy¡ô˟^IL-23¥ʧŸy¡s¥˩kw

ҹȱu¢Th17Оѐ»«Ì±«ðέάm(J Immunol. 2006 Oct 15;177(8):5377–85)_ӫɖIL-27

ŚνʧŸĴήôԌ^ͣʇƐCD4ԴʇTОѐkέάu¢¡ŚνʧŸʇ»«Ì±«ðf¡IL-10έάlҹȱu¢¡s¡slϣu¢_s¢э˳Ǯm^ėǜʞ`EAU¥ҹȱɳ^Ύπlτάw͒ՄƐwgõԧjq¡С˰φIL-27^IL-10ϑŤ^ƣìðÕЈjq¡τΨСӽ¥ҥ̑w_^ƴxIL-12ԨӶ»«Ì±«ðf^ӫɖ}ŚνʧŸĴήl͟ϊu¢mg¡IL-35ϒϊ^EAUҹȱɳ^С˰φìðÕΩ¥˂ƨwIL-27͇ӣy¡ɮIL-35ɱƃg96̩ҩ¥ҏ_Ċĥ 6ӷհC57BL/6â¬¿Interphotoreceptor retinoid binding protein (IRBP)ΰ̍ÞÛÇÍj

Complete Freund’s Adjuvant (CFA)¥ήgϑΩ^ʢȻìðÕЈjTОѐ¥Гҙ^ʩCD3ʩıjјѥ¥ˍŰwϟ͊×IRBPź·ø

EAU¥ҹȱɳ0, 7, 14, 21ˤϊóÀ½¿Êä¥ήgCD4Դʇâ«Ìâ«½ðCůΪɳјОѐŠǭաw_ϑŤͫΆìðÕΩԨw

IL-27P28IL-10τΨ¥FACSjPCR

̩ҩw_ìðÕЈ^јОѐԨw

ì¹ð×ͳƈw^IFN-γ, IL-17έά¥3ˤɳELISAӡŨǝȍτΨ¥PCRÎðÌIL-27(rIL-27)j^7ˤɳFACS¥ήgrIL-35¥̩ҩw_

̩ҩw_

ŦĕBūÖ
EAUҹȱɳ^С˰φ˂ƨ^ГҙwCD4ԴʇTОѐjgτΨFACS¡ҥ̑day21ɴ`ǹƈw

^IL-27p28jIL-10g_ճǠպմPCR¡τΨƴ̮ŐƷlҞ¢_IL-27lIL-10¥έάwEAUΎπ¥ʧŸwg¡ƭёʇlf¡тi¢_Ʊ˰̃ìðÕΩ¥in vitror-IL27ź·y¡^IL-10τΨȩӉ͇ӣw ǹƈw_ճǠ2մ

Ǡպ

97

Ǡջ

 EAUƱ̃ʢȻìðÕЈòјѥkГҙwCD4Оѐ¥rIL-27^rIL-35ź·wIFN-γ, IL-17^ӡŨǝȍτΨ¥PCR̩ҩwճǠռմ_IFN-γ, IL-17έ

ά¥3ˤɳELISA

̩ҩw_rIL-27ź·^FACSճǠսմ¥ήgφӡŨǝȍ(T-bet)τΨ÷˨j
_rIL-35EAUŴ̃ˠgτΨ¥ʧŸl¢_ELISA

Th1Ξλ

Th17ΞλφӡŨǝȍ(RORγt)τΨ͸ɪl¢IFN-γέάʧŸjEAUƱ̃jgƴ̮Ɗ̓lҞ¢_98

˿ʒIL-17

Ǡ
ռ

99

Ǡս

ğ÷

^IL-27ΎπŴ̃Th1ҹȱòΎπɳ̃Th17ʧŸ^IL-35ΎπŴ̃Th1ʧŸòΎπƱ̃jg

Th17ʧŸĴήlf^ý»«Ì±«ðϑΎπ¥ʧŸy¡ƭёʇlϣǊu¢_Ψǥin vivojq¡»«Ì±«ðƊ̓Ԩy¡̩ҩ¥yy

g¡_

ń žƈć
1. EBI3 is pivotal for the initiation of experimental autoimmune uveitis. Takeda A,
Hasegawa E, Fukuhara T, Hirakawa S, Yamada H, Yang Y, Yoshimura T,
Hisatomi T, Oshima Y, Yoshida H, Sonoda KH, Ishibashi T. Exp Eye Res. 2014
Jun 11;125C:107-113.
2. IL-10 is significantly involved in HSP70-regulation of experimental subretinal
fibrosis. Yang Y, Takeda A, Yoshimura T, Oshima Y, Sonoda KH, Ishibashi T.
PLoS One. 2013 Dec 20;8(12):e80288
3. Melanocyte-secreted fibromodulin promotes an angiogenic microenvironment.
Adini I, Ghosh K, Adini A, Chi ZL, Yoshimura T, Benny O, Connor KM, Rogers MS,
Bazinet L, Birsner AE, Bielenberg DR, D'Amato RJ. J Clin Invest. 2014 Jan
2;124(1):425-36.

100

4. Suppression of autoimmune retinal inflammation by an antiangiogenic drug.
Yoshimura T, Benny O, Bazinet L, D'Amato RJ. PLoS One. 2013 Jun
13;8(6):e66219.
5. Simultaneous analysis of multiple cytokines in the vitreous of patients with sarcoid
uveitis. Nagata K, Maruyama K, Uno K, Shinomiya K, Yoneda K, Hamuro J,
Sugita S, Yoshimura T, Sonoda KH, Mochizuki M, Kinoshita S. Invest
Ophthalmol Vis Sci. 2012 Jun 20;53(7):3827-33.
6. Aminoimidazole carboxamide ribonucleotide ameliorates experimental
autoimmune uveitis. Suzuki J, Yoshimura T, Simeonova M, Takeuchi K,
Murakami Y, Morizane Y, Miller JW, Sobrin L, Vavvas DG. Invest Ophthalmol
Vis Sci. 2012 Jun 28;53(7):4158-69.
7. IL-23-independent induction of IL-17 from γδT cells and innate lymphoid cells
promotes experimental intraocular neovascularization. Hasegawa E, Sonoda KH,
Shichita T, Morita R, Sekiya T, Kimura A, Oshima Y, Takeda A, Yoshimura T,
Yoshida S, Ishibashi T, Yoshimura A. J Immunol. 2013 Feb 15;190(4):1778-87.
8.

A Novel Platelet-Activating Factor Receptor Antagonist Inhibits Choroidal
Neovascularization and Subretinal Fibrosis. Zhang H, Yang Y, Takeda A,
Yoshimura T, Oshima Y, Sonoda KH, Ishibashi T. PLoS One. 2013 Jun
27;8(6):e68173.


1. șեφѨɌŚνʇhѢΎjq¡ IL-27 j IL-35 ɱƃ. ɕɄ͔ɨգ^Ƴ̻̋^̻ίЋł^ȀɁҗư^Ʉԕɢô^Ϙ̴ӿ́. Ѐ 118 ǜˤ̇ϑϯȑħЯħ^̎Ĕ^2014 ɖ 4 ˾.

101ϙ ϸ Ҿ Ֆƫњ÷χОѐűƐh¸Òä®Ø¾­ÑÊªÈµǽƐϙϸĞҔуǧ÷ϼӒճƫњ͗ςȑӂɠò̽ƽοȑűԕò˕ˀմ Ɓš ƫњŤΞɼφ÷χĞҔw¤¢^}¢~¢g˼jg¸Òäj®Ø¾­ÑÊªÈµǽƐg^sջЖg

űƐg¡å±ÏÀägӷհ^YƫњБѢ÷χZ̽Ɵʇ÷χЖРиlf¡_¤¢Ȁȑԯάșեēi^ėɳȺ̂¥Ƹϒϊwg¡_̇ǰƼ

^ʉɑʇЩʶå±ÏÀä^сƐҪӤy¡_ƫњБѢ÷χg^ɖհƴўâ¬¿ƫ҃ҤƐ̽шРиÌëð¿µìÛÌóä¥͇ӣw_ ɖհâ¬¿^ ӷհâ¬¿͇ӣw ԄĨȍτΨԖl˿ʒǹƈw^˿ʒ͸ȳwճg_́Ɵʇ÷χЖРиgԄĨȍτΨԖlմԄĨȍ˿ʒτΨԖǽƐҸk_̽^ʉɑʇ¥ŁРиw

̽РиɘОѐgϒϊw^'=E  $1AτΨlʉɑφЩʶu¢¡s¥ŚνРиȑφϞҸw_YƫњБѢ÷χ®Ø¾­ÑÊªÈµǽƐg ƫњБѢ÷χͬƐЇŜƫάı˽Ǿȼĭкwy¡_Ҕχ^ҤƐ÷χБѢ÷χlfj^ʔ̕ȩy¡Ôì©w^ƫњŤԌĭΞλφýуlűɎw

̵ё

g¡_ƫњ

ŤҤƐ÷χűɎλɑ̽ƽΎӸҏɰՉ¥úi¡^БѢ÷χҕҝu¢ՎǬҤƐ÷χ¥ϰ̨y¡͗ςҏ¤¢g¡_s¢sk^ƫњ÷χОѐτΨԄĨȍ¥Ылφҥ̑w^ҤƐ÷χОѐΞλφτΨy¡ԄĨȍ¥ҿ^s¢ԄĨȍέΝ¥ƫњŤʔ̕πξʌʔƩʇf¡gсƐâó±óűȍԨӶqʽi¡sʒоlf¡тi¢¡_ ̇ɖȀȑԯ¥Ɩ̪w̋÷^҅ΪȑȽձ˕ˀŕ÷χаЩѴОѐk¡Ŧ̭ЊæËí¥Ĵʝw^÷χҤƐ¥˻˞u{¡ԄĨȍτΨ̵̭gÊ³ðź·

ҥ˩w±¿ÕóÂ  ϒϊw^®Ø²ï±m_Ȁȑԯά  ɣ̏l^ƴ̮Ƚձ˕ˀʷȱŕâ¬¿÷χОѐ̛jq¡ ! ԄĨȍτΨŸɷ̵̭ҥ˩ʸ¦g¡_ēĈBĊĥ
 ӷհ
ϺМ
̑

ɖհƴўâ¬¿¥»µìÙ¨«¿wɳ^όƫ҃ҤƐ̽шРи¥˂ƨw^ͭıʆӴūŭ^ӳ͝wl;&# ¥ʮŰɳ^֎# Ʋʝ¥ҏÌëð¿µìÛÌóä¥͇ӣw_102

# â«µï©îóҥŦĕBūÖ
ɖհâ¬¿^ ӷհâ¬¿͇ӣwȍτΨԖl˿ʒ͸ȳwg_́

 ԄĨȍτΨԖl˿ʒǹƈw^



ճ

ԄĨ

մԄĨȍ˿ʒτΨԖǽƐҸk_^ƽǟРи͇ӣwύȩτΨԖl˿ʒըgԄĨȍ^ҤƐԨӶy¡·ëÇðԨӶÅðÕµӕ¥¹óÍy¡lǿk_s¢ԄĨȍԮw

ɖհâ¬¿jg^ ӷհâ¬¿͇ӣύȩτΨԖl͸ȳy¡ԄĨȍlǿgslhkl¤¢_îFÚĒ ҤƐƫ҃̽ш÷χРиÌëð¿µìÛÌóäƈi^ҤƐwgƫњБѢ÷χРи^}þԧφɮӕ¥˿y¡˄Ʋ÷χ^s¢ɮӕЩʶԨ¤¡тi¢g¡÷χøТƲРиÌëð¿µìÛÌóä¥ҿ^ύč͇ӣy¡s^ƫњ÷χÌëð¿µìÛӨ¦aƈÌóäΞɼ¥Ылφ˩kwg_^sҥ̑kÅó¸ÈÌԄĨȍ¥Уհ¡τΨǽƐ¸Òä®Ø¾­ÑÊªÈµǽƐύԨ˃͍^ѨΓτπy¡̽ƽΎРиȑφ^ОѻȑφҔΨǩǽƐ˃͍brg_Zr̽՚Ų̽jq¡̽Ɵʇ÷χƋʖg ƫњŤΞɼφ̽Ɵʇ÷χw^®Îåí÷χ^˫ΠЫ^ÜíÌ×ÈÖ÷χՇ^âëÈÁ÷χ́Ԅ^˄Ʋ÷χlf^u®Îåí÷χ®Îåíӕ¥o¡ÅðÕµ¥ű͜y¡ghΞɼlf¡_ÖÌjg^̽ɘОѐghm̽ɮʝ¥ư¡ǗȖ^̽ɮʝ˰˽̝ȴ÷χРиƸ¢g¡тi¢¡_wkw^r̽՚Ų̽jgɘОѐ¦}ĭк¥ǽiz^÷՗ø՗ĪШqg^РиОѐ¥ˆĹwШq¡_sʒƾj^sr̽՚Ų̽Ҹ¢¡̽էɘОѐсƐĩhɰՉ¥˽ƩqogРиôтi¡slm¡_sϙϸ¥̫¡s^űƐсƐɰՉ¥Ʃqog^ʉɑʇ¥ҹȱy¡ԄĨφэ˳l˩km¡ƭёʇlf¡_ sșեȀȑԯ  ÿȶҏjРиĴʝŚν̕ѱ^%& ͝¥ҏȆȍƓȀպɖԧϙԢ¥ҏ^āǧ÷lʤҐʤʦԦτОѐǭա^ÿȶlοΪg¡_̇ɖkȀȑԯƖɳƉ˕˂ήu¢̧^̎Ĕ^̝̽ѢОѐűƐҹȱ̝̽Ѣ½óÌĴʝˋ¤

g

¡_

ēĈBĊĥ »ó×±ííóÛОѐűԿǭաҲάɳ  ˤհâ¬¿kø՗Ų̽¥ƸРи¥ƙԿw^Ëª¿ÕóÂůΪ¥ҏ

103

÷χ̽Ȳ

ǘ¥űԿw^»ó×±ííóÛǭա˽Ԃw̌Ģ¥̩Нw_ '=E  $1A юά̃kəѷâ¬¿Ѫ¡Ƌʖgюά յ յ  ˤհյάɳ յ ˤհâ¬¿kø՗Ų̽¥ƸhРи¥ƙԿw^όß í â ì ð  ǡ ȗ w ^ ӳ ͝  ɵ g Ų Κ  Ĵ ҙ ¥ ҏ   _  ̕ ѱ ղРиԌĭ¥ϞҸɳ^'3E23A3?;7<7<5?357=<-0=E '=E ԴʇОѐȸǥȣɟ¥ŚνРиƐȑφҿ_ մâ¬¿̝ȴԌОѐǲϰ̨^άɳˤհâ¬¿kˍŰw 13?C71/::==> ԌРиλʢʇϝРиɮʝё^ˍŰРи¥ ӷհâ¬¿љѥχѢøϰ̨w¢Ϙ΍ƐΝԖ»«À¥ôȗ̃ԧ՟ыɳ^â«µï ( Җк¥ήgϰ̨ԌĭɮʝuұĻw_

ŦĕBūÖ »ó×±ííóÛОѐűԿǭաg »ó×±ííóÛǭաg^ğø̌ĢʝƇwg¡_Y»ó×±ííóÛƽǟаЩѴОѐ¥Ƹ̝ȴԌОѐ¥Ŵ̃ǭաwǱƲ^Иպӷԧ©¬Ì¶ï¬¿w^ƽǟаЩѴОѐ¥ԏw÷χОѐǲlɮʝu¢¡_Z»ó×±ííóÛ¥ƨŰw^Α¹óÌ^¹ëó¸ðÅ«Û  ¹óÌu¢ËªÈ½è©¬Ì¶ï¬¿wg_[»ó×±ííóÛ¥ƨŰw^âÌì¸í¹óÌu¢ËªÈ½è©¬Ì¶ï¬¿lƭ

ё_ռӷԧռվ;; Ȁmuʳl¡_\»ó×±ííóÛ¥ƨŰw^"ճâ¬¿юĚаЩѴОѐմ÷кo^âÌì¸í¹óÌƴxÞó¿©¬Ì¶ï¬¿y¡_]Y֐\ŝ

»ó×±ííóÛ¥ôǲw

Ʋf¡_¹ë¸ÎóÂůΪ¥ҏËªÈ½è÷кm^©¬Ì¶ï¬¿u{ǱОѐ¥ÔëÔëwǱƲ^̌Ģf

wk_^ЧĞˎĴĩОѐ¥ÔëÔëwǱƲάԣwk_±Ôó²ë¿÷âÌì¸í¥кgŴ̃ǭաės£ʝƇw '=E  $1A юά̃kəѷâ¬¿Ѫ¡Ƌʖg

άԣ

gg_



Śν̕ѱŠΒΏîó¼óՙɺԡ¡ңȧюάəѷâ¬¿ƫњРиjg'=E τΨԌĭ}С˰φǽƐ¥ŚνРиƐȑφ̩Нws£^юά̃jάɳâ¬¿jgw

g_ușե̃ԧ¥ӳxҞŰw_u $1A g'=E τΨОѐƫњБѢ÷χ̽яȸǥ

^'=E  !/07/:13?C71/::==> ԌԮȸw

^'=E ƴ̮ɘОѐʅ¤¢¡ĭкjgs¥ңȧw_

104τΨy¡s¥
ɬτΨw

g¡





 մâ¬¿̝ȴԌОѐǲϰ̨ 13?C71/::==> ԌРи¥ϰ̨wљѥϘ΍ƐΝlҸ¢_!/07/:13?C71/::==> Ԍ^â¬¿Ų̽®ÎåíӕɮʝԨúy¡Риf¡sƲ¤{^13?C71/::==> ԌРиϝРиɮʝё¥ʶОѐűƐwh¡ОѐlƸ¢^'=E }¢®ÎåíɮʝԨ¤¡ɘОѐâó±ó¡ƭёʇlf¡тȧw_â¬¿̝ȴԌОѐǲϰ̨փάɳ 2 ˤհâ¬¿kˍŰw cervical loop ԌРиλʢʇϝРиɮʝё^ˍŰРи¥ 4 ӷհâ¬¿љѥχѢøϰ̨wɳ^â«µï CT Җк¥ήg΍ƐΝԖ»«À¥

4 ӷԧ՟ы

ϰ̨Ԍĭɮʝu¢ϘұĻw_îFÚĒ â¬¿ø՗Ų̽»ó×±ííóÛ¥ƨŰw^s¢¥ 7<C7C= ø՗Ų̽ƴxԌĭϰ̨y¡˟͝¥Ҳҏԝһ̆Ȕʝw_s¢shșեЖǰƼΑo^Ŧ̨æËíws¢¥τȺw^ϙϸԃʫщ¥ʳr¡s¥̱Нw

×±ííóÛ¥ƨŰw^s¢¥Ó«ÚìÈÍ̽яwg¡_šıφ % â¬¿»óϰ̨y¡s®Îåíӕ¥ɮʝy¡ОѐlάıŤhűƐy¡k¥ӭӛwg_ӫɖ^ÜíÌ×ÈÖ÷χՇl÷χԧѿӡˇ¥ӗswÁåðÌӕűƐy¡ǰƼ˖Ҟu¢¥Ұ˩y¡sɱϻтij^¤¢¤¢șեЖså±ÏÀä

g¡_

ńžƈć

1. Morotomi T, Kitamura C, Okinaga T, Nishihara T, Sakagami R, Anan H (2014)
Fever-Range Heat Stress Induces Thermotolerance in Odontoblast-leneage cells,
Archives of oral biology, ̗ҽ˿ 59: 741-748, 2014.
2. Nishida E, Miyaji H, Takita H, Kanayama I, Tsuji M, Akasaka T, Sugaya T,
Sakagami R, Kawanami1 M (2014) Graphene oxide coating facilitates the bioactivity ofscaffold material for tissue engineering, Jpn. J. Appl. Phys, ̗ ҽ ˿ 53 06JD04
doi:10.7567/JJAP.53.06JD04, 2014.

105

3. Murakami H, Okamura K, Aoki S, Sakagami R, Yamazaki J. (2013) Association of
caspase-14 and filaggrin expression with keratinization of the oral mucosa andreconstruction culture rat models.. Journal of Periodontal Research, ̗ ҽ ˿ doi:
10.1111/jre.12152, 2013.
4. Mori, N., Ohno, J., Sakagami, R., Hayakawa, T., Fukushima, T. (2013) Cell
viabilities and biodegradation rates of DNA/protamine complexes with two different
molecular weights of DNA. J Biomed Mater Res B Appl Biomater, ̗ҽ˿ 101: 743-751,
2013.
5. Ohgi, K., Kajiya, H., Okamoto, F., Nagaoka, Y., Onitsuka, T., Nagai, A., Sakagami,R., Okabe, K. (2013) A novel inhibitory mechanism of nitrogen-containing
bisphosphonate on the activity of Cl- extrusion in osteoclasts. Naunyn Schmiedebergs
Arch Pharmacol, . ̗ҽ˿ 386: 589-598, 2013.
6. Sano, S., Sakagami, R., Sekiguchi, M., Hidaka, M. (2013) Stabilization of MAPO1 by
specificbindingwithfolliculin

andAMP-activatedproteinkinaseinO6-methylguanine-induced apoptosis. Biochem Biophys Res Commun, ̗ ҽ ˿
430:810-815, 2013.
7. Lim TH, Fujikane R, Sano S, Sakagami R, Nakatsu Y, Tsuzuki T, Sekiguchi M,
Hidaka M. Activation of AMP-activated protein kinase by MAPO1 and FLCN induces
apoptosis triggered by alkylated base mismatch in DNA.. DNA Repair (Amst). ̗ҽ˿211: 259-266, 2012ȑħτҔ
1. Mori N, Washino K, Iwata T, Yoshida T, Fukushima T, Sakagami R, Yamato M,
Okano T. (2013)Optimal conditions for creating rat periodontal ligament-derived
multipotent

mesenchymal

stromalcell(RPDL-MSC)

sheets.

12thCELL

TRANSPLANT SOCIETY, Milan Italy
2. Ohgi K, Kajiya H, Okamoto F, Tsusumi T, Onitsuka T, Nagai A, Sakagami R, Okabe
K (2012) Bisphosphonate as a novel target to the Clcn7 Cl- transporter in osteoclasts.
Ѐ 89 ǜˤ̇άΪȑħȀħ, ̏̇106

3. ̋÷ ɧ, ȿ̋ ǂɯ, ǧ÷ ϼӒ, Ƚձ Й (2012) ëÈÌƫњБѢŦ̭ЊЖjq¡ԔȼƐòҤƐ÷χ±¿ÕóÂ 14 τΨ. Ѐ 85 ǜˤ̇҅Ϊȑħɖħ, ĔԎ
4. Murakami H, Okamura K, Sakagami R, Yamazaki J (2012) Expression of caspase-14
in stratified and cornified epithelium in a rat oral mucosal reconstruction model. Ѐ 85ǜˤ̇҅Ϊȑħɖħ, ĔԎ
5. ÿȶό̳, ȿ̋ǂɯ, ӇƫԉĂ, ǧ÷ϼӒ (2012) â¬¿ø՗Ų̝̽ȴԌǿёʇɘОѐjq¡ Sox2 τΨ. Ѐ 39 ǜϫȿ̽ϯȀȑȑħ, ϫȿ
6. ɣ̏ ĕ, ŞίŘü, ǧ÷ϼӒ, Ƚɂ Й (2012) ǭա÷χОѐjq¡ Cl-ÇçÑíҿЈǝȍԄĨȍτΨҥ̑. Ѐ 54 ǜ̽ϯǮϢƓȑħȑҐȀħ, ԋȽ
7. Ȁǫɏмȍ, ȿԌɗư, իǳɶą, ͌ď ͱ, ǧ÷ϼӒ (2012) ϺМƸ˿×¿Ù¯¿Ù¯
ÑóÌ (NBPs) ϛզОѐ ClC7 ǩ Cl-ӧӮı (Clcn7) ̵ё¥ʧŸy¡շЀ 55 ǜˤ̇̽ƽοȑħ˭ȐȑҐȀħ, ̈ɓ
8. ̋÷ ɧ, ȿ̋ǂɯ, Ƚɂ Й, ǧ÷ϼӒ (2012) Epigallocatechin-3-gallate (EGCG) ¡ƫњБѢűƐȩy¡ɰՉշ Ѐ 55 ǜˤ̇̽ƽοȑħ˭ȐȑҐȀħ, ̈ɓ
9. į ԕ w j, ǧ ÷ ϼ Ӓ , Ԩ ƫ ϓ Ȃ , ˤ ը ϐ Й (2012) © á Ì ó ½ ¿ ӽ ϱ  j q ¡MAPO1 ȓȗƐ. Ѐ 35 ǜˤ̇űȍάΝȑħɖħ, ϫȿ
10. Sakagami R, Nagai A, Kaneko N (2012) Surface roughness of curettes sharpened bydiamond dressers. American academy of periodontology 98th annual meeting, Los
Angels
11.

Nagai

A,

SakagamiR(2012)

Phylogenetic

mappingofchronic

periodontitis–associated microbiota to the human microbiome. American academy ofperiodontology 98th annual meeting, Los Angels107ϙ ϸ Ҿ ՖÛïÔ«°Êªµ¿ƫњξʌϙϸĞҔуɣ҇ƗԻճЯƲ̽ϯȑӂɠòЯƲ̽ϯȑűԕò˕ˀմƁš ćԑѻ^ŚνӔͣƐĴή^¹î¿ÊïóíĮ͸Ĵή^ʩѻĴή^άıԫɷ̵ё¥τˈy¡ѻ̛lǿo^ӫɖs¢¥ѝŤΫǸqoƫњΫǸŋŝƐŷήwhghƋmlŰ

g¡_¤¢¤¢ŋɑĖàëðÊª©¥ȩӉwëðÆäƐ͇ӣҲե^ǔΔнjgÛëóµĝϒ̽ƽá·ÈÌˑǐlǰƼu¢ćԑѻ Lactobacillus

salivarius WB21 (Ls WB21) ̛ϒϊw^̇ѻƫѩʧŸƊ̓¥ҿs£^ǿoƫѩʌуl 2 ӷԧЧШˌƨƫѩˑǐ¥ϣw (Iwamoto T et al. Oral Surg Oral Med

Oral Pathol Oral Radiol Endod, 110:201-208, 2010)_sϙϸՅϋ̩Ҳեf^̇ϙϸ Ls WB21 ԏƲÅÚîÈÌƫѩʧŸƊ̓¥˩ky¡^ƫѩʌу¥ŷήwČԔϋ̩ëðÆäƐµï¿°óÔóҲե¥șˡw (˛Τ 2)_}Т̓^Ls WB21
̃ÛëÁà̃͇ӣwˈτʇϜծƐƲΝ (volatile sulfur compounds, VSCs) ̽ƽá·ÈÌl˿ʒˑǐw_нŤ͇ӣ Ls WB21 ̃Ûïó×ð¶˰ŰҎΦ
(bleeding on probing, BOP) l˿ʒ͸ȳwl^ÛëÁà̃ǽƐl¢k_sh Ls WB21 ÅÚîÈÌƫѩ̽ƽРиˑǐƊ̓lf¡sl˩k_ ^ÅÚîÈÌһǙƝԳʇlf¡ԹȞуըհуʁή¥ʐȗw^Ls WB21 ԏ
Ʋ°«í¥Ԧτw^}Ɗ̓¥ѧɛφ̩ҩw (˛Τ 12)_̽ƽοʌу¥ȩӉwÛëÁàȩΕČԔϋ̩͇ӣҲե¥ҏs£^Ls WB21 ԏƲ°«íнÛëÁà°«íн͇ӣw^4 ӷԧĘŜ̃ԧjq¡ BOP ˑǐΦl˿ʒŔ¢ ćԑѻԑ¥έάw^hҋοɆg_űԿu¢¡sk^hҋԨӶʇlϣǊu¢g¡_}s 2 ϲ՚ćԑѻԏƲÅÚîÈÌ (Ls WB21 ԏƲÅÚîÈÌj Ls TI2711
ԏƲÅÚîÈÌ) ˌƨόɳhҋì¿µǝȍǽƐ¥ҿs£^gz¢hҋì¿µǝȍ¥ǹƈu{¡so^LS WB21 ÅÚîÈÌãèóÅð¿ѻ˙͸ȳl^
Ls TI2711 ÅÚîÈÌź·ǍͭԖǍͭвҒёǹƈl¢^hҋì¿µǝȍȩwʭʩʇ¥ϣyŐƷlf_ ćԑѻg̮`ƫѩʧŸſg^ƫѩƫњŤΫǸúi¡ɰՉ¥ҿ¡ɿҜlf¡_̇ϙϸ^ÖÒ³Ç°óíԏƲƫњ·©ή¾­í^ǵƐÁÇíØì¾Ï¬ä(ʩѻʝű)ò¶ìÇíìÇðԑČ±ì¬ä (Риńɸʝű)ò³³ê¬®³¿ (Ǎͭű͜ĿӸʝű)  3 ϲ˿Ɗʝű¥ԏƲwÌïóÇ^ĐԚ«°ðg^ƫѩƫњŤΫǸ^ƫњŤОѻƪúi¡ɰՉ¥ҿ^ϙϸʝ̓¥ǰƼw (˛Τ 1, 5)_
108


ō ŕňŅ
 ӫɖ^˙ǿoĘӆсĖŁŋˡҫϫϦˡҫlԦҫu¢ǿoҜĘӆըհуòԹȞуlŜʢwg¡_sՎǬjg^ƫњŤ̽Λ̽ƽРиοφʎƐl^ƫѩ^ƾҡԹȞ^ƫњ̵ёǙø̵ёĮø¥ʱm^һǙʇьΎĮ̘ա^ҸϕπӸҏl¡u¢^ƫњ·©¥Ƹ̽ϯ͗ςԔҜʇlɬoϣǊu¢հуòԹȞуƫњŤΫǸΠʖ¥ϣyʷ̰w
њŤÛïÔ«°Êªµ¿̬ʃ¥ƨwȓŝʇϞҸu¢g¡_Ξ^ƫѩҜĘӆըϒϊu¢g¡_̇ϙϸϊφ^ƫŜ¢^ҜĘӆըհуòԹȞу^ƫњ·©Ķήg¡˿ήʇըgćԑѻ˿Ɗφʨú˟͝¥Ϟϻw^ćԑѻ¥ƫњŤОѻƪŠȎu{¡sƫњŤОѻƪ¥ǽƐu{^̽ƽξʌ¥ƸƫњŤŋɡΠ͙¥ˑǐu{¡^}s¡ŝӟφŋɡˑǐ¥Ǡ¡f¡_ z^yƫѩʌу¥ȩӉwՅϋ̩Ҳեjg
ѻ Lactobacillus salivarius WB21 ̛¥ήgƫѩ˿Ɗʇ¥ǰƼwćԑ^ɵ̍ÅÚîÈÌÅ«ÛkѮ¡slùƭёʌуŷή¥тʘw°«íÅ«Û¥Ԧτw^̽ƽοʌуȩw^ÛëÁà¥ȩΕwČԔϋ̩ëðÆäƐ͇ӣҲե¥șˡw_ÅÚîÈÌgżǜϙϸlՅϋ̩Ҳեf^ƫѩʌуȩw^ÛëÁà¥ȩΕwČԔϋ̩µï¿°óÔó͇ӣҲե¥șˡw^ƫѩ˿Ɗʇ¥ϞҸw_ŕ̍ćԑѻӸҏwhҋοɆԿu¢¡slϕ¢
Չ¥ϞҸw

j

ű

^ԑ¥έάy¡sk^ŷήy¡ćԑѻlhҋúi¡ɰjoɿҜlf¡_}^ćԑѻԏƲÅÚîÈÌˌƨżɳjq¡hҋì¿µǝȍǽƐ¥ҿ_^ćԑѻğǾƫѩʧŸſgњŤΫǸƣyɰՉg^Ɗ̓ϱɟƫƔű̩ҩu¢ȳg_̇ϙϸ^ÖÒ³Ç°óíԏƲƫњ·©ή¾­í^ǵƐÁÇíØì¾Ï¬äò¶ìÇíìÇðԑČ±ì¬äò³³ê¬®³¿ 3 ϲ˿Ɗʝű¥ԏƲwÌïóÇ^ǵƐĐԚ͋΀ͭg^ƫѩƫњŤΫǸ^ƫњŤОѻƪúi¡ɰՉ¥ҿ_Ċĥ
YLs WB21 ƙº]XFƝńB·Ű¦ĶÊE2QìƨFęƄ

 Ls WB21 ԏƲ°«íĴҙ^¤kҙ̛҅ɥħϥĺՔw_ôѯԦ̪̽ϯƓԯŴүʌу 42 Ƶȩw^ÛëÁà¥ȩΕwČԔϋ̩ëðÆäƐ͇ӣҲե¥șˡw_ôˤ 3 ǜ͆՝ɳ^ѭэþȃԌ°«í¥ 5 ΁΁øw^ѭ¥ķ°«í¥ƫњŤ¦¦oҏm͹¡hʷϣw (4 × 108 CFU/day)_°«íˌƨ 2 ӷԧЧШw^șեԦȉżԦȉ 2 ӷԧɳƫњŤү̗Ǎͭ˂ƨ¥ҏ_șե̃ԧþƫњʹʿпʗ¥ǽighʷϣw_șե̃ԧþʩѻ҅̀ή̽ϯ͗ς¥ϩ̹w_̽ɥ^̽ƽá·ÈÌ^BOP^ź·ǍͭԖ^pH^ǍͭþОѻ˙¥ҿ_uǍͭ»ðÛí109

g

T-RFLP ͝¥ήgѻƪҥ̑¥ҏ_&Ls WB21 ƙºk}mpF·Ŵûª¯ĕ ƫѩ¥āҮwϫȿ̽ϯȀȑƓϯ̽ϯЯƲοԯƫѩµìÏÈµϯ¥Ʃүwϐʇƫѩπʌу 26 Ƶȩw^ëðÆäƐČԔϋ̩ÛëÁàȩΕµï¿°óÔóҲե¥ҏ_ҕեу¥ 2 н (A нj B н) ΑĴΐƃĝqw^Ѐ 1 ̃w

A н Ls WB21

ԏƲÅÚîÈÌ (2 × 109 CFU/day) ¥ B нÛëÁà¥ӶШw

2 ӷԧ 1 ˤ 3 Џˌƨw_}ɳ 2 ӷԧĦ҅̃ԧ¥С^Ѐ 2 ̃w^A нÛëÁà¥^B н Ls

WB21 ԏƲÅÚîÈÌ¥ 2 ӷԧˌƨw_ýˌƨ̃ԧżɳ^ƫѩ̩̗ƫњŤү̗¥șˡw_̩̗ɭˤ^ӗɛ˰՞՝^̽Նʹʿ^ǔΔƫњͣƋ¥ϩ̹w_'Ls WB21 ƙºk}mpF1ź

h`E×:Qìƨ ϫȿ̽ϯȀȑ 6 ɖά 64 Ƶ¥ȩӉwՅϋ̩ëðÆäƐ͇ӣҲե¥șˡw_ҕեу¥oxɦm

ΑĴΐ 4 н¤q^Ls WB21 ԏƲÅÚîÈÌ^Ls TI2711 ԏƲÅÚîÈÌ^͇ӣȩӉǆw

Streptococcus mutans ȩy¡ʩı¥ԏƲw°óÔí¸ð DCԏƲÅÚîÈÌ^³½ìÌóíԏƲÅÚîÈÌgz¢k¥ƃɭ (Ҕ 1)_ÅÚîÈÌǖzѮ¡hʷϣw^ˌƨżˌƨ 10 űɳãèóÅð¿ѻ˙^ćԑѻ˙^ź·ǍͭԖ^Ǎͭ pH^ǍͭвҒёǽƐ¥ұĻw_
Ҕ 1. ҲեнƃĝŤҭ
н
(n)
ǎǆʝű
ǎǆƵ

˿Ɗʝű
(1 Ԝf
ƾ)

WB21(n=17)

LS1(n=16)°óÔí¸ð DC(n=13)³½ìÌóí
(n=18)

¦ǐΧѻ WB21
ÅÚîÈÌ (¤kҙ҅)
L. salivarius WB21:
6.7 J108 CFU
Xylitol: 280 mg
ãðÌ¿óÕóµìÈ½è
(ÙîðÊò«ðÅóÎ½êÎí)
L. salivarius LS1: 2.8
J108 CFU
Xylitol: 450 mgµìóðãðÌ

Ó³ë (×óð¿Åóµ)WB21 ÅÚîÈÌkćԑѻ¥ƨ ԰g(¤kҙ҅)Xylitol: 280 mg

S. mutans GTF ʩı
Xylitol: 100 mg
°îð¾

ãðÌ

[ yv_l]ƙºgZEOQ·Űīþ5·ŴE2Qìƨ ϫȿ̽ϯȀȑƓϯ̽ϯЯƲοԯƫѩµìÏÈµϯ¥Ʃүwϐʇƫѩπʌу 18 Ƶȩw^ëðÆäƐ͇ӣҲե¥ҏ_ҕեуΑĴΐÖÒ³Ç°óíԏƲ¾­íн (șեн^9 Ƶ) ÖÒ³Ç°óíΑԏƲ¾­íн (ȩΕн^9 Ƶ) ƃʿ 1 ˤ 3 ǜ (͆՝ɳ)^ğøӳɭ¢_ƫњʹҏhhʷϣw_1) ̽Úë½¾­í¥ 1 cm ƨ¡^2) ̽̽шʹʿ¥ 3 űԧҏh^3) ѭÚë½ 5 ǜѭʹʿ¥ҏh^4) ̽ϠmПĉɳygɳ^Ŧɟ¾­í¥ 2cm ʷƨ^ƫњŤŝıâÈ»ó¾wlɚr^ʹʿɳ 30 ű՞՝¥wg_ķήԦȉż (Ýó¿ë«ð)  4 ӷɳ^ƫѩ̩̗ƫњŤү̗¥șˡw_
110)3 ŔFđ¯ø©Sƙº9=·Ű¿ÂŸF·Ŵûª¯ĕ ϫȿ̽ϯȀȑ 6 ɖά 82 Ƶ¥ȩӉwՅϋ̩ëðÆäƐ͇ӣҲե¥șˡw_ҕեуoxɦmëðÆä 4 н¤q¢^1 ԜfǵƐÁÇíØì¾Ï¬ä (CPC) 1 mg^¶ìÇíìÇðԑČ±ì¬ä 2.5 mg^³³ê¬®³¿ 20 mg (Ɵά҅ˇІԖ: 80 mg)  3
ϲ˿Ɗʝű¥ԏƲwƫњǅǑ҅ (ïóÀ¬«ðÍ)^CPC 1 mg ¥ԏƲwƫњǅǑ҅ (ÛïÊµÌÍïÈÛ)^˿Ɗʝű¥ԏƲwgʹͮѼȍ (Ùì¿µ)^͋¡͡ƫgz¢klƃ

ɭ¢_ˌƨf¡g͡ƫżɳ^ƫѩ^ѭŁͽɟ^ź·ǍͭԖ^Ǎͭ pH^ǍͭвҒёǽƐ¥ҿ_ƫѩȳgҕեуlǿg^ƫѩͻȗż 1 mM
åÇ°Ïð͋΀ͭ͡ƫw^ҹτw VSCs Ήɟl 80 ppb ğ÷ǱƲ¥ҥ̑ȩӉw_
Ҕ 2. ʝűҔƃĝ (n ҥ̑ȩӉу˙)
Ҳեн

ïóÀ

ÛïÊµÌ

Ùì¿µ

͋͡ƫ

¬«ðÍ

ÍïÈÛ

(n=14)(n=14)(n=15)(n=14)

ǵƐÁÇíØì¾Ï¬ä

1 mg

1 mg

–

¶ìÇíìÇðԑČ±ì¬ä

2.5 mg––³³ê¬®³¿

20 mg

–

–

(Ɵά҅ˇІԖ)(80 mg)˿Ɗʝű(1 Ԝf

)
*yp·Ű¦Ťŷ¶E×:QƜX]Fìƨ zϫȿ̽ϯȀȑ̽ȑԌȑά 21 Ƶ¥ȩӉ^ϖ̃ĘŜșե¥ҏ_ɍӍ͋ 3 ˤԧ͡ƫ^Шg

3 ˤԧ¬¯È½è©¬Ì̃ԧ¥ʺ¦^0.1%ǵƐĐԚ΀ͭ 3 ˤԧ͡ƫ¥ҏ_͡ƫôˤ 3 ǜ^5 mL ͭ 1 űԧșˡw_͡ƫԦȉżˤ 3 ˤϊП̪ɳ^3ˤϊ˯՝ɳ͡ƫk 5 ˰ԧɳ^ź·Ǎͭ¥˂ƨw_Ǎͭ»ðÛíkʮŰwОѻ DNA ¥ʮŰw 16S rRNA ԄĨȍ¥ŷήwըӴ½ó·ð¿ҥ̑͝Оѻ̭ʝ͑ȗ¥ҏ_ű̑̩ŰΦ 0.3%̅;ѻϲ¥ҥ̑ȩӉǾw_ ̷^ϫȿƓςϖ̃Ȁȑȑά 20 Ƶ¥ȩӉw^ԣ̃ĘŜșե¥șˡw_ҕեу^0.3%ǵƐĐԚ΀ͭ 5 mL ôˤ 3 ǜ^4 ӷԧ͡ƫ¥ҏ_͡ƫԦȉż 4 ӷԧɳП̪ɳ^՞՝j͡ƫk 4 ˰ԧğ÷Сӽw̌Ģź·Ǎͭ¥˂ƨw_ǍͭwОѻ DNA k^16S rRNA ԄĨȍ¥ PCR ʮŰǹɒw^ըӴ½ó·ð¿ҥ̑͝

1150 õìóÍ˙ (И 2.8 œǵǮ) ԏųlɶ¢_OTU ҥ̑ɳ^ƫњŤОѻ 16S

rRNA ǵǮԏųËóÅÝó¿¥ήgύƴʇ̩Н¥ҏg^ѻƪҥ̑¥ҏ_Ŧ ĕBūÖ%Ls WB21 ƙº]XFƝńB·Ű¦ĶÊE2QìƨFęƄ
Ls WB21 н 20 Ƶ^ÛëÁàн 22 Ƶf_ɖհ^ʇŶ^șեԦȉżѧɛjОѻÕëåóÅнԧ͇ӣjg^ХҨȑφ˿ʒɋ¢k_șեԦȉż
111

 2 ӷԧɳѧɛÕëåóÅǽƐgҥ̑ws£^ýн BOP ͸ȳź·ǍͭԖǹƈl˿ʒҸ¢_Шg

BOP ǽƐg£^Ls WB21 нÛëÁàн͇ӣw

BOP l˿ʒ͸ȳwjнԧ͇ӣ¥ҏs^̇ѻΎπˑǐёƆ¥ϞҸy¡slm (Ǡ 1)_Ǎͭþѻ˙ҥ̑^ŝѻ˙l WB21 н˿ʒ͸ȳw_˿ʒɋgl^Ls WB21 н̽ƽοОѻ Prevotella intermedia, T.

forsythensis, Treponema denticola, Fusobacterium nucleatum ѻ˙l͸ȳw_s¢ȩwÛëÁàн̽ƽοОѻ͸ȳ¢z^P. intermedia jg˿ʒǹƈw_L. salivarius ѻ˙ Ls WB21 н˿ʒǹƈwlĜƫњŤОѻȩwѻ˙ȳo^ӽƂǹ͂Ҹ¢k_T-RFLP ҥ̑¡ѻƪҥ̑^Ls WB21ʨúΞɼφǹ͸y¡ѻϲҸ¢k_Ǡ 1. BOP ͸ȳΦ. * P < 0.05.

&Ls WB21 ƙºk}mpF·Ŵûª¯ĕșե̃ԧþіѾwу 1 Ƶʩѻ҅¥̀ήwу 2 Ƶ¥ű̑ȩӉǾw^23 Ƶ (βʇ 4Ƶ^Ȇʇ 19 Ƶ^ɕǨɖհ 44.3±11.6 ̾) g͇ӣű̑¥ҏ_ýн Ls WB21

ԏƲÅÚîÈÌˌƨ̃ԧÛëÁàˌƨ̃ԧ͇ӣw˿ʒ͸ȳ¥Ҹ (Ǡ 2, Ҕ 3)_

112^VSCs ̽ƽá·ÈÌɕǨŉ

Ǡ 2. VSCs ǽƐVSCs ¥ 3 ʝűű՚w Ls WB21 ˌƨ̃ԧÛëÁàˌƨ̃ԧ¥͇ӣwТ̓^
Ls WB21ˌƨ̃ԧhlϜƐ͋МΉɟåÇíåí±ÛÅðΉɟjg˿ʒ͸ȳlңȧu¢

_ϜƐ͋МåÇíåí±ÛÅðƫњΰ̍āҜƫѩʝűfΰ̍ƫѩȩwʧŸĴή¥ϣyslϣǊu¢_̽ƽá·ÈÌ¥ 4 ãìğ÷^5 ã

ìğ÷^6 ãìğ÷Ԍĭ˙¤q

Ls WB21 ˌƨ̃ԧÛëÁàˌƨ̃ԧ¥͇ӣwТ̓^Ls WB21 ˌƨ̃ԧ 6 ãìğ÷á·ÈÌ˙jg·ÈÌ˙jg

Ls WB21 lƫњ˿ʒ͸ȳ^5 ãìğ÷á͸ȳŐƷ¥ϣw_Ȗё̩̗^BOP^ѭѵĝϒԖ^ǍͭͤŰԖjgý̃ԧˑǐw^ýуԧХҨȑφԀgl¢k_ćԑѻ Ls WB21
ԏƲÅÚîÈÌˌƨ^VSC îÝí͸ȳ^Ξƫњΰ̍ƫѩwԔҜϜƐ͋МåÇíåí±ÛÅð͸ȳ^5 ãìğ÷̽ƽá·ÈÌ͸ȳ¥w^ƫѩĊԫƫѩ͗ςôƉ¡ƭёʇlϣǊu¢_'Ls WB21 ƙºk}mpF1ź

h`E×:Qìƨ

 Ls WB21 ԏƲÅÚîÈÌн^Ls TI2711 ԏƲÅÚîÈÌн^°óÔí¸ð DC ÅÚîÈÌн^gz¢³½ìÌóíÅÚîÈÌн͇ӣwãèóÅð¿îÝí¥ʧi¡ŐƷl¢ (Ǡ 3)_Ls WB21 ԏƲÅÚîÈÌн³½ìÌóíÅÚîÈÌнԧХҨȑφ˿ʒɋlҸ¢_ćԑѻîÝíg^Ls WB21 ԏƲÅÚîÈÌнj

Ls TI2711 ԏƲÅÚîÈÌн^ՙҀǍͭþćԑѻ˙lǹƈw^°óÔí¸ð DCÅÚîÈÌн^³½ìÌóíÅÚîÈÌнԧХҨȑφ˿ʒɋl¢_s¢ÅÚîÈÌˌƨάmćԑѻlĴήwg¡slϞҸu¢_ź·ǍͭԖg^Ls TI2711 ԏƲÅÚîÈÌǹƈw^³½ìÌóíÅÚîÈÌԧХҨȑφ˿ʒɋl¢_ÅÚîÈÌ¥Ѯ¡sǍͭԖlǹƈy¡Ċʐwgl^Ls

WB21 ԏƲÅÚîÈÌ°óÔí¸ð DC ÅÚîÈÌǍͭǹƈ¢k_Ǎ113ͭ pH g^gz¢нÅÚîÈÌˌƨɳǍͭ pH ǹƈl¢^нԧХҨȑφ˿ʒɋ¢k_ǍͭвҒёg^³½ìÌóíÅÚîÈÌнǍͭвҒё͸ȳl¢_s¢ȩw Ls TI2711 ÅÚîÈÌн°óÔí¸ð DC ÅÚîÈÌнǹƈŐƷl¢^³½ìÌóíÅÚîÈÌнԧХҨȑφ˿ʒɋ¥Ҹ_
 Ls WB21 ԏƲÅÚîÈÌˌƨɳãèóÅð¿îÝí͸ȳl^Ls TI2711 ԏƲÅÚîÈÌź·ǍͭԖǍͭвҒёǹƈl¢^s¢ÅÚîÈÌˌƨhҋì¿µȩwʭʩʇ¥ϣysl¤k_Ǡ 3. ãèóÅð¿îÝíǽƐ. P < 0.05.

(yv_l]ƙºgZEOQ·Űīþ5·ŴE2Qìƨ Ýó¿ë«ðҥ̑jg^șեнȩΕнԧƫѩîÝíƫњŤΠʖХҨȑφԀg¢k_Ýó¿ë«ð 4 ӷɳТ̓¥͇ӣws£^ƫѩ̩̗jg^șեнȖё̩̗¿¹©^ϜƐ͋МΉɟ^åÇíåí±ÛÅðΉɟ˿ʒˑǐl^ȩΕнȖё̩̗¿¹©˿ʒˑǐlҸ¢ (Ǡ 4)_Ξșեн 2 Ƶl^Ȗё̩̗¿¹©aƫѩwbŵȗy¡¿¹© 1 ğøˑǐw_ƫњŤү̗jg^șեнɕǨ̽ƽá·ÈÌ^BOP ƃƲ^Ûëóµĝϒʷ˙˿ʒ͸ȳl¢_ô˟^ȩΕн BOP ƃƲѷɔˑǐlf^ХҨȑφ˿ʒɋ¢k_ѭѵ¿¹©ѭҔՆŁͽɟg^ýнǽƐwk_ÖÒ³Ç°óíԏƲƫњ·©ή¾­í¡ƫњʹʿ^̽ƽРиΠʖ¥ˑǐy¡sѩˑǐȢúy¡тi¢¡_114ƫǠ 4. Ȗё̩̗¿¹© (÷) ϜƐ͋М (Ɉ) åÇíåí±ÛÅð (Ʈ) ǽƐ

)3 ŔFđ¯ø©Sƙº9=·Ű¿ÂŸF·Ŵûª¯ĕ ƫѩͻȗŉyн͸ȳw_ïóÀ¬«ðÍн^ÛïÊµÌÍïÈÛн^Ùì¿µнˌƨżɳХҨȑφ˿ʒɋl¢^gz¢͋Ŕ¢ƫѩʧŸƊ̓lf¡sl¤k (Ǡ 5)_ïóÀ¬«ðÍнÛïÊµÌÍïÈÛнjg^ӳɑƫѩlgy 100 ppb ğøˑǐw^CPC ¡ʩѻĴήlтi¢¡_Ǡ 5. VSCs îÝíǽƐ. P < 0.05.

 ѭŁͽɟïóÀ¬«ðÍнǹƈŐƷ¥ϣw_³³ê¬®³¿̹͵Ĵήlf¡115

ҧ¤¢¡_ƫњĈΙƫѩôǝf¡тi¢j^ïóÀ¬«ðÍŁͽƷ÷¡ƫѩʧŸƊ̓ʶШʇl̃ɲu¢¡_ïóÀ¬«ðÍǍͭ pH ^ÛïÊµÌÍïÈÛǍͭвҒё^}¢~¢ˌƨɳ˿ʒǹƈl¢^s¢Ǎ̵ͭё¥̺ɑƐw^ƫњŤΫǸŋŝƐőoslϣǊu¢_*yp·Ű¦Ťŷ¶E×:QƜX]Fìƨ ϖ̃ĘŜșեjg^3 ˤԧǵƐĐԚ΀ͭ¡͡ƫżɳѻǽƋ¥ҿs£^18 ѻϲlǹƈ^18 ѻϲl͸ȳw_ՙҀǹƈwѻϲ Actinomyces ȻStreptococcus Ȼƫњɑǥѻf_Porphyromonas Ȼ Fusobacterium Ȼ VSC έάѻХҨȑφ˿ʒ͸ȳw^ǵƐĐԚ͡ƫlƫѩ¹ðÌïóí˿ήf¡slϣu¢_ P. gingivalis ŮԽԨľlϕ¢¡ S. gordonii ˿ʒ͸ȳw_ĐԚ«°ð P. gingivalis ÅðÕµТƲy¡sP. gingivalis  S.

gordonii ŠŮԽ¥ԬȞy¡ghϙϸǰƼlf ^ĐԚ«°ðlѻƪǽƋԧ˄φĴήwg¡ƭёʇlϣǊu¢_ 2 ñ˾ԣ̃ĘŜ^Terrahaemophilus aromaticivorans^Porphyromonas ȻОѻ^
Fusobacterium nucleatum^Corynebacterium durum l͸ȳw^ƫѩƟǝѻwǰƼu¢g¡ѻϲlҚ˙Ƹ¢g_ô˟^Rothia Ȼ^Actinomyces Ȼǹƈy¡ѻϲlҞ¢_wkw^ŝıw

Оѻƪ̭ʝϲjq¡ȀmǽƋҞ¢z^ĐԚ«°ðɰՉ¥Ʃq¡ϲôԌԮ¢¡slŵ_ƫѩƟǝѻwg¡lҚ˙͸ȳy¡sl˩kϕ¢^ĐԚ«°ðˈτʇϜƐΝТƲy¡qo^ƫѩƟǝѻάы¥ʧi¡sƫѩ¥ʧŸy¡Ɗ̓¥uyslϣ
Ǌu¢_

ń žƈć
1. ġқȕĘ^ԙ̄ȅȃ^ЍίԼҗ^ȽίΆô^ɣ҇ƗԻ^ƫѩ԰ơ¥Ɗёy¡ƫњǅǑ҅ (ÌïóÇſ) ѧɛφұĻ^ˤ̽ŁȎҷ^2014 ƜŹþ (̗ҽf).

2. Suzuki N, Yoneda M, Tanabe K, Fujimoto A, Iha K, Seno K, Yamada K, Iwamoto T,
Masuo Y, Hirofuji T. Lactobacillus salivarius WB21-containing tablets for thetreatment of oral malodor: a double blind, randomized, placebo-controlled crossover
trial. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, 2014,
117(4):462-470 (̗ҽf).

3. Suzuki N, Yoneda M, Haruna K, Masuo Y, Nishihara T, Nakanishi K, Yamada K,
Fujimoto A, Hirofuji T. Effects of S-PRG eluate on oral biofilm and oral malodor.
Archives of Oral Biology, 2014, 59(4):407-413 (̗ҽf).

4. Nakano Y, Takeshita T, Kamio N, Shiota S, Shibata Y, Suzuki N, Yoneda M, Hirofuji116

T, Yamashita Y. Supervised machine learning-based prediction of oral malodor basedon the microbiota in saliva samples. Artificial Intelligence in Medicine, 2014,
60(2014):97-101 (̗ҽf).

5. Iha K, Suzuki N, Yoneda M, Takeshita T, Hirofuji T. Effect of mouth cleaning withhinokitiol-containing gel on oral malodor: a randomized, open-label pilot study. Oral
Surgery, Oral Medicine, Oral Pathology, Oral Radiology. 2013, 116(4):433-439.,
doi:pii:S2212-4403(13)00276-9.10.1016/j.oooo.2013.05.021 (̗ҽf).

6. Seno K, Ohno J, Ota N, Hirofuji T, Taniguch. Lupus-like oral mucosal lesions in
mercury-induced autoimmune response in brown norway rats.  BMC Immunology.
2013; 14: 47 doi: 10.1186/1471-2172-14-47.(̗ҽf).

7. ЍίԼҗ^ƬӑƕȰ^ԙ̄ȅȃ^ըƷǂț^Ť҇ ɽ^ӈ̋ϙƺ^ԗŘѳԊ^ɣ҇ƗԻ^ƫѩʈʄГϧϯοԯŜԯƈς¥Ҝwπĸ^ˤ̇̽ϯɾӟƓȑħԾҷ^27(1,2) 31-36, 2012 (̗ҽf).

8. Yoneda M, Kashio N, Uchida H, Suzuki N, Matsuura H, Naito T, Koga C, Yasukochi
H, Matsuura M, Hirofuji T. Awareness among dental hygienists with regard totreatment options for halitosis. International Journal of Clinical Preventive
Dentistry 2012, 8(3):173-179 (̗ҽf ).
9. ζԕŔȍ^ԙ̄ȅȃ^ЍίԼҗ^ɣ҇ƗԻ ćԑѻԏƲ̽Ϡſ (©Ôð×óÀ) ƫњґάˑǐƊ̓gѧɛϙϸ^ˤ̽ŁȎҷ 55(3):219-226, 2012 (̗ҽf).

10. Yoneda M, Suzuki N, Masuo Y, Fujimoto A, Iha K, Yamada K, Iwamoto T, Hirofuji
T. Effect of S-PRG eluate on biofilm formation and enzyme activity of oral bacteria.
Int J Dent, 2012, ID814913, 6 pages, doi:10.1155/2012/814913 (̗ҽf).

11. Suzuki N, Tanabe K, Takeshita T, Yoneda M, Iwamoto T, Oshiro S, Yamashita Y,
Hirofuji T. Effects of oil drops containing Lactobacillus salivarius WB21 on
periodontal health and oral microbiota producing volatile sulfur compounds. J
Breath Res, Mar;6(1):017106, 2012. Doi:10.1088/1752-7155/6/1/017106 (̗ҽf).

12. Takeshita T, Suzuki N, Nakano Y, Yasui M, Yoneda M, Shimazaki Y, Hirofuji T,
Yamashita Y. Discrimination of the oral microbiota associated with high hydrogensulfide and methyl mercaptan production. Scientific Reports 2:215, 2012. DOI:
10.1038/srep00215, 2012 (̗ҽf).

13. Masuo Y, Suzuki N, Yoneda M, Naito T, Hirofuji T. Salivary β-galactosidase
activity affects physiological oral malodor. Archives of Oral Biology, Jan 57(1):87-93,
2012 (̗ҽf).

14. Yoneda M, Suzuki N, Mocedo SM, Fujimoto A, Iha K, Koga C, Matsuura M, Hirofuji
T. The variable etiology of oral pathologic halitosis: a case series. Smile Dental
117

Journal 7 (3) 50-56, Sep 2012.
ЯҼ
15. Suzuki N, Yoneda M, Hirofuji T. Mixed red-complex bacterial infection inperiodontitis. Int J Dent. Volume 2013, Article ID 587279, 6 pages, 2013 (̗ҽf).

Ҁ˼
16. Suzuki N, Yoneda M, Hirofuji T. Relationship between oral malodor and oral
microbiota. Oral Health Care-Prosthodontics, Periodontology, Biology, Researchand Systemic Conditions (ISBN 978-953-51-0040-9), In Tech, Feb, 2012.

1. ҇̇˶͏^Ӈƫȅȃ^ĥ͞ɗĴ^ЍίԼҗ^Ƚίǂɯ^Όԕʊғ^ɣ҇ƗԻ^ÖÒ³Ç°óí Porphyromonas gingivalis ȩy¡ʩѻĴήƫѩˑǐƊ̓g^Ѐ 55ǜˤ̇̽ϯƓςЇΪȑħЯħòȑҐȀħ^̈ɓɍ^2014.7.18-20.
2. ġқȕĘ^ԙ̄ȅȃ^҇̇˶͏^ĥ͞ɗĴ^΋ď ʙ^ϫǦͨ˛^ЍίԼҗ^ɣ҇ƗԻ^ƫѩ԰ơ¥Ɗёy¡ƫњǅǑ҅ѧɛφұĻ^Ѐ 5 ǜˤ̇ƫѩȑħ^
3. ȽίΆô^ԙ̄ȅȃ^ġқȕĘ^ĥ͞ɗĴ^҇̇˶͏^΋ď ʙ^ЍίԼҗ^Ƚίǂɯ^̢ȶԴĘ^ѽȶĵԈȍ^ɣ҇ƗԻ^3 ϲ˿Ɗʝű¥ԏƲwƫњǅǑ҅ƫѩʧŸƊ̓^Ѐ 140 ǜˤ̇̽ϯŁȎȑħ˭ȐȑҐȀħ^Ȁ͢ɍ^2014.6.19-2014.6.20.
4. қƟǈü^ԙ̄ȅȃ^҇̇˶͏^ЍίԼҗ^ίԇôʝ^Ƚίǂɯ^ɀŕϕă^ȓ ʂȀ^ĥ͞ɗĴ^Όԕʊғ^ɣ҇ƗԻ^ćԑѻԏƲÅÚîÈÌlhҋì¿µǝȍúi¡ɰՉѧɛφұĻ^Ѐ 140 ǜˤ̇̽ϯŁȎȑħ˭ȐȑҐȀħ^Ȁ͢ɍ^2014.6.19-2014.6.20.
5. Όԕʊғ^Ȁԕ Й^Ƚίǂɯ^Ӈƫȅȃ^ɣ҇ƗԻ^ëÈÌ̽шΎæËíŚνʁ
ЄP|ѧɛφʖɟԀglŰ¡kօ Ѐ 140 ǜˤ̇̽ϯŁȎȑħ˭ȐȑҐȀħ^Ȁ͢ɍ^2014.6.19-2014.6.20.
6. ԙ̄ȅȃ^ЍίԼҗ^ίԇôʝ^ɣ҇ƗԻ^ćԑ̣ѻ Lactobacillus salivarius ԏƲÅÚîÈÌlhҋì¿µǝȍúi¡ɰՉ^Ѐ 63 ǜˤ̇ƫњґάȑħЯħ^Ζ̇ɍ^
2014.5.29~5.31.
7. ÷̋ƶЦ^ЍίԼҗ^ѹǱҗм^ɀ̋җм^̉̇ΰЗȍ^Ȁȟϕȍ^ԙ̄ȅȃ^ɣ҇ƗԻ^ϫȿ̽ϯȀȑƫњƓςÁðÅóƫѩµìÏÈµʌуű̑^Ѐ 57 ǜˤ̇̽ƽοȑħ˭ȐȑҐȀħ^ɕʝ 26 ɖ 5 ˾ 22-24 ˤ^Ⱦԩɍ
8. Όԕʊғ^ȀԕЙ^Ƚίǂɯ^Ӈƫȅȃ^ɣ҇ƗԻ^ëÈÌŝӟʇŚνʁЄæËíjq¡̽шΎοʖ^Ѐ 139 ǜˤ̇̽ϯŁȎȑħϮ̃ȑҐȀħ^ϫȿɍ^2013.10.17-18,
2013.
118

9. Όԕʊғ^ȀԕЙ^Ƚίǂɯ^Ӈƫȅȃ^ӇƫԉĂ^ɣ҇ƗԻ^°óÌÙ¨¾ó cancer
sphere ɮʝёԨӶ^Ѐ 40 ǜϫȿ̽ϯȀȑȑħ^ϫȿɍ^2013.12.15, 2013.
10. ɀŕϕă^ԙ̄ȅȃ^ЍίԼҗ^Ƚίǂɯ^̢ȶԴĘ^҇̇˶͏^ĥ͞ɗĴ^Όԕʊғ^ɣ҇ƗԻ^ÛïÔ«°Êªµ¿¥ήgƫњξʌĊԫЇΪƨ Р^̽ϯĖԧɇȑħ^ƵƬȹɍ^2013.11.22-23, 2013.
11. Όԕʊғ^Ȁԕ Й^Ƚίǂɯ^Ӈƫȅȃ^ɣ҇ƗԻ^ЯƲ̽ϯүςϯjq¡Оѐүșӝ^ЯƲ̽ϯƘӅħ^̎Ĕ^2013.11.16-17, 2013.
12. ĥ͞ɗĴ^ԙ̄ȅȃ^ЍίԼҗ, Ƚίǂɯ, ɀŕϕă, ̢ȶԴĘ, ҇̇˶͏, Όԕʊғ,˭ƵôĖ, ȓ ʂȀ, Ŝ͏Āĵȍ, қƟǈü, ġқȕĘ, ɣ҇ƗԻ^ÖÒ³Ç°óíԏƲ¾­í¥ήgƫњ·©ƫѩˑǐƊ̓^ЯƲ̽ϯƘӅħ^̎Ĕ^2013.11.16-17, 2013.
13. ҇̇˶͏^ЍίԼҗ^ԙ̄ȅȃ^Ť҇ ɽ^ȽίΆô^ɣ҇ƗԻ^ƫѩʈʄГϧϯοԯŜԯƈς¥ҜwπĸճĠմ^ˤ̇̽ϯŁȎȑħ^Ϯίɍ^2013.
14. ˭ƵôĖ^ԙ̄ȅȃ^ЍίԼҗ^ȽίΆô^̢ȶԴĘ^қƟǈü^ġқȕĘ^Ƚίǂɯ^ɀŕϕă^҇̇˶͏^ĥ͞ɗĴ^Όԕʊғ^ȓ ʂȀ^Ŝ͏Āĵȍ^ɣ҇ƗԻ^S-PRG΀ŰͭlƫњÔ«°ÙªíäƫѩƣyԬȞĴή^ˤ̇̽ϯŁȎȑħ^Ϯίɍ^10.17-10.18, 201315. Suzuki N, Yoneda M, Tanabe K, Fujimoto A, Iha K, Seno K, Iwamoto T, Yamada K,
Masuo Y, Haruna K, and Hirofuji T, Improvement of oral malodor using

Lactobacillus salivarius WB21-containing tablets, WCPD, Budapest, 10.9-12, 2013.
16. ҇̇˶͏^ԙ̄ȅȃ^ЍίԼҗ^ĥ͞ɗĴ^Ƚίǂɯ^ɀŕϕă^̢ȶԴĘ^Όԕʊғ^ɣ҇ƗԻ^ƫѩԨӶОѻȩy¡ÖÒ³Ç°óíʩѻĴήÖÒ³Ç°óíԏƲ¾­í¡ƫњ·©ƫѩˑǐƊ̓^Ѐ 4 ǜˤ̇ƫѩȑħ (̲ͦɍ)^7.13, 14, 2013.
17. ĥ͞ɗĴ^ԙ̄ȅȃ^ЍίԼҗ^Ƚίǂɯ^ɀŕϕă^̢ȶԴĘ^҇̇˶͏^Όԕʊғ^˭ƵôĖ^ȓ ʂȀ^Ŝ͏Āĵȍ^қƟǈü^ġқȕĘ^ɣ҇ƗԻ^ÖÒ³Ç°ó
íԏƲ¾­í¥ήgƫњ·©lƫѩƣƫњŤΫǸúi¡ɰՉ^Ѐ 138 ǜˤ̇̽ϯŁȎȑħ˭ȐȑҐȀħ (ϫȿɍ)^6.27, 28, 2013.
18. ̏ͧ͠ʀ^ЍίԼҗ^ԙ̄ȅȃ^ȿίѲмȍ^҇̇˶͏^ɣ҇ƗԻ^ԣ̃ԧʍu¢gƫњλɑʔlƫњĈΙȩy¡ůкͬȄwπĸ^Ѐ 138 ǜˤ̇̽ϯŁȎȑħ˭ȐȑҐȀħ (ϫȿɍ)^6.27, 28, 2013.
19. þԕǐȂ^ԙ̄ȅȃ^ЍίԼҗ^ɣ҇ƗԻ^̲Όƍм^̡ί˛ɗ^ÖÌƫњŤОѻƪ̭ʝȩy¡ĐԚ«°ðɰՉ^Ѐ 85 ǜˤ̇άƐȑħȀħ (ϫȿɍ) 12.14-16, 2012.
20. ̉̇ΰЗȍ^ЍίԼҗ^ԙ̄ȅȃ^ɣ҇ƗԻ^ùԂƲńɸΝ԰ơj̽ƽǾϯƫѩlȔŝͬȄwπĸ^Ѐ 55 ǜˤ̇̽ƽοȑħȑҐȀħ (oɍ) 9.23,

2012.
21. ̏ͧ͠ʀ^ЍίԼҗ^ԙ̄ȅȃ^Ť҇ ɽ^ɣ҇ƗԻ^ƫѩ͗ςg119

ʒӄP̽ϯ

ґάǻ¥ȩӉwҿ̗Т̓P^Ѐ 137 ǜˤ̇̽ϯŁȎȑħϮȐȑҐȀħ (ɚɁɍ)
11.22-23, 2012.
22. ̢ȶԴĘ^ԙ̄ȅȃ^ЍίԼҗ^ȓ ʂȀ^ġқȕĘ^҇̇˶͏^ĥ͞ɗĴ^Όԕʊғ^Ƚίǂɯ^ɀŕϕă^ɣ҇ƗԻ^S-PRG ΀Űͭ S-PRG ԏƲ̽ՆϙϠſƫњÔ«°ÙªíäɰՉ^Ѐ 137 ǜˤ̇̽ϯŁȎȑħϮȐȑҐȀħ (ɚɁɍ) 11.22-23, 2012.
23. ĥ͞ɗĴ^ԙ̄ȅȃ^҇̇˶͏^ЍίԼҗ^Ƚίǂɯ^ɀŕϕă^̢ȶԴĘ^қƟǈü^ԗȍŕ͊^˭ƵôĖ^ɣ҇ƗԻ^ÖÒ³Ç°óíԏƲƫњ·©ή¾­í¡ƫњʹʿƫѩˑǐƊ̓^Ѐ 137 ǜˤ̇̽ϯŁȎȑħϮȐȑҐȀħ (ɚɁɍ) 11.22-23, 2012.
24. ̢ȶԴĘ^ԙ̄ȅȃ^ЍίԼҗ^ȓ ʂȀ^ġқȕĘ^҇̇˶͏^ĥ͞ɗĴ^Όԕʊғ^Ƚίǂɯ^ɀŕϕă^ɣ҇ƗԻ^S-PRG «°ð΀Űͭ S-PRG ԏƲ̽ՆϙϠſƫњÔ«°ÙªíäɰՉ^Ѐ 39 ǜϫȿ̽ϯȀȑȑħЯħ (ϫȿɍ) 11.18, 2012.
25. ĥ͞ɗĴ^ԙ̄ȅȃ^҇̇˶͏^ЍίԼҗ^Ƚίǂɯ^ɀŕϕă^̢ȶԴĘ^қƟǈü^ԗȍŕ͊^˭ƵôĖ^ɣ҇ƗԻ^ÖÒ³Ç°óíԏƲƫњ·©ή¾­í¡ƫѩˑǐƊ̓ѧɛϙϸ^Ѐ 39 ǜϫȿ̽ϯȀȑȑħЯħ (ϫȿɍ) 11.18, 2012.
26. ƈǵȅ͢ɏ^ЍίԼҗ^ŤίŴм^ԙ̄ȅȃ^Ť҇ ɽ^дίǂ̸ȍ^կίмǂȍ^Ɔ̻Кΰм^ɣ҇ƗԻ^ƫѩ͗ςԨy¡̽ϯґάǻʒӄҿ̗^Ѐ 39 ǜϫȿ̽ϯȀȑȑħЯħ (ϫȿɍ) 11.18, 2012.
27. ЍίԼҗ^ƬӑƕȰ^ԙ̄ȅȃ^Ť҇ ɽ^ɣ҇ƗԻ^ϫȿ̽ϯȀȑƫњƓςÁðÅóƫѩϯʌуҥ̑jƫѩʈʄπ 1 πĸ^Ѐ 27 ǜˤ̇̽ϯɾӟƓȑħЯħòȑҐȀħ^ɕʝ 24 ɖ 9 ˾ 1 ˤ^2 ˤ^Ʉәɍ
28. ҇̇˶͏^ԙ̄ȅȃ^ЍίԼҗ^ĥ͞ɗĴ^ίԇôʝ^Ƚίǂɯ^ɀŕϕă^̢ȶԴĘ^ɣ҇ƗԻ^ϐʇƫѩπjq¡ Lactobacillus salivarius WB21 ̛ԏƲԜѼ˿ήʇ̩ҩ^Ѐ 3 ǜˤ̇ƫѩȑħ^ɕʝ 24 ɖ 7 ˾ 7, 8 ˤ^̎Ĕ29. ԙ̄ȅȃ^þԕǐȂ^ЍίԼҗ^̲Όƍм^̡ί˛ɗ^ɣ҇ƗԻ^ǵƐĐԚ΀ͭ͡ƫ¡ƫњŤОѻƪǽƋ^Ѐ 3 ǜˤ̇ƫѩȑħ^ɕʝ 24 ɖ 7 ˾ 7, 8 ˤ^̎ĔԎ
30. ԙ̄ȅȃ^þԕǐȂ^ζԕŔȍ^ЍίԼҗ^̲Όƍм^̡ί˛ɗ^ɣ҇ƗԻ^ǵƐĐԚ˹Ղ¡ƫњОѻ̭ʝǽƐ^Ѐ 136 ǜˤ̇̽ϯŁȎȑħ˭ȐȀħ^ɕʝ 24 ɖ 6
˾ 28, 29 ˤ^Șԕͼɍ
31. ҇̇˶͏^ԙ̄ȅȃ^ЍίԼҗ^ίԇôʝ^Ƚίǂɯ^ɀŕϕă^̢ȶԴĘ^ĥ͞ɗĴ^ɣ҇ƗԻ^Lactobacillus salivarius WB21 ̛ԏƲԜѼƫѩʧŸƊ̓gѧɛϙϸeëðÆäƐČԔϋ̩ÛëÁàȩΕµï¿°óÔóҲեe^Ѐ 136 ǜˤ̇̽ϯŁȎȑħ˭ȐȀħ^ɕʝ 24 ɖ 6 ˾ 28, 29 ˤ^Șԕͼɍ
32. ƈǵȅ͢ɏ^ЍίԼҗ^ŤίŴм^ԙ̄ȅȃ^Ť҇ ɽ^̋÷˦Ѷ^ȓ͖Ť^ɣ҇ƗԻ^ƫѩ͗ςԨy¡̽ϯґάǻʒӄҿ̗^Ѐ 55 ǜˤ̇̽ƽοȑħ˭ȐȀħ^ɕʝ 24 ɖ 5 ˾ 17-19 ˤ^̈ɓɍ120

ϙ ϸ Ҿ ՖƈհĩhƫњΫǸǽƐjƫњΫǸˑǐϙϸĞҔуЍί ԼҗճЯƲ̽ϯȑӂɠòЯƲ̽ϯȑűԕò˕ˀմƁš εՆ̵ёʇ²ë¿ surface pre-reacted glass-ionomer (S-PRG) Ʊϲ«°ð¥ɴ˓y¡slϕ¢j̮`άΝͣʇlҸ¢g¡_¤¢¤¢ƫњОѻȩy¡ɰՉ¥ҿøҪТ̓¥ɶ_S-PRG ΀Űͭ Porphyromonas gingivalis ÛïÊ©óÂͣʇ^ÂëÇðűҥͣʇ¥ʧŸw^Fusobacterium nucleatum ŠŮԽ¥ԬȞw_¶ëäԴʇѻ¡Ô«°Ùªíäɮʝ¥ʧŸwl^β-²ëµÌ½ÆóÂȩy¡ĴήҸ¢k_ǍͭþОѻ¡Ô«°Ùªíäɮʝ¥ԬȞw^uɮʝu¢ǍͭÔ«°Ùªíä¥ϛǺy¡ёƆҸ¢_ğ÷Т̓k S-PRG hҋ̽ƽΎĊԫƊ̓lf¡тi¢¡_}wƈհĩhƫњΫǸǽƐȩʁwƫњΫǸˑǐӌΤy¡̃ɲu¢¡_ ōŕňŅƈհĩgƫњŤΫǸɴ`ǽƐy¡l^}ΫǸʎƐ¥ĿӸy¡ǝȍw ƫњŤОѻɰՉlтi¢¡_̽ϯČȀξʌf¡hҋ̽ƽο^ŠƫњŤɺάΝ ӗs¡ʔ̕πf¡_ËðÅíÛëóµy¤ƫњÔ«°Ùªíä^ҚԾОѻԧύčĴή Ĵ¢^uvѻΰ̍οƟǝȍ¥˿y¡_εՆ̵ёʇ²ë¿
surface pre-reacted glass-ionomer (S-PRG) ËðÅíÛëóµɬg̽ϯ̊˜w ͟ϊu¢ j ^s¢ S-PRG ԏƲî¾ðʩÛëóµĴή^S-PRG Ƹ˿̝ЇŖǶſʩѻĴήlǰƼu¢ g¡_}˿Ɗǝȍw ^S-PRG «°ðɴ˓ʇl
ϣǊu¢ g¡_S-PRG ÙÈМ^ß¬М^¿ÌïðÇ¬äЂ̮`«°ð¥˓Űy¡slϕ¢ j ^ОѻάΝͣʇɰՉ¥jw g¡тi¢¡_̇ϙϸОѻοƟʇ¥ S-PRG ʧŸy¡s¥̩ҩw_āϊφğøӳ f¡_
1. P. gingivalis ÛïÊ©óÂͣʇȩy¡Ĵή̽ƽοƟʇОѻ P. gingivalis lέάy¡ÛïÊ©óÂ^̇ѻ˽ԔҜοƟǝȍf¡_̇ѻÛïÊ©óÂͣʇȩy¡ S-PRG ΀ŰͭɰՉ¥ҿ_
2. P. gingivalis ÂëÇðűҥͣʇȩy¡ĴήÂëÇðűҥё̽ƽРиϛǺԔҜf¡l^̽ӕȩw ńɸΝіԿ¥ĿӸy¡ǝȍw Ĵήy¡_̇ϙϸ P. gingivalis ÂëÇðűҥͣʇƣy S-PRG΀ŰͭɰՉ¥ҿ_
3. P. gingivalis  Fusobacterium nucleatum ŠŮԽȩy¡ĴήŠŮԽОѻРиȗϒ¥ĿӸy¡ǝȍw ԔҜf¡_āҜ̽ƽοƟʇОѻƴǻŮԽƣy S-PRG ΀ŰͭɰՉ¥ҿ_121

4. β-²ëµÌ½ÆóÂȩy¡Ĵή
β-²ëµÌ½ÆóÂ^¶ëäԴʇΩѻ¶ì¹½ÆóÂ^ѻȗϒОѐļŜԨúw^ьΎΩѻ Streptococcus pneumoniae jg οƟʇwԔҜf¡_ƫњŤОѻ^S. salivarius, S. mitis, S. gordonii ̽ՆŴ̃ĝϒОѻhҋƟǝѻf¡ S. mutans ̇ԐМͣʇlf¡slϕ¢ g¡_̇ϙϸ^Escherichia coli ΰ̍β-²ëµÌ½ÆóÂ¥ŷήw ^S-PRG ΀ŰͭɰՉ¥ҿ_
5. ƫњÔ«°Ùªíäɮʝȩy¡ĴήƫњÔ«°ÙªíäɮʝŴ̃̓ԷԨľy¡Оѻg ^Þìµíĝϒȩy¡ S-PRG ΀ŰͭɰՉ¥ҿ_^ǍͭþОѻ¡Ô«°ÙªíäɮʝʧŸyɮʝu¢Ô«°ÙªíäϛǺёƆg̩ҩ¥ƈi_ĊĥպշS-PRG ΀ŰͭĴʝ (̛ɥħϥ ̏՛)_  S-PRG Ùªëó¥ҁη͋þ 24 ˰ԧˏʰɳ^ԁɾ^Ίӽ͋΀ʇʝű¥ǜƧ_ ̇

lot ΠʖøҪӳ f¡_pH7.3^Al: 1.5ppm, B: 890.5ppm, Na: 368.2ppm, Si:
6.0ppm, Sr: 78.4ppm, F: 105.0ppm
ջշP. gingivalis ÛïÊ©óÂȩy¡Ĵή

P. gingivalis ATCC 33277 ̛¥ӘՈ͞ϛϚw^ԁɾɳ÷ʹ¥ÛïÊ©óÂ»ðÛí
ճP.g SEմw_ԐМͣʇ^Bz-Arg-pNA ǵԑǵճBAPNAմ¥ǮӕήgτѱƦʁ ұĻw_ƦʁͭРʝ^1 mM BAPNA, 0.2 M Tris-HCl, 0.1 M NaCl, 5mM CaCl2, 10 mM L-cysteine, 1/10 P.g SE, distilled waterճdwմor S-PRG ΀Űͭf¡_S-PRG ¥ͳƈwǱƲwgǱƲ^5 űt 30 űԧ^ƹŘɟǽƐ¥ҿ_
ռշP. gingivalis ÂëÇðűҥͣʇȩy¡Ĵή
P.g SE  dw  S-PRG ΀Űͭ¥ƈi̓ԷɏԒw_ÂëÇð¹óÊªð¶w®
Èµ¿аÙªíäճKodak Ultraspeedմ 20μl z¿áÈÌw^ͽɟ 100%Πʖ37T^ջ˰ԧ«ð³èÝóÌw_Ùªíä¥ͤ͋ø͋͡ɳ^¿áÈÌwҔՆlƀԿwǱƲ¥ÂëÇðűҥͣʇf ŵȗw_
սշP. gingivalis  F. nucleatum ŠŮԽȩy¡Ĵή
P. gingivalis ATCC 33277 ̛ F. nucleatum ATC25586 ̛¥ͭıǭաwŠŮԽÔÈÙ¨óͥ͡w_dw  S-PRG ΀ŰͭɏԒwŠŮԽÔÈÙ¨óʜΈwýу¥ͲƲw_ŮԽТ̓ŵȗ S.A.Kinder ˟͝Ϳx шϑҏ_
վշβ-²ëµÌ½ÆóÂȩy¡Ĵή
E. coli ΰ̍β-²ëµÌ½ÆóÂ¥ŷήw^o-nitrophenyl-β-D-galactopyranoside ¥ǮӕήgτѱƦʁƹŘɟ¥ͻȗw_Ʀʁͭ 10%f¡g 50%¥ S-PRG ΀Űͭкˇw^ƦʁόɳƦʁ 1 ˰ԧɳƹŘɟͻȗ¥ҏ_ȩΕнw ^S-PRG ΀Űͭ¥ dw кˇwƦʁͭ̰Ϳ˺аĴҙή˽ԂвҒͭ¥ķήwƦʁͭ¥ήg_տշƫњÔ«°Ùªíäɮʝȩy¡Ĵή
122

S. mutans JCM 5705 ̛^Enterococcus faecium WB 2000 ̛g ^96 Ϸâ«µïÛîóÌ¥ŷήwÛëóµɮʝșե¥ҏ_ǍͭҔՆůΪw¬­í^ƹŘɟ
OD660 = 1 ҿҙwОѻ¥ 20 µl ̓ԷɏԒw S-PRG ΀Űͭ¥ƸǭǦ¥ 160 µl¥ͳƈw^37ºC  16 ˰ԧȌ͊ǭաw_ͩӻОѻ¥԰ơw^ͥ͡òĈΙɳ^0.25%
safranin ̕ѱwƹŘɟ¥ͻȗw_ǍͭþОѻ¡Ô«°Ùªíäg̩ҩ¥ƈi_ŋɑĖվĖȓՄ˰Ǎͭ¥ͲƲw¥Ǎͭ»ðÛíw ķήw^÷Ҫƴ̮Ô«°Ùªíä¥ңȧw_ɮʝu¢Ô«°ÙªíäϛǺșեøҪӳ ҏ_ǍͭÔ«°Ùªíälɮʝu¢â«µïÛîóÌ S-PRG ΀Űͭ¥
ƈi 37ºC  24 ˰ԧȌ͊ǭա^÷ʹ¥԰ơwƹŘɟ¥ͻȗw_Ŧ ĕBūÖ
1. P. gingivalis ÛïÊ©óÂȩy¡ĴήǠպ^0.05 g  P. gingivalis ATCC 33277 ̛ҿҙwÛïÊ©óÂƦʁ¥ϣy_
S-PRG ΀Űͭ¥ͳƈwǱƲ^ͳƈwgǱƲ͇ Ʀʁ˺аlȀmoǽƐw^ͣʇlʧŸu¢ g¡ŐƷl¢ճǠպմ_ô˟^0.08~0.1 g ѻı ҿҙwÛïÊ©óÂƦʁ^ըΉɟÛïÊ©óÂ 5 űɳȔŝƦʁwʅ¤¢^S-PRG ΀Űͭ¥ͳƈwǱƲͳƈwgǱƲԀgl¢kճËóÅՅҔϣմ_^P. gingivalis ջ̛ճATCC33277 ̛^381 ̛փǠջմg ƴ̮Т̓lɶ¢_ÛïÊ©óÂͣʇʧŸå±ÏÀäėɳ̩ҩy¡ɿҜlf¡l^
S-PRG k΀Űw«°ðlԐМͣʇþɾĴήw g¡ƭёʇlf¡_Ǡպ. 0.05 g  P. gingivalis ATCC 33277 ̛123ҿҙwÛïÊ©óÂƦʁ

A.

B.

Ǡ 2. P. gingivalis ջ̛ÛïÊ©óÂȩy¡ɰՉճA: ATCC33277 ̛^B: 381 ̛մ

ռշP. gingivalis ÂëÇðűҥͣʇȩy¡ĴήƦʁͭ S-PRG ΀Űͭ¥ 40%ğ÷ƈi¡^P.g SE ÂëÇðűҥͣʇlʧŸu¢ճǠռմ_ÂëÇðűҥͣʇ̽ƽРиɰՉ¥jyl^̽ńɸΝіԿԨľy¡тi¢g¡_S-PRG l̽ƽΎӸҏĊԫńɸΝȪǀɤԣɱϻƭёʇlf¡_ǠռճɈփÂëÇðÙªíä̮ȍ ƮփÂëÇðűҥͣʇʧŸТ̓մ

սշP. gingivalis  F. nucleatum ŠŮԽȩy¡ĴήŠŮԽÔÈÙ¨óɏԒ˰ dw ¥ S-PRG ΀Űͭкˇy¡ P. gingivalis  F.

nucleatum ŠŮԽlʧŸu¢ճǠսյվմ_ŠŮԽÔ«°ÙªíäʝԣʝΗԨľy¡тi¢ g¡_S-PRG ̇ͣʇ¥ʧŸy¡s ÛëóµĝϒԬȞ̽ƽΎτπʧŸӌΤw g¡ƭёʇlf¡_124        ǠսշŠŮԽ̮ȍ  ǠվշS-PRG ΀Űͭ¡ŠŮԽʧŸ

վշβ-²ëµÌ½ÆóÂȩy¡ĴήǠտ^Ʀʁͭ 50%¥ S-PRG ΀ŰͭкˇwƦʁͭ¥̓ԷɏԒw»ðÛí^Ʀʁόɳ (Ɉ)  1 ˰ԧɳ (Ʈ) Т̓¥ϣy_S-PRG ΀Űͭ dw ¥ķήwǱƲ^˽ԂвҒͭ¥ŷήwǱƲ͇ӣw ѷɔƦʁlɪ¡l^ýуԧԀg¢k_10% S-PRG ΀Űͭ¥ƸƦʁͭg ƴ̮Т̓f_S-PRG ΀Űͭ^ϖ˰ԧβ-²ëµÌ½ÆóÂͣʇ¥ɈƮy¡Ĵήgʅ¤¢_

125

Ǡտ.

50% S-PRG
S PRG Ʀ ʁ ό ɳ(Ɉ)  50% S-PRG Ʀʁ 1 ˰ԧɳ (Ʈ)տշƫњÔ«°Ùªíäɮʝȩy¡Ĵή

S. mutans JCM 5705 ̛ (Ǡ 7A)  E. faecium WB2000 ̛ (Ǡ 7B) ^S-PRG ΀Űͭͳƈ Ô«°ÙªíäɮʝlʧŸu¢_^Оѻϲ՚ ʧŸϱɟlλl^s¢ԗȻ«°ðȩy¡ѻʔƩʇТƲʇΞλʇԀg Ψ¢ƭёʇlf¡_S-PRG ΀Űͭ¡Ô«°Ùªíäȩy¡ʧŸǍͭÔ«°Ùªíäjg Ҹ¢_S-PRG ΀ŰͭΉɟĺȎφǍͭÔ«°Ùªíäɮʝ¥ʧŸw (Ǡ 8A)_^S-PRG ΀Űͭɮʝu¢Ô«°Ùªíä¥ϛǺy¡ёƆ¥˿y¡s˩k (Ǡ 8B)_S-PRG ƫњŤÛëóµɑ˄y¡Ǳʢķήu¢j ^Ô«°ÙªíäʧŸĴήlf¡s S-PRG Ƹ˿̊˜lhҋĊԫ̽ƽξʌĊԫό˄ɱϻ g¡тi¢¡_
A

B

A.

                 B.
B.
A

B

Ǡր. S-PRG ΀ŰͭÔ«°ÙªíäɮʝĴή_S. mutans JCM 5705 (A)^ E. faecium WB2000 (B)_

126

A

B

Ǡ 8. S-PRG ΀ŰͭǍͭÔ«°ÙªíäĴή_ǍͭÔ«°ÙªíäɮʝԬȞ(A)^ǍͭÔ«°ÙªíäϛǺ (B)Ŧ ƈ
S-PRG ΀Űͭ P. gingivalis ÛïÊ©óÂͣʇճBAPNA űҥͣʇմ¥ʧŸw_

P. gingivalis ÛïÊ©óÂ̮`άΝͣʇ¥˿w^̽ƽΎτπ^ǹʎɬoԨ¤g¡_S-PRG ΀Űͭ¡ʧŸå±ÏÀäù˩f¡l^ÛïÊ©óÂԗȻ«°ðТƲ¥ S-PRG ΀ŰͭþƱϲ«°ðlϾƲԬȞw g¡ƭёʇlтi¢¡_^S-PRG ΀Űͭ P. gingivalis ÂëÇðűҥͣʇʧŸw_ÂëÇðűҥͣʇńɸΝіԿԨľy¡тi¢ j ^S-PRG Ƹ˿̊˜ńɸ͗ςԣ̃Ċɳ¥Ѱȇy¡sl̃ɲm¡_^S-PRG ΀Űͭ P. gingivalis  F. nucleatum ŠŮԽʧŸw_ŠŮԽʧŸg  S-PRG ΀ŰͭþƱϲ«°ðlԨúw g¡ƭёʇlf¡_ėɳ^ԐМͣʇŠŮԽʧŸå±ÏÀä¥ҥ˩y¡ɿҜlf¡_β-²ëµÌ½ÆóÂѻȗϒОѐļŜԨúy¡qoƫѩέάԨľy¡sϕ¢ g¡lėǜϙϸ S-PRG ΀Űͭ¡ɰՉҸ¢k_wkw^¶ëäԴʇѻÔ«°Ùªíäɮʝȩw  S-PRG ΀ŰͭlʧŸφőosl˩k_u^ǍͭÔ«°ÙªíäɮʝԬȞϛǺ¥y¡ёƆlf¡sl˩k_S-PRG ¶ëäԴʇѻ^¶ëäԲʇѻάΝͣʇ¥ʧŸy¡sk^hҋ̽ƽΎĊԫɱϻтi¢¡_ô˟^ɬƆ̈́ѻё¥˿wgl}ű^άıȩy¡ɰՉȳgтi¢¡_S-PRG ńɸΝ̽ՆϙϠſķήu¢¡slǿo^ԣ̃φĴήy¡s ƈհĩhƫњΫǸʎƐ¥ԫpƊ̓l̃ɲu¢¡_ėɳƫѩʧŸЂ^QOL Ʒ÷Ԩy¡ɰՉ¥̩ҩy¡Ċȗf¡_ńžƈć ƱƵƳƴƵơƲ
1. Masuo Y, Suzuki N, Yoneda M, Naito T, Hirofuji T. Salivary β-galactosidase activity affects
physiological malodour. Arch Oral Biol 2012, 57(1): 87-93. ̗ҽ˿
2. Discrimination of the oral microbiota associated with high hydrogen sulfide and methyl
127

mercaptan production. T. Takeshita, N. Suzuki, Y. Nakano, M. Yasui, M. Yoneda, Y.
Shimazaki, T. Hirofuji, Y. Yamashita, SCIENTIFIC REPORTS | 2 : 215 | DOI:
10.1038/srep00215, 2012 ̗ҽ˿
3. Book title: Oral Health Care-Prosthodontics, Periodontology, Biology, Research and
Systemic Conditions (ISBN 978-953-51-0040-9) Chapter 9: Relationship between
oral malodor and oral microbiota Authors: N. Suzuki, M. Yoneda and T. Hirofuji.
Edt by Mandeep Singh Virdi. In Tech (Croatia), pp 121-130, 2012
4. N. Suzuki, K. Tanabe, T. Takeshita, M. Yoneda, T. Iwamoto, S. Oshiro, Y.
Yamashita, T. Hirofuji. Effects of oil drops containing Lactobacillus salivarius
WB21 on periodontal health and oral microbiota producing volatile sulfur
compounds. J Breath Res. 6 (2012) 017106 (7pp) doi:10.1088/1752-7155/6/1/017106
̗ҽ˿
5. Effect of S-PRG eluate on biofilm formation and enzyme activity of oral bacteria. M. Yoneda,
N. Suzuki, Y. Masuo, A. Fujimoto, K. Iha, K. Yamada, T. Iwamoto, T. Hirofuji. Int J Dent,
volume 2012, article ID 814913, 6pages, doi:10.1155/2012/814913. ̗ҽ˿
6. The variable etiology of oral pathologic halitosis: a case series. M. Yoneda, N. Suzuki, Sonia M.
Macedo, Akie Fujimoto, Kosaku Iha, Chihiro Koga, Masaro Matsuura, Takao Hirofuji. Smile
Dental Journal 7 (3): 50-56, 2012
7. Awareness among dental hygienists with regard to treatment options for halitosis. M. Yoneda,
N. Kashio, H. Uchida, N. Suzuki, H. Matsuura, T. Naito, C. Koga, H. Yasukochi, M. Matsuura,
T. Hirofuji. Int. J. Clin. Prev. Dent. 8 (3) 173-179, 20128.

Effect of mouth cleaning with hinokitiol-containing gel on oral malodor: a randomized,
open-label pilot study. Iha K, Suzuki N, Yoneda M, Takeshita T, Hirofuji T. Oral Surg, Oral
Med Oral Pathol Oral Radiol.

2013;116(4):433-439. doi: 10.1016/j.oooo. 2013.05.021. Epub

2013 Aug 19. ̗ҽ˿
9.

Lactobacillus salivarius WB21-containing tablets for the treatment of oral malodor: a double
blind, randomized, placebo-controlled crossover trial. Suzuki N, Yoneda M, Tanabe K,
Fujimoto A, Iha K, Seno K, Yamada K, Iwamoto T, Masuo Y, Hirofuji T. Oral Surg, Oral Med
Oral Pathol Oral Radiol. 117: 462-469, 2014. doi;10.1016/j.oooo. 2013.12.400. ̗ҽ˿

10. N. Suzuki, M. Yoneda, T. Hirofuji Mixed red-complex bacterial infection in periodontitis. Int. J.
Dent. Volume 2013 (2013), Article ID 587279, 6 pages http://dx.doi.org/10.1155/2013/587279
̗ҽ˿
11. Supervised machine learning-based prediction of oral malodor based on the microbiota in saliva
samples. Nakano Y, Takeshita T, Kamio N, Shiota S, Shibata Y, Suzuki N, Yoneda M, Hirofuji
T, Yamashita Y.

Art Int Med. 60: 97-101, 2014. ̗ҽ˿128

12. Effects of S-PRG eluate on oral biofilm and oral malodor. Suzuki N, Yoneda M, Haruna K,
Masuo Y, Nishihara T, Nakanishi K, Yamada K, Fujimoto A, Hirofuji T. Arch Oral Biol. 2014
Apr;59(4):407-13. doi: 10.1016/j.archoralbio.2014.01.009. Epub 2014 Feb 1. ̗ҽ˿Ñ ńž
պշ'%& ΀Űͭ '%& ԏƲ̽ՆϙϠſƫњÔ«°ÙªíäɮʝɰՉ ̢ȶԴĘ^ԙ̄ȅȃ^ЍίԼҗĜ ˤ̇̽ϯŁȎȑħɖɖɟϮȐȑҐȀħճЀ ǜմ^ɚɁ^˾

ջշ'%& ΀ŰͭlƫњÔ«°ÙªíäƫѩƣyԬȞĴή ˭ƵôĖ^ԙ̄ȅȃ^ЍίԼҗĜ ˤ̇̽ϯŁȎȑħɖɟϮȐȑҐȀħճЀ

˾



129

 ǜմ^Ϯί^ɖϙ ϸ Ҿ ՖԑƐÐµî°ÇÍԄĨʏǰτΨλɑϙϸĞҔуďƫ ŞԊ ճсƐŸɷϙϸÁðÅóòȚǇ˕ˀմҜИ̇ϙϸ^ԑƐÐµî°ÇÍf¡ 8-°³Ã¶©Ïðճ8-oxoGմӗǝy¡a©ðÔóϹΓǽλҽӽtwblըՓɟӗs¡ȀѝѻãèóÅðÌ¥ǿ˙űԿwҥ̑w_}Т̓^űԿwãèóÅðÌ^Ðµî°ÇÍάƲʝľ¤¡ԄĨȍ^RNA  DNA
áìåëóÂԄĨȍ^ѢÅðÕµӕԄĨȍ^ÅðÕµӕάƲʝőoǝȍԄĨȍãèóÅðÌf¡sl¤k_s¢ԄĨȍ^ĸi 8-oxoG ¥ƨgh^f¡gĴήwghőgӨg¡l^ãèóÅðÌ}hwŸɷ¥ҬȠy¡hf¡˅ͻw_ЫлφôӶãèóÅðÌ¥ҥ̑y¡s^ԑМ¿Ìî¿ȩʩwőoԄĨȍτΨҿЈ̵̭¥˩kwhwg¡_̇ϙϸjq¡ãèóÅðÌ DNA ǵǮԏųҥ̑^Gmk ԐМճguanylate kinaseմГҙjƦʁͻȗЂĥ̎Ϊüȍƚǻճϫȿ̽Ȁò̵ёάΝƐȑӂɠմ^ãèóÅðÌ
̛k RNA áìåëóÂГҙƦʁͻȗάƐȑφșեԨƫΣƚǻճĄȀԯòƓòűȍάΝȑ˕ȜմŠƴϙϸ¡_ϙϸϊφԑƐÐµî°ÇÍ 8-oxoG l DNA ƨ}̵̭Ԩwҵwoϙϸu¢Ө¢¡ըՓɟϹΓǽλlӗm¡_s¢m_ô˟^8-oxoG  DNA qo RNAƨ Ө¢¡l^sǱƲԄĨʏǰτΨλɑ¥y_ ˽ӫ^8-oxoG ¥Ƹ RNA ξʌòсƐԨӶl͟ϊu¢^ԑƐ¿Ìî¿ RNA ĞӃϙϸlԔҜҾՖg¡_StrainȀѝѻ mutT ԄĨȍ̶ˊ̛

BT3701
lacZam
mutT 
X

lacZ 

lacZam

DNA

GAG
CTC

TAG
ATC

TAG
ATC
Go

mRNA

ҽӽtwblӗs¡slϕ¢

tRNA

CAG
GUC

Gln 

g¡_sΨӉ in vivo  8-oxoGsΨӉ¥Ҽ˩y¡æËíǠf¡_

BT370

Genotype(8-oxoG)  a©ðÔóϹΓǽλ̩ϕm¡ǋôЖf¡_Ǡպ

BT369

lacZam
mutT 

ԑƐÐµî°ÇÍ 8-°³Ã¶©Ïðӗǝy¡ԄĨʏǰτΨλɑ¥ԛ˔

CR63

UAG
STOP

TAG
ATC
Go
Go

GoAG
C UU

GoAG
C UU

Glu 

Glu 

LacZ
protein
Colonies on
LB plates with
X-gal and IPTG

Ǡպa©ðÔóϹΓǽλҽӽtwb}¢¥ǹȀu{¡ãèóÅðÌæËíǠ130̇ϙϸ^Ǡþ XնҔw˞ϹΓǽλ^a©ðÔóϹΓǽλҽӽtwblǹȀy¡hãèóÅðÌ̛¥űԿw^}ԄĨȍƴȗòҥ̑^jԄĨȍ̵ёάƐȑφҥ̑¥ҏhs^ԑƐ¿Ìî¿¡ԄĨȍτΨλɑ¥űȍîÝíkϙϸy¡_˟͝Ǡ 2 ãèóÅðÌűԿ˟͝¥ϣwf¡_ a©ðÔóϹΓǽλҽӽtwblǹȀy¡hǽλɿՍԄĨȍճessential geneմǽλf¡ƭёʇlf¡_}ǱƲ̶ˊǩãèóÅðÌw

ɶ¡sՀwo^̌Ģѫ̿ǽλ̛gűԿy¡slmg^șեͺɟʔƩʇճtsմãèóÅðÌwűԿ¥Ҳ_šıφ^ÔµÊì©ОѐѨӟάыͺɟʔƩʇf¡l^άыƭёĮͺa©ðÔóϹΓǽλҽӽtwblǹȀy¡ãèóÅðÌ X-gal ¥ƸÛîóÌ÷ΉgÚíóƻѱw¹ïÏó¥Ĵ¡s¥ʷ̰w

űԿw_ãèóÅðÌͺɟʔƩʇʇӕ}űԿɿҜfsƈióÅðÌͺɟʔƩʇʇӕԕάǩύҘʇÊ¿Ìâó±ów^ãèήg¢^ãè

óÅðÌԄĨȍƴȗ¥Ƞ˪w_ǠռãèóÅðÌԄĨȍҥ̑̬ι¥ϣwf¡_
BT370 (mutT::Cmr lacZam)

ts-mutants

Penicillin screening at 42 for 120 min
Plate on LB containing X-gal (250 mg/ml) and IPTG (100 mM)
Incubate at 30 for 48 hComplementation test
using a mixture of 10 Kohara’s  phage clones
The second round of complementation test
using a single Kohara’s  phage clone

Pick up light blue colony

DNA Sequencing for the gene(s)locating in the corresponding region

X

BT370 (48 clones)Ǡջ ãèóÅðÌűԿˎĴǠռ ãèóÅðÌԄĨȍҥ̑˟͝̬ιТ̓тȧͺɟʔƩʇ^a©ðÔóϹΓǽλҽӽtwblǹȀwãèóÅðÌw

87 ̛ãèóÅðÌ¥ΡϻűԿw_Ǡս^ŢǩφãèóÅðÌ̛a©ðÔóϹΓǽλҽӽtwblǹȀw

g¡s¥MQ²µÌ½ÆóÂͣʇͻȗϣwf¡_a©ðÔóϹΓǽλҽӽtwbǹȀ^y¤MQ²ëµÌ½ÆóÂͣʇǹƈԑƐ¿Ìî¿ 8-oxoG lԨ¤g¡s^(1) ãèóÅðÌ̛Ûë¿ãÍ

mutT + ԄĨȍ¥ȱŜwǱƲ^(2) Ȍ͊̌ĢøǭաwǱƲMն²ëµÌ½ÆóÂ
ͣʇǹƈҞ¢o¡s˩kf¡_
131

ß-Galactosidase activity












































9 0 2 2 
9 8 5 
36 37 0- 1- 2-1 4-1 -4
BT BT ts ts ts ts ts 09 0 2 2 9 8 5 
36 T37 s 0- s 1- 2-1 4-1 0-4
T
t ts ts tstB B  8 5  9  0 2  2  9

36 37 0- 1- 2-1 4-1 -4
BT BT ts ts ts ts ts 0

BT370X 

BT370X  (mutT + )BT370X 

Aerobic growthAnaerobic growthǠս ãèóÅðÌMQ²ëµÌ½Æó̷Ҕ^ãèóÅðÌ̛ǽλԄĨȍƴȗ¥ҏТ̓¥_StrainMutantGene

Phage clone(s)complemented

-galactosidase
activity

BT3701

ts0-2

gmk

571, 572

BT3704

ts0-42

rpoC

BT3706

ts0-45

BT3707

MutationDNA

Protein

17.6

C119T

Thr40Ile

533

8.4

G2699A

Gly900Asp

rpoC

533

15.5

G2699A
G82A

Gly900Asp
Asp28Asn

ts1-2

dnaB

636

13.6

G1135A

Val379Met

BT3714

ts2-19

msbA

217

6.6

G808A

Ala270Thr

BT3722

ts4-5

rpoC

533

9.9

G3760A

Glu1254Lys

BT3728ts4-18

dnaN

565

10.6

G470A

Gly157Asp

BT3750

Rif

r

rpoB

15.0

A1538C

Gln513Pro

BT3723

ts4-7

prfB

467, 468

14.1

T397G

Ser133AlaBT3749
BT3750BT3751
BT3752
BT3753
BT3755
BT3756

ts12-7
ts12-9ts12-14
ts12-21ts12-24
ts12-29
ts12-30

prfA
prfA
prfA
prfA
prfA
prfA
prfA

247, 248
247, 248
247, 248
247, 248
247, 248
247, 248
247, 248

20.9
15.1
17.4
19.7
 19.9
 20.0 21.3

T275G
T275G
T275G
T275G
T275G
T275G
T275G

Leu92Arg
Leu92Arg
Leu92Arg
Leu92Arg
Leu92Arg
Leu92Arg
Leu92Arg-3 պմGMK ãèóÅðÌ
ãèóÅðÌ ts 0-2  guanylate kinase ԄĨȍճgmkմǽλlҞŰu¢_in vitro
mutagenesis ^sԄĨȍ 119 κϊǵǮ¥ĖɇφǽiǱƲ^Ϟka©ðÔóϹΓǽλҽӽtwblǹȀy¡ҔΨǩ¥ңȧŰ̍sk^sԐМǽλla©ðÔóϹΓǽλҽӽtwbǹȀľ¤g¡s˩k_Gmk ԐМ GMPWGDP ìðԑƐ¥Ҧȋy¡l 8-oxoGMP ìðԑƐmg_ãèóÅð
Ì Gmk ԐМǮӕΞλʇlвoƨ8-oxoGDP ¥άʝw^8-oxoGTP ¥С

mRNA 

Ө¢¡_}Т̓ 8-oxoG ¥Ƹ©ðÔó¹ÍðlǹȀy¡s

^}¢ĩ

132

 aҽӽtwblǹȀy¡˅ͻu¢¡_In vitro șեw^ãèóÅðÌ Gmk¥ΉеòГҙw^ԐМͣʇ¥ҿ_ãèóÅðÌ Gmk Įͺøԕάǩ Gmk ͇ҀwoͣʇlĮk_ǮӕΞλʇҿl^8-oxoGMPW8-oxoGDP ìðԑƐϞҸmk_ãèóÅðÌ Gmk ùȓȗ^ԐМͣʇl¤zkwko^˻ǮӕΞλʇǽƐĮîÝíf¡y¢^in vitro ϞҸՀwgkw¢g_ջմRNA áìåëóÂãèóÅðÌ
ãèóÅðÌ ts0-42, ts0-45, ts4-5 ռ̛ RNA áìåëóÂM’»ÚéÏÈÌԄĨȍ^

rpoC ãèóÅðÌf¡slŵ˩w_s¢ in vitro ϙϸ^RNA áìåëóÂǮӕw

GTP  8-oxoGTP ¥͇ӣwǱƲ^8-oxoGTP  RNA ƨ GTP j} 15%ӽngslϕ¢Өg¡_̇șեɶ¢ rpoC ãèóÅðÌ^ǮӕΞλʇlвo^8-oxoGTP f֏RNA ǿoƨӨ¢¡y¢a©ðÔóϹΓǽλҽӽtwbǹȀlҼ˩m¡_șԸãèóÅðÌ
k RNA áìåëó¥ʮŰòГҙw^ǮӕŷήƊΦ¥ 32P ̰ӄw GTP  8-oxoGTP¥ήgҿ _́ʃlТ̓Ñ²ÊÚ^ãèóÅðÌԐМ 8-oxoGTP lmRNA ĳҨƨӨ¢¡gТ̓ɶ¢k_Gmk ԐМǱƲƴ̮^in vivo  in vitro șե´çÈÛ¥ȈĲw Ǫ¡k́u¢ՀwgҾՖf¡_
RNA áìåëóÂM»ÚéÏÈÌԄĨȍճrpoմǽλa©ðÔóϹΓǽλҽӽtwbǹȀl¢¡ãèóÅðÌűԿ¥Ҳ^s¢ʝƇw_ʩάΝӕìÙ¨ðØ½ð RNA áìåëóÂԬȞſfԄĨȍѾ¡slϕ¢^s҅ſфʇǽλճrif Rմ rpoBg, ìÙ¨ðØ½ðфʇ X-gal ÛîóÌ÷ΉgÚíó¹ïÏó¥Ĵ¡¥ԃŶw_ΡϻűԿwãèóÅðÌ RifR-2, RifR-3,
RifR-4 ռ̛^DNA ǵǮԏųҥ̑Т̓k^rpoB ԄĨȍ 1538 ĭǵǮ AWC ǵǮкˇ^RpoB ÅðÕµӕ 513 ĭ GlnWPro ǽƐf^ռ̛ƴxǽλf¡slŵ˩w_RNA áìåëóÂϻı̭ӵlҥkg¡l^̇ϙϸɶ¢ãèóÅðÌǽλĭк¥ϻı̭ӵ÷Ξȗwm¡^}¢ NTP ԔƲƐԸaʂșɟbľ¤¡ͣʇԌĭf¡sl¤k_̺ɑ RNA áìåëóÂǮӕճ4ϲ NTPմƠwgԃʫʇճʂșɟմ¥˿y¡l^ėǜɶãèóÅðÌsԃʫʇճʂșɟմlȳwв¦^8-oxoGTP ¥ƨӨ¦ mRNA ¥ǿoƲʝy¡^a©ðÔóϹΓǽλҽӽtwbǹȀlӗm¡˅ȧu¢¡_ռմ DNA ƲʝԨӶԄĨȍѢÅðÕµӕԨӶԄĨȍãèóÅðÌ
ts1-2  ts4-18  dnaB^dnaN  DNA ƲʝԨӶԄĨȍ^ts2-19  msbA ѢÅðÕµӕԄĨȍãèóÅðÌf¡sl DNA ǵǮԏų͑ȗŵ˩w_dnaB Қҙ DNA Üì±óÂ¥^dnaN  DNA áìåëóÂ III Mն»ÚéÏÈÌ¥¹óÍw
133

g¡_
a©ðÔóϹΓǽλҽӽtwǹȀblӗm¡ RNA  8-oxoG lƨ Ө¢¡slό˄Ɵǝf¡тi¡l^ãèóÅðÌűԿòҥ̑̇ϙϸ^in vivo  DNA ƲʝԨ¤¡ԄĨȍl RNA Ʋʝőgh̵̭lőg
¹óÍwg¡s¥˩ϞϣǊwg¡_

g¡kù˩f¡_msbA  ATP-binding transport ÅðÕµӕ¥g¡l^RNA Ʋʝ DNA Ʋʝ}¢~¢Ŷҏ¤¢¡o^Ѣ̭ӵ¥Ęw ôɊȀՕЏճÐµî°ÃóäմwĴήw

g¡gk˅ͻu¢¡_̭ʝʝűf¡ DNA ƲʝԨӶԄĨȍέΝǱ¥ˆĹy¡ѢÅðÕµӕǽλ^RNA áìåëóÂʂșɟlɰՉu¢Т̓l 8-oxoG ӗǝy¡a©ðÔóϹΓǽλҽӽtwbзl¡тi
 4)

g¡_

ÅðÕµӕƲʝԨ¤¡ǝȍãèóÅðÌ

ts12-7 k ts12-30 ãèóÅðÌ prfA ԄĨȍ^ts4-7  prfB ԄĨȍǽλkҞŰu¢_prfA/B  polypeptide releasing factor ¥¹óÍw¿ÌÈÛò¹Íð¥Ҹӄwg¡_Prf ÅðÕµӕǝȍ^ĪɫlŊ̹Πʖf¡ÞÛÇÍԠ¥ìàÃóäҥԿu{¡őm¥y¡ǝȍf¡_ėǜҞŰwsãèóÅðÌըͺ}̵ёlĮøy¡^ìàÃóä¢8-oxoG ¥Ƹ©ðÔó¹ÍðÞÛÇÍԠ¥ҥԿu{¡lӺ^}ԧaҽӽtwblӗm¡f£h˅ͻwg¡_mutT ԄĨȍȱŜȌ͊̌ĢǭաaҽӽtwbҞ¢o¡sk^©ðÔó¹ÍðƸ¢¡ 8-oxoG ¥ƠȣҸӄw

άz¡ΨӉf¡sԧԀig_ΡϻűԿwր̛ŝԌlƴx»«Ìƴxǽλ¥s Prf ÅðÕµӕǝȍ¹ÍðƠȣűȍҸӄȎǥ¥ʒƾy¡тi¡_ė ɳϙϸȺԦãèóÅðÌ¥ЫлφűԿòҥ̑y¡s^ԑƐ¿Ìî¿ 8-oxoG lԨľy¡ԄĨȍ¥͡gŰyslm_}¢¥ű՚w¡^1) Ðµî°ÇÍòÛóíԨy¡^2) RNA áìåëóÂʂșɟԨyճDNA ƲʝԨy¡ÅðÕµӕѢÅðÕµӕ¥ƸÐµî°Ãóä¥ҠԕŜ¢¢¡_sĜ 4) w

մ3) рҭ̓ԷãèóÅðÌȀŶu

^8-oxoG ¥Ƹ mRNA űҥńɸgîÝíãèóÅðÌlтi¢¡l^űԿòҥ̑Ѫgg_s¢s¢űԿ˟͝ˎĴφ^ʔɟφùƔű^˞űԿЖ¥̭Њy¡ɿҜlf¡_˽ӫs¢ʸʠw^ìàÃóä RNA  8-oxoG lƨӨ¢ŷήy¡Ж¥Ԧτw_y¤ 8-oxoG l RNA ƨʔƩʇ

άx¡҅ſфʇʇӕ¥ɉӨ¢¡¿ÌîÛÌâ«½ð

^mutT ԄĨȍȱŜf¡gȌ͊̌Ģфʇ¡ãèóÅðÌ¥ķhЖf¡_iÖÌ cDNA ë«Úëìó¥ȱŜwфʇ¡¥ƙԿòҥ̑134

y¢^mutT ԨӶy¡ԄĨȍ¥ԛ˔ûƊΦoɶ¡slŰ̍¡тi
Ӹ

ϙϸ¥

g¡_

ń žƈć
1.

Search for Protein Required for Accurate Gene Expression under Oxidative Stress.
Roles of Guanylate Kinase and RNA Polymerase. H. Inokuchi, R. Ito, T. Sekiguchi,
and M. Sekiguchi. J. Biol. Chem., 2 88, No. 46, 32952-32962, November 15, 2013.

Ñńž
1.

ԑМ¿Ìî¿øԄĨȍτΨ̵̭_ďƫŞԊ^ĥ̎Ϊüȍ^ԨƫΣ^ԨƫϓȂˤ̇ԄĨȑħЀցվǜȀħ^̲ͦ^2013 ɖ 9 ˾_
2. Ȁѝѻjq¡ցն°³Ã¶©Ïð¥ƸÐµî°ÇÍˁ԰̵̭_ĥ̎Ϊüȍ^ďƫŞԊ^ԨƫΣ^ԨƫϓȂˤ̇ԄĨȑħЀցվǜȀħ^̲ͦ^2013 ɖ 9 ˾_135